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Current immunotherapies designed to stimulate specific T cell-mediated immunity have thus far 
yielded modest objective clinical response rates, despite the increase of tumor-specific T cells 
have been observed in treated patient blood. Since the majority of tumor antigens being targeted 
in immunotherapies are non-mutated, “self” antigens, current clinical results may relate, in part, 
to the low-to-moderate avidity, negatively-selected T cell repertoire in patients that is being 
asked to regulate tumor progression. In the current thesis, I hypothesized that by conditionally 
enhancing the proteasomal degradation of tumor antigens, I could generate a “synchronized” 
pool of derivative peptides that could then be presented in a “wave-like” temporal fashion in 
MHC class I complexes on the tumor cell surface.  For at least a transient period thereafter, I 
theorized that specific CD8+ T cell recognition and anti-tumor activities would be improved.  I 
selected a family of tumor-associated antigens, receptor tyrosine kinases (RTK) for study, as 
their overexpression has been linked with poor clinical prognosis in many forms of cancer. In 
this thesis, I show that EphA2 agonists, as well as, HSP90 inhibitors effectively promote EphA2 
degradation via a proteasome- dependent manner, providing the delivery of EphA2 peptides into 
the classical MHC class I presentation pathway. I also show that specific CD8+ T cell recognition 
of EphA2 peptides derived from both the extracellular and intracellular domains of this 
transmembrane protein was improved as a consequence of tumor cell treatment with these agents 
being in consistent with the use of TAP- and ER-associated degradation. Notably, the 
combination of both drugs further enhanced anti-EphA2 T cell recognition of tumor cells, 
suggesting these modalities work via complementary, but not identical mechanisms. Importantly, 
complete tumor eradication was achieved in vivo (in a Hu-SCID tumor model) using a 
combinational therapy consisting of agonist administration just prior to the adoptive transfer of 
human anti-EphA2 CD8+ T cells, where either single modality was minimally beneficial. 
DEVELOPING COMBINATIONAL IMMUNOTHERAPIES TARGETING TUMOR 
RECEPTOR TYROSINE KINASES 
 Mayumi Kawabe, PhD 
University of Pittsburgh, 2009
 v
Preliminary data from additional studies targeting the tumor cell-overexpressed RTKs, Her2/neu 
and EGFR, suggest that this core treatment paradigm may be generalizeable to many (if not all) 
RTKs.   
 vi
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1. Introduction 
Many observations, including our own, suggest that most forms of cancer coordinately 
overexpress multiple receptor tyrosine kinases (RTKs), leading to constitutive kinase activation 
and enforcement of the proliferative or metastatic potential of neoplastic cells [1].  One goal for 
cancer therapy is, therefore, to decrease RTK levels of expression or their associated kinase 
activity. Numerous pharmacological agents that interfere with RTK-mediated signal transduction 
have been developed, however, in clinical trials these agents have proven only modestly 
effective and have exhibited toxicities when applied as single modalities [2].  A second major 
goal for cancer (immuno)therapy, we believe, may be to increase the frequency of RTK-derived 
antigenic peptides presented in MHC class I complexes on the tumor cell surface [3]. Such 
complexes are critical for RTK-specific CD8+ T cell mediated eradication of cancer cells. How 
one may conditionally and selectively manipulate tumor cell presentation of T cell epitopes 
derived from endogenous antigens remains an understudied area of translational/clinical 
research. Of the many RTKs that have clinical implications in the cancer setting, I have chosen 
to focus predominantly on EphA2, which is overexpressed/dysregulated in virtually all solid 
cancers [4-6], where its degree of overexpression is associated with a poor clinical prognosis [4-
7]. An additional rationale for this choice of target antigen was that we have previously defined 
EphA2 peptide epitopes that are recognized by HLA-A2-restricted CD8+ T cells [8], making my 
experiments feasible. My data suggest that CD8+ T cell recognition of EphA2+ tumor cells may 
be dramatically improved by promoting the conditional proteasomal processing of the EphA2 
protein as a consequence of tumor cell treatment with RTK agonists or HSP90 inhibitors. While 
my EphA2 modeling provides “proof-of-principle” data, I have also investigated the generality 
of these findings in parallel models based on the RTKs EGFR (ErbB1) and Her2/neu (ErbB2), 
which are also commonly overexpressed/dysregulated in a broad range of cancer histologies.   
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1.1. Receptor Tyrosine Kinesis 
Receptor tyrosine kinases (RTKs) are a subclass of cell-surface growth-factor receptors that 
exhibit an intrinsic, ligand-controlled tyrosine-kinase activity. They are comprised of 58 known 
members, that are distributed among 20 sub-families (Table 1), which regulate diverse cellular 
functions including proliferation, differentiation, migration, and survival [1].   
 
 
Table 1. Human receptor tyrosine kinases (RTKs). 
 
Subfamily Member 
EGFR (epidermal growth factor receptor) ErbB1(EGFR), ErbB2(Her2/neu), 
ErbB3*, ErbB4 
InsR (insulin receptor) INSR, IGF-1R, IRR 
PDGFR (platelet-derived growth factor 
receptor) 
PDGFR-α, PDGFR-β, CSF-1R, 
KIT(SCFR), FLK2(FLT3) 
VEGFR (vascular endothelial growth factor 
receptor) 
VEGFR-1, VEGFR-2, VEGFR-3 
FGFR (fibroblast growth factor receptor) FGFR-1, FGFR-2, FGFR-3, FGFR-4 
KLG/CCK (colon carcinoma kinase) CCK4* 
NGFR (nerve growth factor receptor) TRKA, TRKB, TRKC 
HGFR (hepatocyte growth factor receptor) MET, RON 
EphR (ephrin receptor) EphA1, EphA2, EphA3, EphA4, EphA5, 
EphA6, EphA7, EphA8, EphB1, EphB2, 
EphB3, EphB4, EphB5, EphB6 
Axl  AXL, MER, TYRO3 
TIE (tyrosine kinase receptor in endothelial 
cells) 
TIE, TEK 
RYK (receptor related to tyrosine kinases) RYK* 
DDR (discoidin domain receptor) DDR1, DDR2 
Ret (rearranged during transfection) RET 
ROS (RPTK expressed in some epithelial 
cell types) 
ROS 
LTK (leukocyte tyrosine kinase) LTK, ALK 
ROR (receptor orphan) ROR1, ROR 2 
MuSK (muscle-specific kinase) MUSK 
LMR (Lemur) AATYK, AATYK-2, AATYK-3 
? RTK106 
 
RTK members in bold type are implicated in human malignancies. An asterisk indicates that the 
member is devoid of intrinsic kinase activity. 
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In normal cells, the binding of ligand to the RTK promotes RTK dimerization/oligomerization 
and phosphorylation, creating binding sites for adaptor proteins that allow for the transmission of 
biological signals into the cell. During this process, the RTK protein is ubiquitinated by Cbl 
family ubiquitin-protein ligases. C-Cbl contains an internal SH2 domain that binds to 
phosphorylated RTKs (pRTKs), and a ubiquitin E3-ligase responsible for the addition of 
ubiquitin molecules to pRTKs [9, 10]. The ubiquitinated RTK is internalized via clathrin-coated 
pits, forming a sorting endosome [11, 12], which is then targeted towards a lysosomal 
compartment for proteolytic degradation (Figure 1).  Prior to degradation this process is 
reversible, so that de-phosphorylated and/or non-ubiquitinated receptors may be recycled to the 
cell surface, where their functional lifespan may be temporally extended [11, 13, 14].  RTK-
mediated signaling is normally modulated reversibly by the action of specific protein tyrosine 
phosphatases (PTPs), as well as, irreversibly by lysosomal degradation [11].  In addition, an 
alternative degradation route has been revealed by recent studies, in which polyubiquitinated 
RTK may be delivered to the proteasome for degradation [15].         
 
Signaling processes associated with  RTKs are often altered in tumor cells, in support of more 
aggressive cellular growth and/or the increased invasiveness of tumor cells, resulting in an 
overall poor prognosis for patients [7, 16-22].  Slightly more than half of the known RTKs have 
been reported to be either mutated or overexpressed in cancer cells; e.g. EGFR, ErbB2-4, 
PDGFR-α/β, VEGFR1-3, FGFR1-4, MET, RON, EphA2, EphB2/4, AXL, TIE, TEK [1, 7, 16-
18, 20-23]. Cellular overexpression of RTK increases dimer concentrations, and causes 
constitutive kinase activation, sometimes even in the absence of specific ligand binding. Many of 
the mutated RTKs acquire increased kinase activity [24, 25] or avoid homeostatic down-
regulation by loss of interaction with the E3-ligase c-Cbl [11].   
 
As a result, RTKs and their down-stream signaling molecules have become rational targets for 
therapeutic intervention, prompting the development of novel pharmacological inhibitors. Such 
agents include neutralizing antibodies against RTK ligands, anti-RTK antibodies targeting either 
overexpressed receptors or receptor heterodimers, and small-molecule inhibitors of RTK-
associated kinase activity [2]. In addition to targeting RTK themselves, one may also consider 
the therapeutic targeting of regulatory PTPs, such as low molecular weight protein tyrosine 
 4
phosphatase (LMW-PTP) and PTP-1B, that have been recently reported to be overexpressed in 
numerous cancer types in concert with overexpressed and hypo-phosphorylated RTKs [26, 27].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. RTK ubiquitination and downregulation of cell surface RTK. 
Binding of ligand to the RTK promotes RTK dimerization/oligomerization and its 
phosphorylation, creating binding sites for adaptor proteins in order to relay biological signals.  
During this process, the RTK protein is ubiquitinated by Cbl family ubiquitin-protein ligases, 
and internalized via clathrin-coated pits, forming a sorting endosome which is then targeted 
towards a lysosomal compartment for proteolytic degradation.  Prior to lysosomal delivery this 
process is reversible, so that de-phosphorylated and/or non-ubiquitinated receptors may be 
recycled to the cell surface where their functional lifespan may be temporally extended. RTK 
signaling is normally modulated reversibly by the action of specific protein tyrosine 
phosphatases (PTPs), as well as, irreversibly by lysosomal degradation.  
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1.2.EphA2 Overview 
1.2.1. Eph Receptor and Ephrin Ligands 
The Eph family of molecules contains 16 members, comprising the largest known cohort of 
receptor tyrosine kinases (RTK) [28] (for nomenclature, refer to http://eph-
nomenclature.med.harvard.edu/cell_letter.html). Based on sequence similarity and binding 
affinities, two classes of receptors, EphA and EphB, and two classes of corresponding ligands, 
ephrin-A and ephrin-B, have been defined. The EphA receptor family consists of 10 members 
(EphA1 – EphA10), and primarily bind 6 ephrin-A ligands (ephrinA-1 – ephrinA-6).  Ephrin-A 
ligands are attached to the cell surface via glycosylphosphotidylinositol (GPI) anchors and tend 
to bind only EphA receptors.  EphB receptor family consists of 6 members (EphB1 – EphB6), 
that primarily bind 3 ephrin-B transmembrane ligands (ephrinB1 – ephrinB3).  However, Eph-
ephrin binding is promiscuous in some cases, as there is some crossover in the interactions 
between Eph receptors and ephrin ligands. For instance, Ephrin-B molecules bind with low 
affinity to EphA4, whereas ephrin-A5 is known to interact with EphB2 [29, 30]. 
 
Like other RTK, Eph receptors are type 1 transmembrane proteins [31], having multiple domains 
as shown in Figure 2.  The extracellular N-terminus of these molecules consists of a highly 
conserved ligand binding region, followed by a cysteine-rich region, and two membrane-
proximal fibronectin Type-III repeats. The intracellular region of Eph receptors is characterized 
by a juxtamembrane segment containing two major auto-phosphorylation sites, followed by a 
conserved kinase domain, which phosphorylates secondary adapter proteins and can also 
phosphorylate Eph receptors themselves [32].  The C-terminal region contains a sterile a motif 
(SAM), and a PDZ binding domain.  The PDZ domain may be involved in receptor 
oligomerization [33], facilitating the binding of adapter proteins [34].  The binding of Eph 
receptors to their corresponding ephrin ligands occurs at a 1:1 stoichiometric ratio, with the 
complex forming a circularized heterotetramer [35]. 
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Figure 2. Schematic view of structural and signaling components of an Eph receptor.  
The extracellular N-terminus of Eph receptor consists of ephrin binding domain, cysteine-rich 
domains and fibronectin Type-III repeats. The intracellular region of Eph receptors has a 
juxtamembrane segment, a conserved kinase domain, a sterile a motif (SAM) and a PDZ binding 
domain. P represents a tyrosine phosphorylation site. 
 
 
 
Eph receptors were originally defined based on their involvement in various embryonic 
developmental processes, such as the formation of tissue boundaries, neural crest cell migration, 
axon guidance, and vascular system organization [16, 36-40]. However the developing embryo is 
not the only area where the Eph/ephrin system exerts its biologic influence.  Eph/ephrin binding 
and subsequent signaling regulates the attachment, shape and motility of adult cells due to 
modulation of integrins/adhesion molecules on the cell surface and/or re-organization of the cell 
cytoskeleton [41-48].  Furthermore, some Eph receptors (in particular EphA2), have also been 
shown to play an important role(s) in neo-angiogenesis in normal adult tissues, as well as, tumors 
[4, 5, 49-51].   
 
1.2.2. EphA2 
One Eph receptor, EphA2, is of particular interest due to recent evidence suggesting it may play 
a role in the development and progression of cancer. The EphA2 gene is located on human 
chromosome 1, and encodes a 130 kDa Type-1 glycoprotein.  EphA2 binds to ephrin-A1, -A3, -
A4, -A5, but does not require ligand binding for its enzymatic activity [51]. Along with other 
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Eph/ephrin family members, EphA2 is involved in the organization of the developing nervous 
system [52] and vasculature [53], and is even expressed in embryonic stem cells [54].  In normal 
adult tissues, EphA2 is expressed at low levels on a broad range of epithelial tissues [55], where 
it is principally localized to sites of cell-to-cell contact, and may play a role in contact inhibition 
of cell growth/migration that is critical for the organization and formation of epithelial layers in 
EphA2+ tissues [48, 56]. EphA2 is also expressed by endothelial cells where it contributes to 
normal tissue (and tumor) neovascularization in the adult [49].  More recently EphA2 expression 
on Langerhans- and interstitial-type dendritic cells (DC) has been reported, suggesting the 
possible role(s) of EphA2 in the localization and networking functions of Langerhans cells in the 
epithelium, as well as their ability to traffic and stimulate T cells under the appropriate activating 
conditions [57-59].   
 
 
 
 
1.3. Regulation of EphA2 Expression 
1.3.1. EphA2 Expression and Life Cycle in Non-transformed Tissues 
In normal adult tissues, EphA2 is expressed at low levels on a diverse array of epithelial tissues, 
where it may stably bind to its ligand, ephrin-A1 [48] which is anchored to the surface of 
neighboring cells [60, 61].  In contrast, malignant cells express high levels of EphA2 protein, but 
these only poorly bind ligand [48, 62].  The EphA2 gene is expressed most highly in tissues that 
contain a high proportion of epithelial cells (e.g., skin, small intestine, lung, and ovary), with 
somewhat lower expression levels typically observed in kidney, brain, spleen, and submaxillary 
gland, and very low expression levels noted for heart, skeletal muscle, liver, testes, and thymus.  
These results diverge from studies of EphA2 protein expression, where strong expression has 
been reported for epithelial cells of kidney and lung, with weaker expression suggested for liver, 
small intestine and skin in the rat [55]. Our own studies using Western blot analysis of mouse 
organ lysates showed that moderate levels of EphA2 protein were expressed in the spleen, liver 
and lung, whereas no detectable expression was noted for brain, heart and skeletal muscle tissues 
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[63].  The observed disconnect between mRNA and protein level assessments in the various 
tissues likely reflects differences in post-translational stability (i.e. the “lifecycle” of EphA2 
protein) in a given organ system.   
 
Upon ligand binding, EphA2 seems to follow a similar destiny with other RTKs as described in 
section 1.1. Using ephrinA1-Fc fusion protein or EphA2-specific agonistic antibody, it has been 
shown that; (i.) cell surface EphA2 is internalized and degraded in response to ligand- or 
antibody-mediated stimulation, (ii.) EphA2 interacts with the c-Cbl adaptor protein in a 
stimulation-dependent manner, and (iii.) the proteasome serves as the major degrader of 
internalized EphA2 protein [64-67].  Overall, these results suggest that cellular levels of EphA2 
protein are sensitive to turnover based on ligand-induced activation, as well as, relative levels of 
“regulatory” protein interactions (i.e. Cbl, PTPs, etc.) that dictate the fate of internalized EphA2 
molecules. 
        
Of note, one striking difference between EphA2 and most other RTKs is that the enzymatic 
activity associated with EphA2 is not dependent on ligand binding or receptor 
autophosphorylation, likely due to the lack of an ‘activation loop’ tyrosine in the EphA2 
cytoplasmic domain [48, 66, 68]. Therefore, in the absence of ligand binding signals, EphA2 
exhibits constitutively active enzyme activity, yet this does not appear to accelerate the turnover 
of EphA2 protein. Such dysregulation may result in the “accumulation” of EphA2 protein 
(overexpression) and a progressive accumulation of EphA2 signal strength (supporting 
tumorigenesis, etc.) [62].  
 
1.3.2. EphA2 and PTPs 
Tyrosine phosphorylation of RTKs in both resting and ligand-activated cells is modulated by the 
dynamic equilibria of tyrosine kinase and protein tyrosine phosphatase (PTP) activities. With 
regard to the latter class of enzymes, the PTP superfamily has approximately 70 members.  
These can be classified into four major categories based on enzyme function, structure, and 
sequence: (i.) tyrosine-specific phosphatases, (ii.) VH1-like dual specificity PTPs, (iii.) cdc25, 
and (iv.) low molecular weight phosphatases [69]. 
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Of these, low molecular weight-protein tyrosine phosphatases (LMW-PTP) have been reported 
to play a major role in acting on pEphA2 as a substrate [26, 70, 71].  LMW-PTPs are a group of 
18 kDa cytosolic enzymes that are constitutively expressed by most cell types [72]. Under 
normal conditions, LMW-PTP removes the phosphate groups on cytoplasmic tyrosine residues 
that are initially added to EphA2 as a consequence of agonist ligand binding. This 
dephosphorylation event is necessary for the homeostatic regulation of secondary signals that are 
generated upon ligand binding. Indeed, LMW-PTP has been reported to negatively regulate the 
ephrinA1-mediated repulsive response, cell proliferation, cell adhesion and spreading, and the 
formation of retraction fibers, as a result of its dephosphorylation of EphA2, suggesting LMW-
PTP acts as a terminator of ephrinA1 signaling through EphA2 kinase activity [70]. 
 
Interestingly, LMW-PTP has been reported to be overexpressed in several cancer types [26, 71, 
73]. This is consistent with additional reports that tumor EphA2 is largely non-phosphorylated,  
while it is prominently tyrosine phosphorylated in nontransformed cells [48, 62, 68]. Hence, high 
levels of EphA2 protein are coordinately observed in cells that overexpress LMW-PTP. This is a 
logical outcome, since elevated levels of LMW-PTP would be expected to be associated with 
decreased levels of pEphA2, leading to enhanced recycling versus degradation of EphA2 protein 
in cancer cells.    
 
Another PTP reported to be involved in pEphA2 dephosphorylation is the SH2-domain-
containing PTP2 (SHP2), which may regulate changes in cell-morphology that occur as a 
consequence of EphA2 activation [5, 47].  And more recently, SHIP2 (Src homology 2 domain-
containing phosphoinositide 5-phosphatase 2) has also been reported to be recruited to activated 
EphA2 via a heterotypic sterile α motif (SAM)-SAM domain interaction, leading to the 
inhibition of EphA2 internalization [74]. The relative hierarchy of LMW-PTP versus SHP2 
versus SHIP2 in regulating EphA2 phosphorylation status and EphA2 accumulation has not been 
comprehensively investigated in normal cells or tumor cells to date. 
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1.3.3. Genetic Regulation of EphA2 
Several stimuli appear competent to efficiently up-regulate EphA2 gene transcription. Most 
interestingly, p53, known as guardian of the genome or gatekeeper for growth and division, has 
been shown to upregulate EphA2 transcription [75-78].  Upregulated expression of p53 family 
members (p53, p73, and p63) increased both EphA2 transcript and protein levels, and a p53 
binding site located within the EphA2 promoter was defined and shown to be responsive to wild-
type p53, p73, and p63, but not mutant p53 or p73 [78]. This turned out not to be a consensus 
p53 binding site, but rather a novel 10-bp perfect palindromic decanucleotide (GTGACGTCAC) 
binding site in the EphA2 promoter region [75]. While at face value, it might appear strange that 
wild-type p53 upregulates EphA2 transcription, it is important to note that levels of p53 are 
upregulated as a consequence of stabilization by mutant p53 protein in many forms of cancer [79, 
80], hence p53 facilitated EphA2 expression becomes a rather logical conclusion.   
 
EphA2 transcription is also enhanced as a result of activating the Ras-Raf-MAPK signaling 
pathway.  Increased EphA2 protein level was observed previously in Ras-transformed mammary 
epithelial cells [68], with more direct evidence demonstrated by Macrae et al. [81], with Raf 
activation shown to stimulate both EphA2 mRNA and protein expression. They also 
demonstrated that EphA2 is a direct transcriptional target of the Ras-Raf-MAPK pathway and 
that ligand-stimulated EphA2 attenuates the growth factor-induced activation of Ras, suggesting 
that a negative feedback loop is created that impacts Ras activity [81].  It is noteworthy that 
ligand binding itself has been shown to upregulate EphA2 mRNA via the MAPK pathway [82].   
 
Various stimuli/stressors that invoke the Ras-Raf-MAPK signaling cascade are potent inducers 
of EphA2 expression.  Interleukin (IL)-1ß, IL-2, EGF, which are known to activate Ras, 
stimulate expression of EphA2 [83]. Deoxycholic acid, a well-known constituent of bile acid and 
cancer promoter, upregulates EphA2, at least partially through activation of the MAPK pathway 
[84]. Hypertonic stress and urea-associated stress increase Ras activity in renal epithelial cells 
[85], in concert with enhancing EphA2 mRNA and protein expression [86]. Thus, EphA2 
expression in the renal medulla may represent an adaptive response to hypertonicity or exposure 
to urea.  In renal ischemia-reperfusion injury, EphA2 mRNA may be increased as a consequence 
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of src kinase activation [87]. In addition, systemic injection of lipopolysaccharide (LPS; a 
MAPK activator via TLR2/4 stimulation) increased EphA2 mRNA expression in the liver [88].  
 
Negative regulators of EphA2 expression have also been identified, with the most notable 
examples being signaling through the estrogen receptor and c-myc [89]. Exposure of non-
transformed breast epithelial cells to physiological levels of estradiol was sufficient to silence 
EphA2 expression. Levels of EphA2 expression in breast cancer cells have also been shown to be 
inversely related to estrogen receptor expression, suggesting that loss of hormone sensitivity may 
override this repressive mechanism and contribute to widespread overexpression of EphA2.  
 
 
 
 
1.4. Signaling Through EphA2 
1.4.1. MAPK 
The mitogen-activated protein kinase (MAPK) pathway is a signal transduction pathway that 
couples intracellular responses to the binding of growth factors with their corresponding cell 
surface receptors. Given the complexity of this signaling pathway, it is perhaps not surprising 
that investigations of how EphA2 receptor ligation impacts MAPK pathway activation have 
proven equivocal. Pratt et al.. demonstrated that ligand stimulation of EphA2 activates 
MAPK/ERK in breast cancer cells and that pEphA2 interacts with the PTB and SH2 domains of 
SHC [82, 90].  Another study also reported that ligand-mediated activation of EphA2 activated 
MAPK/ERK pathway and increased cell proliferation of glioblastoma cells [91].  In contrast, 
Miao et al. reported that EphA2 activation via ligand-binding potently inhibited the Ras/ERK 
signaling cascade in fibroblasts, endothelial cells, as well as normal and transformed epithelial 
cells. Moreover, EphA2 activation was shown to antagonize Ras/ERK activation in response to 
EGF, VEGF and PDGF in concert with reduced cellular proliferation [92].  More recently, this 
same group showed that ephrin-A1 stimulation of wild-type, but not EphA2-null, keratinocytes 
attenuates ERK1/2 activation [93]. Similarly, the attenuation of VEGF-induced MAPK pathway 
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activation by ligand-stimulated EphA2 has been confirmed by other groups in analyses of breast 
cancer or retinal endothelial cells [81, 94]. While these discrepancies may be simply due to 
differences in the cell type analyzed [93], more investigations are clearly needed to further 
clarify the impact of EphA2 stimulation on MAPK activity. 
 
1.4.2. FAK 
Focal-adhesion kinase (FAK), a cytoplasmic kinase localized to sites of cellular adhesion (i.e. 
where cells make contact with the ECM via integrins, etc.), is a major phosphoprotein species 
associated with changes in both the actin and microtubule cytoskeleton in adhering cells [95-97].  
Phosphorylated FAK exhibits stronger kinase activity versus unphosphorylated FAK and appears 
important in recruiting signaling and adaptor proteins important to the strength of cellular 
adhesion to matrix. Miao et al. reported that activation of EphA2 results in the 
dephosphorylation of pFAK, which in turn, suppresses integrin function [47]. They showed that 
EphA2 is constitutively (physically) associated with focal-adhesion kinase (FAK) in resting 
cells, and that upon stimulation with the ligand ephrin-A1, the protein tyrosine phosphatase 
SHP2 is recruited to EphA2, followed by the rapid dephosphorylation of FAK (within two 
minutes) and dissociation of the FAK-EphA2 complex. As a result, integrins assume an inactive 
conformation, with cell spreading, migration and integrin-mediated adhesion co-coordinately 
inhibited.  In contrast, Carter et al. showed that EphA2 activation by ephrinA1 induces FAK 
phosphorylation and cell adhesion and actin cytoskeletal assembly in fibroblasts [98]. These 
apparent discrepancies may be simply the result of when FAK phosphorylation status was 
evaluated after EphA2 activation (i.e. FAK may be quickly dephosphorylated, then re-
phosphorylated at later time points).   When studies of steady-state cells were performed using 
EphA2 siRNA or EphA2 transduction procedures, EphA2 silencing induced FAK 
dephosphorylation and reduced cellular invasiveness [99]. On the other hand, ectopic EphA2 
overexpression in cells results in increased FAK phosphorylation, however, after one hour of 
ephrin-A1 ligation, FAK phosphorylation is reduced  and the invasive phenotype attenuated 
[100].  
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1.5. Role of EphA2 in Cancer 
1.5.1. Overexpression of EphA2 in Cancer 
Overexpression of EphA2 has been observed in an ever-expanding range of cancer types [4-6].  
For example, EphA2 has been reported to be overexpressed at levels 10-100 times greater in 
metastatic prostate carcinoma cells when compared to non-invasive prostate epithelial cells 
[101].  EphA2 protein is also expressed in greater amounts in malignant mammary tissue when 
compared to benign mammary epithelia [62, 89].  Similarly, EphA2 is vastly overexpressed in 
aggressive MUM-2B melanoma cells when compared to poorly invasive MUM-2C melanoma 
cells [102], and EphA2 mRNA levels were significantly higher in cell lines derived from distant 
metastases versus primary melanomas [103]. PANC1, a poorly-differentiated pancreatic 
adenocarcinoma that is highly invasive, overexpresses EphA2 when compared to the non-
invasive Capan-2 pancreatic cancer cell line [99].  In renal cell carcinoma (RCC), we have 
reported that EphA2 is expressed in metastatic RCC cell lines to a degree exceeding that for 
primary RCC cell lines, a trend recapitulated when analyzing freshly-resected RCC clinical 
specimens [8]. More recently, we compared RCC and normal adjacent kidney (NAK) tissues and 
found that EphA2 expression varied between different tumors and that RCC lesions expressing 
higher levels of EphA2 were significantly higher in grade and tended to be larger, more-
vascularized tumors [7].   
 
Given such strong evidence supporting an association between EphA2 overexpression and tumor 
aggressiveness and metastatic potential, one would predict that the degree and distribution of 
EphA2 protein expression by primary tumors may prove predictive of clinical outcome in 
patients with EphA2+ tumors.  Indeed, it has been recently suggested that the quantitative levels 
of EphA2 expressed by lung cancer cells or esophageal squamous cell carcinoma might provide 
useful prognostic information with regard to the metastatic potential of human carcinomas in situ 
and the clinical course of cancer patients [17, 18, 64]. Consistent with this hypothesis, our group 
has also shown that the degree of EphA2 overexpression by biopsied RCC tissues (versus normal 
matched autologous kidney tissue) is predictive of short-term (<1 year) versus longer-term ( 1 
year) disease-free interval, as well as, overall survival [7].  Among the RCC patients evaluated, 
individuals with tumors exhibiting the lowest levels of EphA2 expression were more likely to 
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remain disease-free for a longer period of time after surgery, whereas those patients with tumors 
expressing high levels of EphA2 relapsed quickly and tended to survive for a shorter period of 
time [7] . 
 
1.5.2. Mechanisms of EphA2 Overexpression in Cancer 
The dominant mechanism by which EphA2 is over-expressed and consequently promotes 
metastasis has not yet been conclusively elucidated.  Several different possibilities impacting 
cellular expression of EphA2 include: gene amplification, decreased rates of protein degradation, 
and increased or stabilized mRNA transcription/translation. An attractive current hypothesis 
associated with EphA2 over-expression by tumor cells involves the disruption of EphA2 
homeostatic protein degradation. 
 
In order for EphA2 to be properly degraded, it needs to become phosphorylated and any 
disruption of this process may result in the accumulation of cell surface EphA2 molecules.  As 
discussed above, LMW-PTP, which preferentially dephosphorylates pEphA2, is overexpressed 
in several cancers [26, 71, 73], and tumor cell expressed EphA2 protein is typically not 
phosphorylated [48, 62, 68]. Overexpression of LMW-PTP by tumor cells is associated with 
decreased levels of pEphA2, and enhanced levels of EphA2 due to enhanced protein stability.   
 
Additional/alternative mechanism(s) linked to elevated EphA2 expression may involve changes 
observed for E-cadherin expression in cancer cells.  E-cadherin is a major protein involved in 
cellular adhesion, and is localized in adherent junctions formed between adjoining cells in tissues 
[104, 105]. In order to mediate proper signaling, EphA2 needs to bind its corresponding ligand 
(i.e. ephrin-A1) on adjacent cells, and in the cancer setting, this ability appears to be perturbed 
due to unstable cell-cell contact. Notably, EphA2+ tumors that lose expression of E-cadherin, 
tend to express the highest levels of EphA2 protein and EphA2 is no longer restricted to sites of 
cell-to-cell contact. Instead, EphA2 adopts a diffuse expression pattern throughout the cell [48].  
Consistent with this notion are observations made by Hess et al. investigating the transient 
knockout of E-cadherin [106].  In this study, the authors found that E-cadherin and EphA2 were 
typically co-localized in cell-cell adhesion junctions, and that E-cadherin regulated EphA2 
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expression by modulating its ability to interact with, and become activated by, ligand ephrin-A1 
[106]. Thus, E-cadherin serves as a “rheostat” in controlling EphA2 expression at the cell surface, 
with an inverse correlation reported between E-cadherin and EphA2 expression in bladder 
carcinoma [107].     
 
Furthermore, as discussed in Genetic Regulation of EphA2 (section 1.3.3.), mutated/decreased 
levels of p53 and decreased levels of estrogen receptor may contribute to tumor cell 
overexpression of EphA2. Indeed, an analysis of ovarian cell lines and human ovarian cancers 
showed that EphA2 overexpression occurred in 91% of tumors with p53 null mutations versus 
only 68% in tumors with wild-type or missense mutations (p = 0.027) [108], suggesting the 
possible role of p53 in EphA2 accumulation in cancer cells. 
 
1.5.3. Role(s) of EphA2 in Tumorigenesis 
The role(s) of RTKs in carcinogenesis have been increasingly characterized over the last decade, 
in particular, with recent research demonstrating that tumor cell EphA2 expression levels may  
correlate with disease progression to metastasis [7, 17, 18, 64].  Metastasis is the process 
whereby cancerous cells leave their tissue of origin; invade the extracellular matrix and traffic 
via either the lymphatics or the bloodstream to distal tissue sites.  Metastatic cancer is most 
deadly and a difficult form of disease to effectively treat. 
 
A foundational study linking EphA2 and tumorigenesis was performed by Zelinski et al [62], in 
which enforced overexpression of EphA2 (via transfection of specific cDNA) was shown to be 
sufficient to promote transformation of mammary epithelial cells, allowing them to form 
invasive tumors/metastases in immunecompromised (athymic) mice.  EphA2 cDNA transduced 
cells exhibited defects in adhesion, EphA2 subcellular distribution, and decreased P-Tyr content 
of EphA2, all of which were reminiscent of the phenotype observed for metastatic breast cancer 
cells [48]. The noted transforming capacity of overexpressed EphA2 appeared related to the 
inability of transgenic EphA2 to interact appropriately with its natural ligand, ephrin-A1. 
However, artificial stimulation of EphA2 was able to reverse the growth and invasiveness of 
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EphA2-transformed cells in this model. This suggests that similar manipulations may be 
effective in the clinical management of EphA2+ cancers.   
 
In addition, enforced overexpression of the EphA2-associated PTP, LMW-PTP, was found to be 
sufficient to transform normal epithelial cells in vitro [71], with LMW-PTP acting as a positive 
regulator of tumor onset and progression in in vivo animal models.  This supports the oncogenic 
potential of LMW-PTP, likely via its ability to efficiently dephosphorylate EphA2, leading to 
EphA2 accumulation [26].  Since tyrosine phosphorylation of EphA2 is not necessary for its 
intrinsic enzymatic activity,  non-phosphorylated, overexpressed EphA2 may serve as a potent 
oncoprotein [26, 48, 62, 66]. 
 
While the detailed mechanism(s) by which overexpressed, hypophosphorylated EphA2 promotes 
malignant transformation remain poorly-defined, one may speculate that this phenotype is 
associated with altered cell adhesion properties (i.e. disruption of E-cadherin and integrin 
binding, [47, 100, 106]).  Additionally, since EphA2 activation via ligand-binding may inhibit 
the MAPK pathway (important for cellular responses to growth factors), the state of EphA2 
hypophosphorylation in cancer cells may be linked to enhanced growth potential [81, 92-94], 
although this conclusion remains somewhat controversial. When taken together, it is likely that 
cellular overexpression/hypophosphorylation of EphA2 results in an abnormal distribution of this 
RTK, disruption of cell-to-cell contacts, and an enhancement in cell-to-extracellular matrix 
attachment, yielding cells with increased motility and invasive properties. The hypothetical 
role(s) of the EphA2/ephrinA1 system in tumor cells is summarized in Figure 3.  
 
1.5.4. Angiogenesis 
As tumors increase in size, they require more nutrients and oxygen for their continued and 
sustained growth.  The inability of progressive tumors to gain access to a new blood supply puts 
the tumor at risk of reaching a growth maxima, above which anoxia and necrosis are likely to 
occur. Hence the successful tumor microenvironment is conducive to neoangiogenesis [109].  
Establishment of neo-vascular vessels also provides primary solid tumors portals through which 
they may metastasize and eventually colonize distant sites. Indeed, neoangiogenesis has been 
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correlated with metastasis and poor-prognosis in several cancers, including breast and pancreatic 
carcinomas [110, 111]. 
 
Many factors, including EphA2 and its ligands, have been implicated in the process of 
angiogenesis.  EphA2, along with its ligand ephrin-A1, are expressed in growing neovessels 
found in breast tumors and sarcomas [112], and EphA2-deficient endothelial cells fail to become 
incorporated into nascent tumor microvessels in vivo [113].  While ephrin-A1 (i.e. EphA2-
ligand) is expressed in both tumor and normal vascular endothelial cells, EphA2 appears to be  
differentially expressed by tumor-associated vascular endothelial cells [114]. Notably, EphA2 
overexpression in both tumor cells and tumor-associated endothelial cells has been linked to 
higher lesional vascularity/angiogenesis and poor clinical outcome in the setting of renal and 
ovarian carcinoma [7, 115]. Soluble EphA2 receptor, which antagonizes EphA2-mediated 
signaling, inhibits VEGF-mediated and ephrin-A1-mediated angiogenesis, and can antagonize 
tumor neoangiogenesis [116, 117] and growth in vivo [114, 118, 119].  Thus, therapeutic agents 
designed to antagonize the expression/function of EphA2 have two potential clinically-
meaningful target cell types; EphA2+ tumor cells themselves and EphA2+ tumor-associated 
neovessels. 
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Figure 3. Hypothetical role of the EphA2/ephrinA1 system in solid tumor cells. 
EphA2 becomes overexpressed possibly due to increased gene expression or a lack of ephrinA1-
induced receptor down-regulation. Tumor cell overexpressed EphA2 protein is frequently non-
phosphorylated and the phenotype is associated with cells exhibiting increased migration, 
invasiveness and malignancy. The binding of ephrinA1 causes receptor phosphorylation and 
subsequent down-regulation of receptor, both of which likely contribute to the tumor-suppressing 
effects of the ligand in tumor cells. (−P), nonphosphorylated; (+P), phosphorylated; PTP, protein 
tyrosine phosphatase.  
 
 
 
 
1.6. Therapeutic Approaches Targeting EphA2 
1.6.1. Interventions Targeting EphA2 Activation/Degradation 
1.6.1.1. Anti-EphA2 Antibodies 
Carles-Kinch et al. were the first to report that an agonist anti-EphA2 antibody could reverse the  
aggressive phenotype of EphA2+ tumors [66]. They generated monoclonal antibodies to 
extracellular domain of EphA2, and found that a subset of EphA2 monoclonal antibodies (mAb) 
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induced EphA2 phosphorylation, followed by the internalization and destruction of EphA2 
protein. Notably, monoclonal antibodies identified a conformationally distinct determinant that 
was differentially expressed by tumor cell-associated EphA2 versus normal cell-associated 
EphA2.  These mAbs were effective in inhibiting human tumor growth in xenograft models, in 
concert with decreased EphA2 protein expression levels and an increased apoptotic index in 
treated tumor lesions [66, 120, 121].  Given their specificity for EphA2 expressed on malignant 
cells, such antibodies have significant potential for clinical benefit, and lessen concern regarding 
untoward toxicity directed against normal EphA2+ tissues. In addition, combinational therapies 
implementing EphA2 agonistic antibodies and chemotherapeutic drugs (such as paclitaxel or 
tamoxifen) may be readily envisioned, as this regimen has been reported to yield superior tumor 
growth inhibition versus either single modality, when assessed in pre-clinical models [122, 123]. 
Such results may be dependent on the relative dominance of EphA2-dependent oncogenic 
processes in tumor cells, however, since a contradictory report suggests that at least in some 
models, agonist anti-EphA2 Abs have little impact on tumor growth [124].        
 
1.6.1.2. Ephrin-A1 Fc 
Ephrin-A1 Fc is a dimerized version of ephrin-A1 fused to human immunoglobulin G (IgG) Fc.  
In vitro experiments suggest that EphA2 ligation by ephrin A1-Fc results in EphA2 
phosphorylation, and consequent degradation of this RTK in concert with reduced tumor growth 
[23, 100]. To investigate the impact of sustained ephrin-A1 delivery on tumor cells in vivo, 
adenoviruses encoding secreted forms of ephrin-A1 Fc have also been investigated [125]. Noblitt 
et al. showed that adenoviral delivery of ephrin-A1 Fc (i.e. rAd.ephrin-A1) into breast cancer 
cells increases the degree of EphA2 activation and degradation, along with inhibited tumor 
growth in vitro. Furthermore, they demonstrated that intra-tumoral injection of rAd.ephrin-A1 
limited human tumor growth in xenograft models [125, 126]. With regard to their potential 
clinical utility, one concern in using ephrin-A1 Fc (protein or gene constructs) as a therapeutic 
agent reflects the fact that ephrin-A1 serves as a ligand for multiple Eph receptors (i.e. EphA4, 
EphA5, EphA6 and EphA7 in addition to EphA2), which may increase chances of unanticipated 
toxicities. While no gross toxicities were noted in the reported xenograft model [125], further 
safety studies prior to clinical translation of this agent would appear warranted. 
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1.6.1.3. Peptide Mimetics 
Koolpe et al. employed a phage display approach and identified two peptides that bind 
selectively to the extracellular domains of EphA2 and antagonize ephrin ligand binding [127].  
One of these peptides stimulates EphA2 tyrosine phosphorylation and signaling, suggesting the 
potential therapeutic utility of this peptide, based on analogy to similar effects mediated by either 
agonist anti-EphA2 mAb or ephrin-A1 Fc. In addition, they found that this peptide targets the 
delivery of phage particles to EphA2+  cells, suggesting  potential therapeutic value in selectively 
delivering therapeutic agents to EphA2+  tumor sites [127].  
 
1.6.2. Interventions Targeting EphA2 Ligands 
Soluble EphA2-Fc, a chimeric receptor of EphA2 fused with an IgG Fc fragment, antagonizes 
EphA2 signaling, and has been found to inhibit VEGF-mediated and ephrin-A1-mediated 
angiogenesis.  Local or systemic administration of soluble EphA2 inhibits tumor angiogenesis, 
growth [114, 118], and even metastasis [119] in in vivo tumor models.  Interestingly, VEGF 
induces ephrin-A1 expression, which in turn activates EphA2-dependent angiogenesis [117]. 
Hence soluble EphA2 would be anticipated to suppress tumor-associated VEGF-, but not basic 
fibroblast growth factor (FGF)-, induced angiogenesis [117].  With regard to safety concerns, 
soluble EphA2 significantly inhibits pathologic retinal angiogenesis without affecting normal 
intraretinal vessels [116], suggesting that this agent may not inflict untoward toxicity on normal 
EphA2+  tissues.   
 
1.6.3. Gene Silencing by siRNA 
Since most human cancers, including RCC, overexpress EphA2, EphA2 gene silencing is a 
plausible therapeutic strategy to reverse malignancy.  A limited cohort of recent studies suggest 
that application of EphA2 siRNA suppresses EphA2 protein expression and cellular 
invasiveness, and that systemic administration of EphA2 siRNA retards tumor growth and 
inhibits metastasis in vivo [99, 124, 128, 129] via the induction of tumor cell apoptosis mediated 
via caspase 9 activation [129].   
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In addition to targeting the EphA2 gene, one may consider targeting PTPs linked to EphA2 
expression/function, i.e. LMW-PTP, SHP2. By reducing the overexpressed levels of these PTPs 
in tumor cells, one might anticipate the normalization of pEphA2 levels and consequent EphA2 
protein degradation. Our own preliminary data demonstrated that LMW-PTP silencing with 
siRNA reduced EphA2 protein expression of metastatic RCC cells (Wesa et al., Manuscript in 
preparation, 2009), suggesting the possibility for an alternative therapeutic method.   
 
1.6.4. EphA2-based Vaccines 
Seven human leukocyte antigen (HLA)-A2 binding and three HLA-DR4 binding peptides 
derived from EphA2 have been identified by our group and by Alves et al. [8, 130]. These 
peptides are immunogenic, being recognized by CD8+ or CD4+ T cells generated from normal 
donors or cancer patients bearing the appropriate HLA types, and by CD8+ T cells developed in 
HLA-A*0201-transgenic HHD mice [8, 130].  In all cases, T cell lines and clones produced 
using EphA2 peptides as a stimulus also recognized EphA2+, HLA-matched tumor cell lines, 
including RCC.  This supports the natural processing and MHC presentation of these epitopes on 
the plasma membrane of tumor cells, in a manner that allows for effector T cell reactivity (i.e. 
interferon-γ production, cytolysis). Such EphA2-specific T cells have been identified in the 
peripheral blood of patients with RCC [8], prostate cancer [130] or glioma [131, 132], suggesting 
that these responses may be naturally-primed during cancer progression. In RCC patients, we 
observed that anti-EphA2 CD4+ and CD8+ T cells were most pronounced in patients that had no 
evidence of disease after therapy or that were long-term survivors in the face of limited tumor 
load [8].  In the anti-EphA2 reactive CD4+ T cell compartment, we noted that T cells isolated 
from patients with active disease were more prone to produce Th2- or Treg-associated cytokines, 
such as IL-4, IL-5 and TGF-β, while patients without disease, or those with better clinical 
outcomes, were more biased towards Th1-type cytokine production (i.e. IFN-γ). The lack of Th1-
type T cells reacting against EphA2 in RCC patients with active disease may reflect the high 
frequency of pro-apoptotic T cell in these populations (Wesa et al., Manuscript in preparation, 
2009). This suggests that therapeutic/protective EphA2+ cancer vaccines may need to expand, 
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appropriately polarize (i.e. Type-1) and protect anti-EphA2 T cells against tumor-induced 
immune-deviation and death.         
 
In this regard, active vaccination against EphA2, in order to elicit and sustain specific T cells is a 
logical endpoint that would be anticipated to provide clinical benefit in EphA2+ cancer patients.  
Regardless of whether an EphA2 peptide, recombinant protein or gene vector (plasmid, viral or 
bacterial) is contemplated as a therapeutic agent in the setting of EphA2+ cancers, their 
application in the context of a DC-based vaccination would be attractive, given the ability of the 
this antigen presenting cell type to prime, polarize and extend the survival of antigen-specific T 
cells [133, 134].  Indeed, Hatano et al. recently demonstrated that DC pulsed with murine EphA2 
peptide epitopes effectively elicit specific CTL responses in vivo that are capable of inhibiting 
syngenic tumor progression in C57BL/6 mice [63]. While there remains a theoretical concern 
that vaccination with EphA2-derived peptides may induce pathologic autoimmune reactions in 
normal EphA2+ tissues (i.e. lung, spleen, kidney and liver), these organs were not infiltrated by T 
cells, nor was tissue pathology observed in vaccinated animals [63] (Komita et al., Manuscript in 
preparation, 2009).  This may reflect greater densities of EphA2 epitopes presented on the 
surface of tumor cells versus normal tissues, with T cells exhibiting moderate avidity only able to 
functionally respond to tumor cells. Under such conditions, while flirting with potential 
autoimmune toxicities that warrant further scrutiny, this type of vaccine may ultimately prove 
both safe and clinical effective.   
 
 
 
 
1.7. Cancer Immunity 
1.7.1. Immunosurveillance: Immune response to cancer 
Cancer immunosurveillance is a hypothesis proposed by Burnet and Thomas [135], some fifty 
years ago, which posits that the immune system protects the host against the development of 
cancers of non-viral origin. This theory was largely discarded until the 1990s due to the lack of 
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appropriate mouse models that allowed for its detailed inspection, however, many recent studies 
support the working paradigm of  immunosurveillance [136-138].  One of the first definitive 
studies, performed by Shankaran et al., showed that RAG2−/− mice (lack T cell, B cell, and 
NKT cell) had higher risks of developing spontaneous carcinoma, as well as, carcinogen-induced 
sarcomas [139].  Subsequent studies employing various strains of immunodeficient mice (with 
defects in innate and/or adaptive immunity) revealed that these animals indeed develop 
spontaneous and carcinogen-induced tumors at a higher rate than their immunocompetent 
counterparts [138]. Furthermore, in humans, a correlation between the number of tumor 
infiltrating lymphocytes (TILs) and better prognosis has been reported for a broad range of 
tumors [140]. The observation that patients with severe deficits of immunity are more likely to 
develop tumors of non-viral origin provides strong support to the generalized 
immunosurveillance theory [141, 142]. 
 
The current consensus regarding immunosurveillance is that there is continuous cross-talk 
between cancer cells and the immune system throughout tumor growth/development which 
occurs within the tumor site, as well as, in the tumor draining lymph node(s) [136, 138, 143]. 
Such operational reciprocity is reflected in: i.) temporal changes in the antigenic repertoire 
expressed by tumor cells; ii.) the disruption of local tissue homeostasis by infiltrating 
macrophages, NKT cells and NK cells; iii.) local inflammation, then recruitment of DCs that 
may acquire tumor antigens and traffic to draining lymph nodes where they may “crossprime” 
antigen-specific T (effector) cells and B (antibody-producing) cells; and iv.) recruitment of 
primed immune cells into the tumor microenvironment where they may mediate direct killing of 
tumor cells and elaborate chemokines/cytokines that facilitate killing of tumor cells and further 
infiltration of tumor lesions by host innate and adaptive immune cells [136, 138, 143]. Under 
such re-iterated rounds of immune attack, cancer cells may be eradicated, or alternatively they 
may accumulate genomic/proteomic alterations that permit escape from immune 
detection/clearance.  
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1.7.2. Immunoevasion 
The evolution of a more malignant cancer cell phenotype under selective immune pressure 
supports the theory that superior immunotherapeutic results will be gained with early disease 
detection and the treatment of early-stage disease, at a time when low numbers of (less 
aggressive) cancer cells may be most effectively managed by host immunity. This is also 
consistent with the overall immune responsiveness of patients, which has been perceived as 
“normal” in early-stage disease, but which frequently exhibits immunosuppressed 
behavior/exhaustion at later stages of disease [144, 145].  
 
There is a broad range of genetic alterations in tumor cells that have been linked to 
“immunoevasion”.  For instance, tumor cells may develop insensitivity against interferon γ 
(IFNγ) produced by DCs, NK cell and T cells [146].  IFNγ is known to exert multiple functions 
on tumor cells, including direct antiproliferatic/apoptic effect on tumor cells, sensitization of 
tumor cells for death receptor-mediated apoptosis and enhancement of recognition by T cells 
through upregulation of MHC class I and II and induction of immunoproteasome as well as other 
members of the MHC antigen-processing machinery (APM) [147]. Loss of TRAIL (death 
receptor signaling) expression has also been observed to contribute to tumor cell survival in the 
face of active immunity [148].   
It has now been well-established that tumor cells down-regulate many molecules involved in the 
processing and presentation of antigenic peptides in MHC class I complexes [149-151]. For 
example, high variability in expression has been reported for human leukocyte antigen (HLA)-
class I expression among ascitic cells from ovarian carcinoma, and for transporters associated 
with antigen processing (TAP) and β-2 microglobulin (β2m) on tumor cell lines [152].  Tumors 
exhibiting low levels of MHC class I expression may conversely be  targeted by natural killer 
(NK) cells, however, tumor cells may also shed tumor associated stress-induced ligands (MICA 
and MICB), which can bind to activating NK cell receptors, such as NKG2D, and serve as 
antagonists for tumor lysis [153].   
In addition, tumor cells may acquire expression of T cell death/inhibitory inducing molecules 
such as FasL and B7-H1, among others. Colon tumors have been reported to constitutively 
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express FasL which may interact with Fas expressed on T cells, thus depleting tumor-infiltrating 
lymphocytes via the induction of their apoptotic death [154]. B7-H1, a co-stimulatory molecule 
that can also inhibit activated PD-1+ effector T cells, has also frequently been found to be 
expressed on tumor cells in situ [155].   
Besides intrinsic tumor changes that allow for immunoevasion, tumor cells may also develop 
mechanisms to prevent the initial activation/priming of anti-tumor T cells by interfering with 
antigen-presenting cell function(s). CD8+ T cell stimulation by (tumor-conditioned) immature 
DC causes the CD8+ T cells to hyporesponsive/anergic T cells in the tumor-draining lymph-
node. This result has been suggested to depend on tumor cell elaboration of suppressive (to DC) 
mediators including vascular endothelial growth factor (VEGF), prostaglandin (PG)-E2, IL-10 
and TGF-β [156]. In addition, unidentified tumor-derived factors modulate phosphorylation 
levels of signal transducers and activators of transcription (STAT)-3 and indoleamine 2,3-
dioxygenase (IDO) expression in DCs [157, 158], resulting in so-called “tolerogenic” DC. IDO 
enzymatically depletes tryptophan, resulting in T cell anergy and in the apoptotic death of 
activated T cells due to the production of toxic metabolites, including kynurenines. Constitutive 
expression of IDO by tumors has also been reported and found to negatively impact T cell 
vitality and function within the tumor microenvironment. 
Accumulation of T regulatory cells (Tregs: CD4+CD25+) within tumor sites and draining lymph 
nodes also supports immnoevasion. Tregs control immunological tolerance to self-antigens by 
impeding the generation and activation of effector T cells, and which results in the suppression 
of anti-tumor T effector cells [159, 160]. Tumor cell-produced TGF-β induces the differentiation 
of naïve CD4+ T cells into Tregs, and interestingly, tumor cells may release chemokines, such as 
CCL22 and SDF-1, which attracts Tregs into tumor sites in vivo [161]. 
In addition to tumor cells themselves, certain myeloid lineage cells residing in the tumor stroma 
may down-modulate immune responses and/or directly support tumor growth. The myeloid 
derived suppressor cells (MDSCs), discovered by Bronte et al. as a population of cells 
expressing the markers Gr1 and CD11b [162], produce immunosuppressive factors such as nitric 
oxide and reactive oxygen species which suppress the proliferation of CD4+ and CD8+ T cells 
and inhibit the function of CD56dim NK cells [163]. Moreover, tumor-associated macrophages 
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(TAMs) are known to release pro-tumoral cytokines, such as IL-4, IL-13 and IL-10 that 
contribute to depress Type-1 T cell responsiveness that is required for effective regulation of 
tumor growth [164].  
 
1.7.3. Immunotherapy 
Over the past decade, immune therapies, such as monoclonal antibodies, immune adjuvants, and 
vaccines against oncogenic viruses, have become a standard treatment for a variety of cancers 
[165].  Fueled by these successes, various modes of immunotherapy have been intensively 
investigated for cancer patients.   
Monoclonal antibody has proven a successful mode of immunotherapy against cancer. Nine 
monoclonal antibodies, targeting six tumor-associated proteins, have been licensed for the 
treatment of cancer [165, 166]. Five of these antibodies bind surface proteins (CD52, CD33 and 
CD20) that are highly-expressed on hematologic tumors. The remaining 4 antibodies target 
either RTK or its ligand; EGFR (Cetuximab, Pantitumumab), Her2/neu (Trastuzumab), or 
VEGF. Infused monoclonal antibodies mediate direct effects against the cancer 
microenvironment and are minimally impacted by active suppression mechanisms in place 
within tumor lesions. Abs recognize “tumor-associated” antigens expressed by tumor cells or 
cells within the tumor-associated stroma without being “restriction” by MHC molecules (as in 
the case of T cells), and therefore, Abs may be applied to all patients regardless of their HLA 
type. By binding to their respective target proteins, antibodies exercise their functions through 
several mechanisms, including steric inhibition and neutralization, complement activation 
leading to direct cytotoxicity of tumor cells, and activation of antibody-dependent cellular 
cytotoxicity (ADCC) mediated by FcR+ effector cells.  Due to their high-degree of specificity 
and general safety profiles, a variety of antibodies are now being investigated as second 
generation agents designed to productively modulate anti-tumor immune cells that would 
otherwise be impaired in cancer patients. Targets for therapeutic Abs include negative regulatory 
receptors on immune cells (CTLA-4 and PD-1; [167, 168]), immunosuppressive cytokines (IL-
10, TGF-β; [169, 170]), TNF family costimulatory receptors (GITR, OX40, CD137, CD40; [171, 
172]), and regulatory T cells (CD25, CCL22, CCR4, IL-35; [173]).  
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Another class of immunotherapies involves the local (paracrine) administration of immune-
activating agents (adjuvants) which induce tumor-associated inflammation and protective 
immunity. BCG is currently used for superficial bladder cancer as standard of care, and TLR7 
agonist imiquimod is approved for the treatment of some type of tumor [165].  A next generation 
of immune adjuvants, including TLR9 agonists has also been extensively evaluated and shown to 
mediate considerable efficacy in preclinical models [174].  
Vaccines continue to represent a primary modality for cancer prevention and treatment.  While 
prophylactic vaccination against hepatitis B virus (HBV) and human papilloma virus (HPV) are 
approved for use in patients with hepatocellular carcinoma or cervical cancer, respectively, the 
development of effective therapeutic cancer vaccines targeting tumor histologies that exhibit no 
known viral etiology remains a substantial challenge [165].  Many strategies for generating 
therapeutic immune responses to cancer have been extensively investigated. Of these, DC-based 
vaccines are now considered as one of the most promising methods by which to stimulate T cell 
mediated immunity.  The vaccines typically consist of autologous monocyte-derived DCs loaded 
ex vivo with antigenic peptides, proteins, or gene vectors ([175, 176]) that are then administrated 
i.v., s.c., i.l., or i.t. to induce antigen specific T cell responses. DC-based vaccines have been 
shown to increase circulating levels of tumor specific T cells in the majority of patients analyzed 
in clinical trials, however, the objective clinical responses noted in these phase I/II evaluations 
have been modest (i.e.  less than 10%; [177]).  
A concept that has now gained wide-acceptance in the field of cancer vaccine research is that 
vaccine monotherapy is unlikely to deliver the necessary stimulus to generate robust and long-
lasting (memory) immune responses that are competent to overcome tolerance, immune escape 
and the immunosuppressive microenvironment of the tumor. Thus, the synergy of vaccines and 
existing (chemo)immunotherapies are envisioned to lead to superior clinical benefits [178, 179].  
 
While technically laborious and costly, adoptive T cell transfer represents another currently en 
vogue modality of immunotherapy that may (at least temporarily) circumvent 
immunosuppressive mechanisms prevalent in cancer patients. Tumor-specific cytotoxic T cells 
(CTLs) are commonly generated/expanded in vitro by repetitive stimulation of peripheral blood 
mononuclear cells with antigen-presenting cells (APCs) “presenting” tumor antigens of interest. 
 28
CTL lines have traditionally been cultured in the medium containing IL-2 to support T cell 
survival and proliferation.  The T cells recovered late in these cultures, however, develop a 
terminal effector phenotype characterized by poor proliferation, low IL-2 production, reduced 
survival in vivo, and an inferior ability to traffic into tumor sites in vivo [180, 181]. 
Accumulating evidence now favors the transfer of memory T cells which exhibit enhanced 
survival, proliferative potential and ability to home into lymphoid tissues, where they may then 
respond to tumor antigens cross-presented by endogenous APC.  Cytokines which support 
memory T cell generation (IL-7, IL-12, IL-15, and IL-21) are also now being considered as 
supportive factors to be co-applied along with T cell transfer in cancer patients [182, 183]. The 
relative importance of sub-classes of memory T cells (TCM and TEM) to anti-tumor efficacy has 
not yet been conclusively demonstrated, and both subsets of T cells have been reported to confer 
some degree of protection in different tumor models [182-185].  
 
Another important aspect of the conventional adoptive T cell transfer approach is that it relies on 
the endogenous anti-tumor reactivity of the transferred CTLs.  Isolated and ex vivo expanded 
tumor associated antigen (TAA)-specific T cells, however, frequently possess low-
affinity/avidity T cell receptors (Tars) and are less effective at killing tumor cells expressing 
modest levels of TAA-derived antigens and/or MHC complexes. To circumvent these 
limitations, genetical modifications of T cells with receptors capable of recognizing low levels of 
TAA/MHC complexes on the tumor cell surface have been studied. Such engineered T cells 
express TCR from high-affinity TAA-specific T cell clones, or chimeric antigen receptors that 
recognize tumor through single-chain variable fragments (scFv) of TAA-specific antibodies 
[186, 187].  
 
 
 
 
1.8. CD8+ Cytotoxic T cell-Mediated Immunity 
Many studies have been performed to identify the importance of CD8+ T cell mediated immunity 
to cancer prevention/regression. Antibody-mediated depletion of CD8+ T cells in both 
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fibrosarcoma and lymphoma models showed that these lymphocytes are critical for controlling 
tumor growth and progression [139, 188]. Activated, effector T cells have been shown to be 
capable of infiltrating tumors in both mice and humans.  For example, CD8+ T-cell infiltration 
has been shown to occur in primary cutaneous melanoma lesions [189] and in lymph node (LN) 
metastases [190] in association with a better clinical prognosis. In the vast majority of cases 
evaluated,  CD8+ cytotoxic T cell (CTLs) are considered as the key effector cells required to 
eliminate tumor cells in vivo [191, 192]. These T cells are commonly referred to as cytotoxic T 
lymphocytes (CTL) due to their potent killing activities. 
 
1.8.1. Generation and Functions Mediated by CD8+ Cytotoxic T cells 
The generation of effector CTL, development of effector function and clonal expansion, requires 
multiple signals contributed by APC and the immediate tissue microenvironment [193, 194]. 
Signal 1 is delivered through TCR/MHC interactions and provides specificity to the response, 
since only T cells that can recognize antigen in the context of MHC class I can be activated. 
Signal 2 is delivered by interaction of a variety of costimulatory molecules expressed on 
activated DCs (e.g. CD80 and CD86) and CD8+ T cells (CD28), and dictates the fate of the 
response (activation/tolerance) providing a regulatory mechanism. Delivery of signal 1 without 
sufficient costimulation is thought to lead to functional tolerance, while inhibitory costimulatory 
molecules, such as CTLA-4 and PD-1, play a role in the active suppression of CTL responses.  
Signal 3 is required for the development of optimal CTL responses and is delivered by cytokines 
(such as IL-12, Type-1 IFN) or by inflammatory signals supplied by TLR ligands or alternate 
“danger signals”.   
 
Following stimulation with Signals 1-3, naïve CD8+ T cells may quickly differentiate into 
activated effector CD8+ T cells as defined by their production of IFNγ, cytolytic function, or both.  
Highly-activated effector T cells exhibit the capacity to traffic into tumor sites, while memory T 
cells display enhanced survival, proliferative potential and the ability to home to lymphoid 
tissues where they may respond to tumor antigens cross-presented by APC.  Memory T cells may 
be further categorized into two populations, central memory T cells (TCM) and effector memory 
T cells (TEM), based on their differential expression of the lymphoid homing markers CCR7 and 
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CD62L [195]. CD8+ TEM cells secrete IFNγ and TNFα, while CD8+ TCM cells secrete IL-2 in 
addition to IFNγ and TNFα. It still remains controversial whether the transition of activated 
effector T cells to TEM cells and TCM cells is linear, as appears to be the case for CD4+ T cells, or 
whether both populations arise and are sustained independently [196, 197]. Continued (chronic) 
antigenic stimulation of CD8+ T cells can lead to the terminal differentiation of effector cells, 
which only produce IFNγ, and are destined for senescence. Terminally-differentiated effector T 
cells display impaired proliferation/survival and poor migration to lymphoid tissues, and given 
these deficiencies, these cells may not represent an optimal population for use in adoptive 
transfer therapies [182, 194, 198].   
 
Effector CD8+ T cells recognize target cells in an antigen- and MHC class I-restricted manner 
and then mediate target cell death via apoptotic/necrotic pathways. Apoptosis is considered a 
major mode of target cell death and can be induced by three pathways [199, 200]; 1) granule-
dependent exocytosis pathway, 2) Fas-FasL intercellular linkage-mediated pathway, and 3) 
cross-linking of TNF and TNFR type I. In the first pathway, lytic molecules such as perforin, 
granzymes, and granulysin are exocytosed into the extracellular space between a CTL and a 
target cell.  Three models are currently proposed for internalization of those molecules, in which 
perforin and granzyme receptor play critical roles [199, 200]. Once released into the cytoplasm 
of the target cell, granzyme B can initiate apoptotic cell death through the direct cleavage of pro-
caspase-3 or, indirectly, through caspase-8 activation. In addition, cleavage of BID results in 
mitochondrial dysfunction which can lead to necrotic death and the release of factors mediating 
caspase-independent cell death. In the second pathway, the interaction of the FasL-trimer on the 
CTL membrane with target cell-expressed Fas induces the trimerization of Fas-associated death 
domain (FADD) molecules of target cell that recruit procaspase 8 or 10. This results in the 
activation of caspase-8 and eventually leads to the activation of caspase-3, which degrades 
chromosomal DNA resulting in target cell death. The third pathway follows a similar mechanism 
using the Fas-FasL pathway after trimerization of TNF receptor (TNFR) on the target cell 
membrane.  
 
In addition to the direct killing activity mediated by CTLs, IFNγ produced by CTLs may also 
exert beneficial anti-tumor effects by promoting DC differentiation/maturation, enhancement of 
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NK cell activity, and induction of Th1-type immune responses [147].  Furthermore, IFNγ may 
exert anti-proliferative/pro-apoptotic effects in treated tumor cells, and may sensitize tumor cells 
for death receptor-mediated apoptosis and enhanced recognition by T cells based on its ability to 
upregulate MHC class I and II expression and/or the MHC class I/II APM [147, 201].  
 
1.8.2. MHC class I Antigen Presentation Pathway 
Major histocompatibility complex (MHC) class I molecules are constitutively expressed by 
virtually all nucleated cells and they present peptides of 8 to approximately 12 amino acids in 
length to CD8+ T cells. Essential components for the formation of peptide-MHC class I complex 
(pMHC) are called as MHC class I antigen-presenting machinery (APM), including at least 
proteasome, ERP1/ERAAP, transporter associated with antigen presentation complex (TAP, 
heterodimer of TAP1 and TAP2), general ER chaperones and tapasin [202].  Two distinct 
pathways, direct and cross-presentation pathways, are well known for MHC class I restricted 
peptide presentation (Figure 4) [202, 203].  To initiate a protective CTL response toward tumors, 
the antigens derived from tumor cells must be processed and presented by professional antigen-
presenting cells (APC) in the context of MHC class I molecules via cross-presentation pathway, 
since tumor cells are generally considered to be poor APCs due to defects in MHC molecule 
expression and/or a skewed balance towards co-inhibitory over co-stimulator molecule 
expression. On the other hand, to exert effector function, tumor specific CTLs need to recognize 
tumor cells in the form of (endogenously synthesized) tumor peptides presented by MHC class I 
through the direct presentation pathway. 
 
Most somatic cells have the capacity to present endogenous peptides in the context of MHC class 
I molecules. Endogenous proteins are degraded by the proteasome into peptides in the cytosol, 
which may then be transported by the TAP complex into the endoplasmic reticulum (ER) for 
loading into newly-synthesized MHC class I molecules (composed of the class I heavy chain and 
non-covalently bound β2-microglobulin). Peptides may be trimmed by an ER-associated 
aminopeptidase (ERAAP or ERAP1) to a preferred (MHC class I) loading length of 8–10 amino 
acids.  Essential molecules for optimal peptide loading into MHC class I complexes include TAP, 
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tapasin, calreticulin and ERp57 [204-206]. Fully-assembled class I molecules are then 
transported through the Golgi to the cell surface.  
 
The degradation mechanism of newly-synthesized and mis-folded proteins (known as the ER-
associated degradation (ERAD) pathway), is currently under intense investigation as a major 
conduit through which endogenous proteins may be delivered back into the cytosol to serve as a 
source of MHC-presented peptides. The current ERAD paradigm suggests that proteins that fail 
to achieve their correct (native) conformations may be ubiquitinylated and retrotranslocated from 
the ER back into to the cytoplasm, where they face degradation by the proteasome [203, 207]. 
This retrotranslocation pathway has also recently been reported to play a role in the ability of DC 
to cross-present antigenic peptides to responder CD8+ T cells [208, 209]. Exogenous antigens are 
first phagocytosed, endocytosed (via specific or scavenger-type receptors), pinocytosed, or 
macropinocytosed by APC. During formation of the phagocytic cup (a structure formed at the 
base of the phagocytic substrate during the initial stages of phagocytosis), ER fuses with the 
nascent phagosome to form early phagosomes that contain ER proteins, including all the 
components required for MHC-I antigen presentation (e.g. TAP, tapasin, MHC-I), ubiquitin-
conjugating enzymes and translocon (proteins associated with translocation such as Sec61). 
From here three alternative routes have been discovered [209]. In the phagosome–cytosol–ER 
route, the antigens are transferred to the cytosol by the translocon, ubiquitinated and processed 
by the proteasome, in a mechanism resembling ERAD.  The degraded peptides are then 
transported to the ER by TAP and loaded onto MHC-I. In the vacuolar route, the antigen does 
not leave the phagosome, but is instead processed by enzymes within the phagosomal lumen and 
then loaded into new or recycled MHC class I molecules. In the phagosome–cytosol–phagosome 
route, antigens are exported to the cytosol, ubiquitinated, processed by the associated 
proteasomes, and then transported back into the same phagosome by TAP, where they may be 
loaded into MHC class I complexes. 
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Figure 4. Major histocompatibility complex (MHC) class I presentation pathways. 
In the direct presentation pathway, endogenous proteins are degraded by the proteasome into 
peptides within the cell cytosol, which are then transported by the TAP complex into the 
endoplasmic reticulum (ER) for loading into newly synthesized MHC class I molecules. Fully-
assembled (mature) class I molecular complexes (consisting of the MHC class I heavy chain, 
non-covalently bound β2-microglobulin and peptide) are then transported through the Golgi to 
the cell surface. In the cross-presentation pathway, exogenous antigens are first phagocytosed, 
endocytosed (via specific or scavenger-type receptors), pinocytosed, or macropinocytosed by 
APC. During the formation of the phagocytic cup, the ER may fuse with the nascent phagosome 
to form early phagosomes that contain ER proteins, including all the components required for 
MHC class I antigen presentation (e.g. TAP, MHC-I), ubiquitin-conjugating enzymes and the 
translocon. Subsequently, internalized antigens in early phagosomes may transferred to the 
cytosol or remain in the phagosome, whereas antigenic peptides generated by proteolysis in these 
compartments may be loaded into nascent/recycled MHC class I complexes that are transported 
to the cell surface. PLC: peptide loading complex.  
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Both the direct- and cross-presentation pathways rely on the cleavage of polypeptides by the 
proteasome [210-212]. The subunit composition of the constitutive proteasome varies in different 
tissues [213]. In addition to the constitutive proteasome, professional APCs and most cells 
exposed to IFNγ express the immunoproteasome which contains three different catalytic 
domains. Due to this change in multicatalytic specificity (versus the conventional proteasome), 
immunoproteasomes exhibit an altered cleavage site preference (high activity of cleavage on the 
C-terminal side of hydrophobic or basic residues) as well as a different cleavage rate. The 
immunoproteasome generally favors the production of MHC-binding peptides and its activity 
serves to increase the efficiency of antigen presentation in cells, since the C-terminal anchor 
residues of antigenic peptides are, in most cases, either hydrophobic or basic amino acids [214-
216]. Depending on the specific protein substrate, however, the activity of the 
immunoproteasome can either negatively or positively influence antigenic peptide production. 
Therefore, the repertoire of peptides presented at the cell surface in MHC class I complexes 
depends on the type of proteasome active within that cell’s cytoplasm.  Thus, the preferential 
presentation of certain peptides in APC versus cancer cells in the absence of inflammation is 
only partially overlapping and CTL crossprimed by DC (that have acquired tumor proteins) may 
fail to recognize tumor cells in certain instances [217] .  
 
1.8.3. Tumor Antigens 
Tumor specific antigens (TSA) are antigens expressed endogenously only in cancer cells, which 
typically result from the inherent genetic instability of cancer cells (i.e. they derive from mutated 
proteins or proteins that result from chromosomal translocations, etc.).  TSAs are ideal targets for 
cancer immunotherapy because they are exclusively expressed by the cancer cell but not by non-
malignant tissues, thereby minimizing the risk of autoimmune destruction of normal cells as a 
result of antigen-specific immunotherapy [218]. Due to their unique mechanisms of expression, 
tumor-specific antigens are, however, uniquely expressed in a given patients’ cancer cells or in 
rare cohorts of patients with a given type of cancer. Treatments based on the targeting of TSA 
represent customized therapies that have been traditionally viewed as too costly and time-
consuming to be adopted as a standard of care [218, 219].    
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Tumor-associated antigens (TAA) are generally normal cellular proteins, which due to changes 
in epigenetic control, are expressed in cancer cells and by only a limited range of normal tissues. 
TAAs can be subdivided into four major categories according to patterns of expression [218].  
Oncospermatogonal antigens (cancer-testis antigens) are expressed by cancer cells but are 
normally found on spermatocytes/spermatogonia (i.e. MAGE, GAGE, BAGE and NY-ESO-1). 
Cancer Differentiation antigens are molecules expressed on non-malignant cells of the same cell 
lineage as the tumor (i.e. TRP-1, gp100, MART-1, tyrosinase, CD20 and EpCAM). Oncofetal 
antigens are antigens found on embryonic and fetal tissues as well as certain cancers (i.e. alpha 
fetoprotein, carcinoembryonic antigen CEA and 5T4). Over-expressed antigens are normal 
proteins whose expression is up-regulated in cancer cells (i.e. PSA, wild-type p53, EphA2, 
Her2/neu and EGFR). Many TAAs have been identified and investigated for their use in 
vaccines, however, such vaccines many times have proven imperfect in breaking operational 
tolerance that exists against “self (tumor) antigens”.  
 
In addition to those antigens expressed on tumor cells themselves (i.e. TSA and TAA), it has also 
become feasible to consider the immune targeting of antigens that may be quantitatively or 
qualitatively expressed in a differential manner by cells that make up the tumor stroma.  The 
vascular endothelia, supporting fibroblasts, and infiltrating leukocytes comprising the stroma are 
uniquely conditioned in the hypoxic tumor microenvironment, and contribute to tumor growth 
and invasion. Recent studies suggest that vaccines targeting antigens expressed by such non-
cancerous supportive tissue (i.e. VEGF, VEGF receptor 2, fibroblast activating protein, HBB) 
can effectively eliminate established tumors [220-222], even in cases where tumor cells cannot 
be directly recognized by host T cells. 
 
1.8.4. CD8+ Cytotoxic T cells Specific for Tumor Antigens 
Despite aberrant expression of TAAs in tumor cells, many of these proteins are also expressed at 
some level in non-malignant peripheral adult tissues. Because of this, the immune system may 
recognize TAAs as self-antigens and limit the T cell immune response through physiological 
tolerance mechanisms, both recessively and dominantly (via regulatory T cells).  
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Recessive tolerance, operating at several levels, deletes or functionally inactivates self antigen-
reactive T cells. In the thymus, the ectopic expression of many, otherwise tissue-restricted, self 
antigens leads to clonal deletion, limiting the escape of the high-avidity, naïve T cell repertoire to 
the periphery [223]. Naïve T cell escapees may subsequently be deleted in peripheral lymph 
nodes following encounter with their cognate antigen [224, 225]. If the self antigen is not 
adequately presented by cells in the periphery, T cells escaping all these processes exist in an 
“ignorant” status. Thus, the naïve T cell repertoire may persist if cognate antigens are poorly 
processed and presented by professional APC, and if cognate antigens (i.e. antigenic peptides) 
have a low-intermediate affinity for MHC presenting molecules.   
 
Due to imperfections in tolerance mechanisms, even though most TAA-specific T cells have 
been reported to have moderate-to-low functional avidity, they can be commonly found in 
normal donors and cancer patients. For example, MART-126–35-HLA-A2.1 multimer+ CD8+ T 
cells are detectable in most healthy HLA-A2 donors [226]. HLA-A2+ breast cancer patient and 
healthy donors were shown to possess CD8+ T cells specific for at least one of MUC-1, 
Her2/neu, carcinoembryonic antigen, NY-ESO-1, or SSX-2 derived peptides [227, 228].  In 
addition to Her2/neu, CD8+ T cells specific for other RTKs such as EphA2, EGFR and c-Met, 
have also been identified in the peripheral blood of normal donors and patients with cancer [8, 
130, 229, 230]. Such circulating, anti-TAA CD8+ T cells appear to represent recent thymic 
emigrants [231]. 
 
 
 
 
1.9 Approaches to Increase RTK-derived Epitope Presentation by Tumor Cell MHC 
Class I Complexes 
Interferons have been used extensively in the clinic, in hopes of improving tumor cell antigen 
presentation via the up-regulation of its antigen processing machinery (APM).  However, CD8+ 
T cell recognition of tumor cells in vivo is reported to be only modestly increased as a 
consequence of treatment with interferons, and moreover, interferons do not increase specific 
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antigen presentation in a selective manner. Our lab has been interested in the identification of 
treatment strategies that allow for biased improvement in tumor cell (MHC class I) presentation 
of RTK-derived peptide epitopes, leading to the evaluation of RTKs agonists, PTP inhibitors and 
HSP90 inhibitors (Figure 5). The first 2 modalities manipulate RTK internalization and 
subsequent proteasomal degradation, while the 3rd  modality is based on the prevention of RTK 
folding/maturation by inhibiting chaperone function, leading to the shunting of such mis-folded 
proteins into the proteasome pathway as a clearance mechanism. In all cases, the derivative 
proteasome-generated peptides may serve as an enriched source of epitopes for MHC class I 
presentation to CD8+ T cells. 
 
1.9.1. RTK Agonists and PTP Inhibition 
As described in sections 1.1 and 1.3.1, upon ligand binding, RTKs may become phosphorylated, 
ubiquitinated and internalized within “sorting” endosomes.  Ubiquitinated RTKs are 
subsequently targeted towards a lysosomal compartment for proteolytic degradation, while de-
phosphorylated and/or non-ubiquitinated receptors may be recycled to the cell surface. Recent 
studies, however, demonstrate that polyubiquitinated RTK may also be delivered to the 
proteasome for degradation [15]. In this context, reagents that promote RTK 
activation/internalization in tumor cells have the potential to facilitate the degradation of RTKs 
by enhancing (the normal life cycle of) RTK destruction by the proteasome. The net impact 
would be expected to be a conditional enhancement of RTK-derived peptide presentation within 
MHC class I complexes (i.e. by selectively driving RTK processing via the proteasome, the 
stochastic level of a given RTK peptide would be increased versus peptide derived from alternate 
source proteins) and improved recognition by low-moderate avidity anti-RTK CD8+ T cells.   
   
For example, RTK agonists (antibodies or ligand-Fc fusion protein) or PTP inhibitors would fall 
into this category and promote RTK internalization through direct activation of RTK or through 
inhibition of RTK dephosphorylation, respectively. Consequent proteasome activity could render 
treated tumor cells more sensitive to anti-RTK specific T cells.  Indeed, recent studies have 
reported that anti-Her2/neu antibody (Herceptin) treatment of Her2/neu+ tumor cells promotes 
enhanced sensitivity to Her2/neu-specific CTLs in vitro [232-234]. In addition to anti-Her2/neu 
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antibodies, many antibodies targeting various RTKs have been investigated in tumor models, 
however, their abilities to increase RTK-derived peptide presentation in MHC class I complexes 
have not been studied. 
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Figure 5. Strategies to increase RTK-derived epitope presentation in tumor cell MHC class 
I complexes. 
Three possible reagent groups, that allow for biased improvement in tumor cell (MHC class I) 
presentation of RTK-derived peptide epitopes, are depicted; RTKs agonists, PTP inhibitors and 
HSP90 inhibitors. RTKs agonists and PTP inhibitors promote RTK internalization and 
subsequent proteasomal degradation, while HSP90 inhibitors prevent the salvage of improperly 
folded RTK proteins by inhibiting chaperone function, leading to the shunting of such mis-folded 
proteins into the proteasome pathway as a clearance mechanism. In all cases, the derivative 
proteasome-generated peptides may serve as an enriched source of epitopes for MHC class I 
presentation to CD8+ T cells.         
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1.9.2. HSP90 Inhibition 
Another rational approach to increase the proteasomal degradation of tumor cell-expressed RTKs 
would be through the inhibition of heat shock protein (HSP) 90, a chaperone required in the 
selection process of whether a misfolded “client” protein is recycled or degraded in cells.  HSP90 
is a constitutively expressed molecule that guides the normal folding, intracellular disposition 
and proteolytic turnover of its client proteins (including RTKs, such as Her2/neu and EGFR) 
[235-238]. Furthermore the increased expression of HSP90 by tumor cells has been observed in 
many tumor types and is presumed to allow for mutant/mal-folded client proteins to be retained, 
while permitting tumor cells to better survive the pathologic consequences of imbalanced 
signaling pathways [238-241]. Therefore when HSP90 function is inhibited, we hypothesized 
that overexpressed and misfolded proteins are delivered to the proteasome, degraded, and 
presented by MHC class I through the direct presentation pathway.  
 
1.9.2.1. HSP90 
HSP90 is one of the most abundant molecular chaperones that regulate folding, maturation, 
stabilization, and renaturation of proteins [237, 238]. Unlike other heat shock protein family 
members, which are involved in the general maintenance of protein folding, Hsp90 only interacts 
with a set of proteins, called client proteins (see 
http://www.picard.ch/downloads/Hsp90interactors.pdf).   
 
Multiple HSP90 client proteins are overexpressed in cancer cells, and involved in six hallmarks 
of cancer [242] mediating acquisition and maintenance of the properties necessary for 
transformation of a normal cell into a cancer cell; ability to evade apoptosis, ability to be self-
sufficient for growth, ability to invade surrounding tissue and to metastasize to distant sites, 
ability to undergo limitless replication, ability to promote neoangiogenesis, and ability to ignore 
antigrowth signals.  Indeed it has become apparent that chaperones can serve as biochemical 
buffers at the phenotypic level for the genetic instability that is characteristic of many human 
cancers. HSP90 thus allows tumor cells to tolerate the mutation of multiple critical signaling 
molecules that would otherwise be lethal. 
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The HSP90 chaperoning cycle is a dynamic process in which client proteins bind to HSP90 in an 
intermediate complex containing the co-chaperones Hsp70, Hsp40, Hip and Hop [243, 244]. 
Upon ATP binding and hydrolysis, HSP90 forms a mature complex, containing p23, p50/cdc37 
and immunophilins (IP), which catalyzes the conformational maturation of HSP90 client 
proteins. Association of HSP90 with client proteins is regulated by the activity of the N-terminal 
ATPase domain, which binds and hydrolyses ATP to mediate a series of association-dissociation 
cycles between HSP90 and client substrates. Interestingly HSP90 exists in an equilibrium 
between an ‘activated state’ prevalent in transformed cells and a ‘latent state’ predominant in 
normal cells.  In activated state HSP90 is exclusively complexed with co-chaperones in a state of 
high affinity for ATP/ADP, whereas HSP90 exist primarily in uncomplexed, low affinity form in 
the latent state.   
 
1.9.2.2 HSP90 Inhibitors 
Many chemicals have been developed to inhibit HSP90 function. These can be categorized into 
two groups depending on the sites of the HSP90 molecule that are targeted; 1) those impacting 
the N-terminal ATP/ADP pocket of HSP90 and 2) those perturbing the C-terminal domain of 
HSP90 [238, 245]. 
 
The N-terminal region of HSP90 contains a regulatory pocket that binds and hydrolyzes ATP. N-
terminal domain targeted inhibitors, therefore, impact ATP binding and hydrolysis, thereby 
locking HSP90 in an intermediate complex. Bound client proteins may then be more readily 
(poly)ubiquitinated and shunted to the proteasome for degradation. Drugs in this category 
include ansamycins (e.g. Geldanamycin; GA) and its derivatives (17-AAG, 17-DMAG), 
Radicicol, purine-scaffold derivatives, Pyrazole (CCT018159). GA, a first generation drug, was 
found to promote severe (liver) toxicity, while second generation inhibitors, such as 17-AAG, 
was far better tolerated in phase I/II clinical trials.  17-DMAG, one of the newest generations of 
HSP90 inhibitors based on geldanamycin, is water-soluble, far less toxic and capable of being 
provided via oral administration. 17-DMAG, however, retains dose-limiting toxicity in 
gastrointestine, kidney, gallbladder and bone marrow as reported in preclinical experiments 
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using rats and dogs [246], and has exhibited limited efficacy against tumor progression in mice at 
well-tolerated doses [247]. Therefore enhancing the therapeutic efficacy of 17-DMAG through 
combinational applications with alternate treatment modalities will be required to optimize its 
“clinical” potential.  This is consistent with a widely-accepted concept in the field of cancer 
therapy which supports the necessity of combinational therapies to affect cures [3, 178, 179]. 
Both 17-AAG and 17-DMAG are currently being evaluated in Phase I/II clinical trials as cancer 
therapeutic agents at the University of Pittsburgh and elsewhere ([248, 249]; Dr. Merrill Egorin, 
personal communication).   
 
N-terminal binders have potential to also interact with additional HSP90 family member proteins 
in tumor cells, since the N-terminal ATP-binding site is highly-conserved among HSP90 family 
proteins (HSP90, gp96 and Trap1). While Ge et al. reported that 17-AAG and 17-DMAG have 
comparable affinities for human HSP90 and canine gp96 [250], Chandarlapaty et al. found that 
GA, 17-AAG and 17-DMAG exhibit (5-7X) higher affinity to human HSP90 versus human gp96 
[251]. The binding of GA to gp96 requires a rearrangement of the Gly hinge and leads to a 
conformational change in gp96, while the binding of GA to HSP90 does not require any 
substantive structural changes, suggesting a possible explanation for the superior binding 
capacity of GA and its derivatives to HSP90 versus gp96 [252].  
 
The contribution of the C-terminal domain region to HSP90 function remains unknown, 
however, it has been hypothesized that this domain might regulate the ATPase activity of the N-
terminal region, and therefore, the cycling of the HSP90 machinery. C-terminal domain targeted 
inhibitors include chemotherapeutic agents such as Novobiocin and Cisplatin. 
 
Interestingly HSP90 in normal cells (uncomplexed form) has a low-affinity for HSP90 inhibitors, 
resulting in the poor accumulation of HSP90 inhibitors and poor drug sensitivity in normal 
tissues [245]. On the contrary, complexed HSP90, as observed in cancer cells, exhibits high-
affinity binding to HSP90 inhibitors. Thus, tumor tissues tend to selectively accumulate HSP90 
inhibitors and exhibit significant sensitivity to drug action in vivo. Indeed, it has been reported 
that HSP90 derived from tumor cells binds to 17-AAG up to 100 times more tightly than does 
HSP90 isolated from normal cells [253].  
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Scope of This Thesis 
The studies performed in my thesis were designed to identify strategies that would allow an 
existing immune system to better recognize tumor cells in order to define a novel 
immunotherapy approach. In particular, I have focused on means to improve tumor cell MHC 
presentation of peptides derived from a class of tumor-associated antigens, receptor tyrosine 
kinases (RTK), allowing for the improved reactivity of specific cytotoxic T cells. Such T cells 
have been intimately linked to the ability of the host to resist tumor development and 
progression, and when activated as a consequence of therapy, they may effectively mediate 
complete tumor regression in vivo.  My findings suggest that treatment of tumor cells with RTK 
agonists and/or HSP90 inhibitors leads to enhanced immune recognition in vitro and in vivo, via 
a mechanism that enforces the generation of, and MHC class I loading with, RTK-derived 
peptides. Such conditional manipulation of tumor cells allows for the design of “pulse” therapies 
in which anti-RTK CD8+ T cells may be activated by specific vaccination or be adoptively 
transferred along with the administration of RTK agonists and/or HSP90 inhibitors to optimize T 
cell recognition of cancer cells in situ, and thereby the clinical benefit associated with such 
cytotoxic cells.  
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Preface to Chapter 2 
   
My goal was to determine whether EphA2 agonists (ephrin-A1-Fc and anti-EphA2 mAb), which 
promote the internalization and degradation of this RTK on/in tumor cells, result in the improved 
recognition of treated tumor cells by anti-EphA2 CD8+ T cells. Western blot analyses were 
performed to monitor EphA2 phosphorylation and degradation status, while ELISPOT/ELISA 
analyses, as well as, 51Cr-release assays were used to assess differential T cell responses against 
agonist-treated versus control tumor cells in vitro. The efficacy of combinational therapy in vivo 
was tested in a Hu-SCID tumor model. We found that both agonists promote EphA2 
autophosphorylation, rapid internalization and proteasomal degradation/processing, with a 
corollary improvement observed in tumor recognition by moderate-to-low functional avidity 
anti-EphA2 CD8+ T cells in vitro and in vivo. Notably, CD8+ T cells recognizing peptide 
epitopes derived from the extracellular (i.e. EphA258-66) or the intracellular (i.e. EphA2883-891) 
domains of the EphA2 protein exhibited higher IFN-γ production in response to agonist-treated 
versus control tumor cells. This suggests that both domains of this transmembrane protein are 
driven into the proteasomal processing and MHC class I presentation pathways. Of perhaps 
greatest importance, the adoptive anti-EphA2 CD8+ T cell therapy was only able to promote 
complete tumor regression in concert with the co-provision of EphA2 agonists in vivo.  
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2. Enhancement in Specific CD8+ T Cell Recognition of EphA2+ Tumors after 
Treatment with Ligand Agonists 
Amy K. Wesa*, Christopher J. Herrem , Maja Mandic*, Jennifer L. Taylor*, Cecilia Vasquez*, 
Mayumi Kawabe , Tomohide Tatsumi , Michael S. Leibowitz , James H. Finke , Ronald M. 
Bukowski , Elizabeth Bruckheimer¶, Michael S. Kinch¶ and Walter J. Storkus*, ,|| 
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These data have been reported in Journal of Immunology 181: 7721-7727, 2008.  Western blot 
analyses and Flow cytometry analyses in Figures 6, 7A and 9A were performed by C.J. Herrem, 
C. Vasquez and M. Kawabe. Generation of SLR20.A2 cell line used in Figures 7B, 7C, 8C, 8D, 
9B was performed by M. Kawabe. Generation of T cell bulk and clone used in Figures 7B, 7C, 8, 
9B was performed by A.K. Wesa and M Mandic. ELISPOT analyses in Figures 7B, 7C, 8, 9B 
were performed by A.K. Wesa, M. Mandic and M. Kawabe. Cr51 release assay (Figure 10) and 
Hu-SCID mice experiments (Figure 11 and Table 2) were performed by E. Bruckheimer and 
M.S. Kinch at MedImmune. 
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 2.1. ABSTRACT  
EphA2, a member of the receptor tyrosine kinase (RTK) family, is commonly expressed by a 
broad range of cancer types, where its level of (over)expression correlates with poor clinical 
outcome. We and others have shown that EphA2 contains multiple peptide epitopes that can be 
recognized by effector CD4+ and CD8+ T cells isolated from tumor-bearing patients. Specific 
CD8+ T cells, however, typically exhibit only moderate-to-low functional avidity (given 
“tolerance” against the “self” antigen EphA2), rendering them marginally competent to 
recognize EphA2+ tumor cells in vitro or in vivo. We hypothesized that conditional promotion of 
tumor cell EphA2 degradation would lead to the selective enhancement in EphA2 peptide 
presentation by MHC class I, rendering tumor cells better targets for recognition by previously 
inept anti-EphA2 T cells.  In this chapter, agonistic mAbs and ligand (ephrinA1)-Fc fusion 
protein were selected as agonists to treat tumor cells. We show that these agonists trigger the 
proteasome-dependent degradation of EphA2 and improve EphA2-derived peptide presentation 
by MHC class I on the tumor cell surface in vitro (as manifested by increased recognition by 
EphA2-specific CD8+ T cells). Notably, peptides derived from both the extracellular and 
intracellular domains of EphA2 appear to be better presented after agonist treatment, supporting 
the effective enzymatic processing of the full-length transmembrane protein. These results 
suggest that strategies targeting the conditional proteasome-mediated destruction of tumor cell 
EphA2 may be effective in improving the anti-tumor efficacy of anti-EphA2 CD8+ T effector 
cells. We also observed that single administration of ephrinA1-Fc fusion protein or agonistic 
mAb into EphA2+ tumor lesions failed to halt tumor progression in a humanized SCID model, 
however, when combined with the adoptive transfer of modestly therapeutic (human) anti-EphA2 
CD8+ CTL, complete tumor eradication was attained. These results support a novel 
combinational therapy strategy to improve the therapeutic benefits of T cell-based 
immunotherapies. 
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2.2. INTRODUCTION 
EphA2, a member of the RTK family of molecules, is a 130kDa (Type I) glycoprotein that 
mediates intercellular interactions via binding to its natural ligands Ephrin-A1, -A3, -A4 and -A5 
expressed on an opposing cell surface [51]. This RTK is expressed at low levels on a broad range 
of epithelial tissues in normal adults, including lung, spleen, kidney and liver [63], where it is 
primarily localized to sites of cell-to-cell contact and plays a role in contact inhibition of cell 
growth/migration that is critical for the organization and formation of epithelial layers in EphA2+  
tissues [48]. In addition to epithelial cells, activated endothelial cells also express EphA2 in 
association with tissue neovascularization in adults [49].  
 
In contrast to non-transformed cells, EphA2 is commonly overexpressed in a range of cancer 
types, including melanoma and many carcinomas [4, 7, 8, 18, 49, 99, 107, 254], where it serves 
as an oncoprotein and a facilitator of metastasis [48, 62]. Clinical observations suggest that the 
level of EphA2 overexpression by tumor cells is an indicator of poor prognosis, since it has been 
linked to reduced time to disease recurrence, and enhanced disease progression and metastatic 
spread [7, 17, 18, 48, 62, 64].  
 
As a consequence, EphA2 represents an attractive target for therapeutic intervention in the 
majority of patients with solid tumors, with several treatment strategies considered for translation 
into the clinic. In particular, a class of agonistic EphA2 Abs and Ephrin-A1 Fc have been 
developed that can induce EphA2 internalization and degradation, thereby reducing expression of 
this powerful oncoprotein. Ephrin-A1 Fc is a dimerized Ephrin-A1 fused to human 
immunoglobulin G (IgG) Fc having increased agonistic function and stability.  Repeated 
administration of these reagents has proven successful in inhibiting tumor cell growth in both in 
vitro and in vivo models, as well as, enhancing the survival of tumor-bearing mice [66, 119-121].  
Another potent strategy to target EphA2+ tumor is dendritic cell based vaccine. Immunogenic 
human and murine EphA2 derived peptides have recently identified by us and others [8, 130, 
132], and dendritic cell-based vaccines incorporating mEphA2 peptides have been reported to 
promote protective T cell responses in murine melanoma and colon cancer models [63, 255]. 
Since EphA2-specific CD8+ T cells have been detected in the peripheral blood of patients with 
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renal cell carcinoma (RCC, [8]), prostate carcinoma [130] or glioma [132], the frequencies of 
these protective T cells would be anticipated to be augmented as a consequence of active 
vaccination [63, 255].   
Those CTLs are, however, expected to be moderate-to-low avidity, given the fact that EphA2 is a 
non-mutated, ”self” antigen that would be predicted to induce central and peripheral tolerance 
mechanisms [256, 257]. Moderate-to-low avidity T cells typically fail to recognize target cells, 
including tumor cells, because tumor cells often exhibit defects in their antigen presentation 
machinery (APM), which can lead to their escape from immune surveillance [150, 151]. Despite 
EphA2 protein overexpression in many cancers, such defects may preclude the effective 
processing and loading of a sufficient number of tumor MHC complexes to allow for the 
activation of specific T cells. In this light, interferons have been used clinically hoping to 
improve the general ability of antigen presentation via its well-known up-regulating effects on 
many components of the APM.  However, MHC class I-restricted T cell responses are typically 
only modestly induced by interferons [258], and moreover, interferons fail to selectively increase 
the processing and MHC class I presentation of peptides derived from a particular antigen. 
Hence, the clinical expectation for single modality vaccines based on EphA2 is that this 
approach would fail to be optimally efficacious, however, combinational therapies that sensitize 
EphA2+ tumors for specific CD8+ T cell eradication might yield enhanced clinical benefits [3].   
 
Therefore, I was interested in evaluating agents that had the potential to alter the life cycle of 
tumor cell EphA2 protein, particularly with regard to its ultimate degradation via the proteasome. 
Classically, endocytosed membrane receptors (such as EphA2) expressed by non-professional 
APC have been believed to be exclusively degraded in mature lysosomes, however, recent 
studies have revealed that such receptors may also gain access to the proteasome [15]. I, 
therefore, selected the ephrin-A1 Fc and agonistic anti-EphA2 mAb208 reagents to trigger the 
internalization of tumor cell EphA2 protein. Herein, I investigated whether the treatment of 
EphA2+ human tumor cells with these specific agonists would induce the proteasome-dependent 
degradation of EphA2 protein and the consequent presentation of its derivative peptides on 
tumor cell MHC class I complexes, thus allowing for improved recognition by anti-EphA2 CD8+ 
T cells in vitro and in vivo.  
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2.3. MATERIALS AND METHODS 
2.3.1. Cell lines and Media 
SLR20 (EphA2+, HLA-A2neg; [8]), SLR24 (EphA2+, HLA-A2+; [8]), SLR20.A2 (EphA2+, HLA-
A2+) and T2 (EphA2neg, HLA-A2+) cell lines were used as peptide presenting cell in ELISPOT 
and ELISA assays.  SLR20.A2 cell line was established via transduction of SLR20 with a 
recombinant retrovirus encoding HLA-A2.1 (provided by Dr. Peter Cresswell, Yale University), 
and selection by puromycin.  SLR20.A2 and SLR24 were tested for their EphA2 protein 
expression under various conditions, while PC-3 prostate carcinoma cell line served EphA2 
positive control. All cell lines were free of mycoplasma contamination and maintained in RPMI-
1640 media supplemented with 10% heat inactivated fetal bovine serum, 100 U/ml penicillin, 
100 mg/ml streptomycin and 10 mM L-glutamine (all reagents from Invitrogen, Carlsbad, CA, 
unless otherwise indicated).   
 
2.3.2. Peptides 
HLA-A2 presented EphA2 peptides, EphA258-66 (IMNDMPIYM; [130]) and EphA2883-891 
(TLADFDPRV; [8]), as well as HIV-nef180-189 (VLEWRFDSRL) were synthesized using 9-
fluorenylmethoxycarbonyl (Fmoc) chemistry by University of Pittsburgh Cancer Institute’s 
(UPCI) Peptide Synthesis Facility, as previously described [8].  The purity of peptides was >96% 
based on high performance liquid chromatography, with peptide identity validated by mass 
spectrometric (MS/MS) analyses performed by the UPCI Protein Sequencing Facility (a Shared 
Resource).  
 
2.3.3. Mice 
Six- to 8-wk-old female C.B-17 scid/scid mice were obtained from Taconic and maintained in 
microisolator cages. Animals were handled under aseptic conditions as per an Institutional 
Animal Care and Use Committee-approved protocol and in accordance with recommendations 
for the proper care and use of laboratory animals.  
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2.3.4. EphA2 agonists 
EphrinA1-Fc (R&D Systems) is a chimeric protein consisting of the ligand binding domain of 
the EphA2 ligand ephrinA1 fused with the Fc portion of a human IgG Ab. mAb208 (kindly 
provided by MedImmune) is a mouse IgG mAb specific for hEphA2 [100]. EphrinB1-Fc (Sigma-
Aldrich) and MOPC21 mAb (mouse IgG; Sigma-Aldrich) were used as specificity controls for 
ephrinA1-Fc and mAb208, respectively. 
 
2.3.5. Western Blot Analyses 
SLR20.A2 and SLR24 cell lines at 80-90% confluency were incubated with 10µg/ml of EphA2 
agonists (ephrinA1-Fc or mAb208) or their controls in RPMI-1640 media for 24-48h, as 
indicated in text. Harvested cells were then incubated with lysis buffer (1% TritonX-100, 150 
mM NaCl, 10 mM Tris-HCl pH7.4, 1 mM EDTA, 0.2 mM sodium orthovanadate, 0.5% NP-40 
in PBS; all reagents from Sigma-Aldrich) containing a protease inhibitor cocktail (Complete 
mini, Roche Diagnostic, Mannheim, Germany) for 30 minutes at 4oC. Lysates were cleared by 
centrifugation at 13,500 x g for 10 min, and proteins in the lysate resolved by SDS-PAGE before 
electro-blotting onto PVDF membranes (Millipore, Bedford, MA). Polyclonal rabbit anti-EphA2 
Ab (C-20) or polyclonal rabbit anti-EGFR (sc-03) and horseradish peroxidase (HRP)-conjugated 
goat anti-rabbit antibody as secondary antibody were used to detect EphA2 or EGFR (all from 
Santa Cruz Biotechnology, Santa Cruz, CA). Mouse anti-β-actin Ab (clone AC-15, Abcam) and 
goat anti-mouse mAb (BioRad, CA) were used to detect β-actin as a loading control. Probed 
proteins were visualized by Western LightingTM chemiluminescence detection kit (Perkin Elmer, 
Boston, MA) and exposed to X-Omat film (Eastman Kodak, Rochester, NY) for 1-5 min. 
Immunoprecipitations for EphA2 were performed using the anti-EphA2 Ab D7 (Millipore). Anti-
phosphotyrosine Ab (clone py99, Santa Cruz Biotechnology) was then used to assess pEphA2 
content.  
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2.3.6. Flow Cytometry 
For phenotypic analyses of control or ligand agonist-treated tumor cells, PE- or FITC-conjugated 
mAbs against total HLA class I complexes (W6/32; pan-class I specific; Serotec), HLA-A2 
complexes (BB7.2 and MA2.1; American Type Culture Collection), or empty HLA-A2 
molecules (HC-A2,  [259], the kind gift of Dr. H. Ploegh, Massachusetts Institute of Technology) 
and appropriate isotype controls (purchased from BD Biosciences) were used, and flow 
cytometric analyses were performed using a FACScan (BD Biosciences) flow cytometer. Cell 
surface expression of EphA2 protein was analyzed using direct immunofluorescence staining 
monitored by flow cytometry. After treatment for 0–24 h at 37°C with 10 µg/ml ephrinA1-Fc, 
ephrinB1-Fc, mAb208, or the MOPC21 mAb, tumor cells were stained for 30 min at 4°C with 
FITC-conjugated anti-EphA2 mAb B2D6 (Millipore; note that this mAb is not sterically 
inhibited by the binding of ephrinA1-Fc or mAb208 to EphA2, data not shown) before washing 
with PBS and analysis by flow cytometry. The results of these assays are reported as percentage 
control (untreated) tumor cell expression based on a comparison of arbitrary mean fluorescence 
intensity (MFI) units obtained for experimental versus control specimens. 
 
2.3.7. Proteasome Dependency Assessment 
The impact of proteasome inhibition in Western blot (evaluating agonist-induced EphA2 
degradation in tumor cells) and T cell ELISPOT (evaluating enhanced anti-EphA2 T cell 
recognition of agonist-treated tumor cells) assays was assessed by treatment of tumor cells with 
either MG-132 (Sigma-Aldrich) or clasto-lactacystin β-lactone (hereafter designated as 
lactacystin; BIOMOL International), as outlined in relevant text and figure legends. 
 
2.3.8. T cell lines and Clones 
Bulk CD8+ T cell lines and clones specific for EphA258-66 or EphA2883-891 were generated as 
previously described [8]. Briefly, mature dendritic cells (DC) were developed from peripheral 
blood mononuclear cells (PBMC; obtained with written consent under an IRB-approved 
protocol) isolated from normal HLA-A2+ donors in 7 day cultures containing rhGM-CSF 
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(Sargramostim; Amgen, Thousand Oaks, CA) and rhIL-4 (Peprotech, Rocky Hill, NJ), then 
pulsed with either the EphA258-66 or EphA2883-891 peptides (10 µM) for 4h at 37oC at 5% CO2 
tension. Autologous CD8+ T cells were stimulated on a weekly basis with peptide-pulsed 
autologous DC for 3-4 cycles (at a T:DC ratio of 10:1) to generate a bulk population of peptide-
specific CD8+ T cells. These T cells were used in tumor recognition assays and for cloning via 
limiting dilution assays; [260]). T cells were maintained in IMDM media supplemented with 
10% human AB serum, 100 U/ml penicillin, 100 mg/ml streptomycin, 10 mM L-glutamine and 
MEM Non-essential amino acids (all reagents from Invitrogen, except human AB serum that was 
purchased from Sigma-Aldrich). After their initial isolation, T cell clones were expanded in vitro 
in IMDM media supplemented with 1µg/ml phytohemagglutinin (PHA; Sigma-Aldrich) and 200 
U/ml rhIL-2 (Peprotech). 
 
2.3.9. Tumor Recognition Assays 
Tumor recognition by anti-EphA2 T cells was evaluated by IFN-γ ELISPOT assays as described 
before [8] or using a commercial hIFN-γ ELISA (BD-Biosciences). For both the ELISPOT and 
ELISA protocols, tumor cells were treated with 10 µg/ml anti-EphA2 mAb208 or control IgG 
(MOPC21 mAb) for 24-48h, prior to their harvest using Trypsin-EDTA (Invitrogen).  After 
washing with PBS (Invitrogen), tumor cells were co-cultured with anti-EphA2 T cell lines/clones 
at an effector:target cell ratio of 1:1 for 24h at 37oC and 5% CO2 tension. To assess the impact of 
proteasome function on EphA2 agonists-treated tumor cells, SLR20.A2 cells were pretreated 
with MG-132 (10 µM) or lactacystin (20 µM) for 3h prior to 24h treatment with EphA2 agonists 
(mAb208 or EphrinA1-Fc).  After harvest, tumor cells were washed twice with PBS, prior to 
using these cells as targets for T cell recognition. 
 
2.3.10. Cytotoxicity Assays 
CD8+ T cell clones E883 (anti-EphA2883–891) and 2E4 (anti-HLA-A2) were evaluated for their 
capacity to lyse EphA2+, HLA-A2+ SLR24 tumor cells using standard 4-h 51Cr-release assays, as 
previously described [261]. Briefly target cells (SLR24) were untreated or treated with either  
ephrinA1-Fc, ephrinB1-Fc or mAb208 for 24h, before radiolabeling with 100 µCi of Na2-51CrO4 
 52
(New England Nuclear-DuPont, Bedford, MA) for 1 h at 37°C. Labeled target cells were washed 
with medium and co-cultured with either E883 or 2E4 T cell clone for 4h in 96 well round 
bottom plate, then 51Cr released into culture supernatants was monitored by gamma counter. 
BB7.2 mAb was added to target cell 30min before cocluture for the HLA-A2 blocking cohort. 
Target cells incubated in medium alone or in medium containing 5% Triton X-100 (Sigma 
Chemical Co.) were used to determine spontaneous and maximum 51Cr release, respectively. The 
percentage of specific 51Cr release was calculated as 100 x (experimental release - spontaneous 
release) / (maximum release - spontaneous release).  
 
2.3.11. Hu-SCID Tumor Model 
1 x 106 SLR24 (EphA2+, HLA-A2+) RCC cells were s.c. injected to right flank of C.B-17 
scid/scid mice and tumors were allowed to establish to a size of ~30 mm2 (i.e., day 18 
postinjection). The tumor-bearing mice were then randomized into groups (five animals per 
group) that received either no treatment, a single intratumoral injection of ephrinA1-Fc, 
ephrinB1-Fc, or mAb208 (all 50 µg in 50 µl saline) on day 18, a single tail vein injection with 
CD8+ T cells (anti-EphA2883–891 clone E883 or allospecific anti-HLA-A2 clone 2E4; 5 x 106 cells 
in 100 µl saline) on day 19, or the combined d18 (EphA2 agonist) plus d19 (CD8+ T cell adoptive 
transfer) regimen. Animals were evaluated every 3–4 days for tumor size, with tumor-free status 
noted on day 44 post-tumor inoculation. For the Western blot analyses of EphA2 content in 
SLR24 tumor lesions, tumors pre- and postadministration of agonists or their controls were 
surgically resected from euthanized mice. Tumors were then digested into single-cell suspensions 
using a DNase, hyaluronidase, collagenase mixture (all reagents purchased from Sigma-Aldrich) 
as previously described [262], and filtered through Nitex mesh (Tetko) before generating lysates 
for Western blotting analyses, as outlined above.  
 
2.3.12. Statistical Analyses 
Two-tailed Student’s t tests were used to evaluate the difference between groups, with p values < 
0.05 considered significant. 
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2.4. RESULTS 
2.4.1. EphA2 agonists induce the phosphorylation and proteasome-dependent degradation 
of EphA2 in tumor cells in vitro. 
EphA2 is phosphorylated upon interaction with its ligands, then internalized and degraded 
following polyubiqutination. Previous studies have demonstrated that tumor cells exhibit 
unstable cell-cell contacts and that this impairs the ability of EphA2 to interact with its ephrinA1 
ligand on neighboring cells [64, 120, 263], and that EphA2 protein in malignant cells is generally 
observed to be in a hypophosphorylated state [101]. Therefore EphA2 levels of RCC tumor cell 
lines, SLR20.A2 and SLR24, were analyzed along with their phosphorylation status after 
exposure to EphA2 ligands (ephrinA1-Fc and mAb208). High expression levels of EphA2 
protein were observed in both renal cell carcinoma cell lines, with undetectable levels of p-
EphA2. Treatment of tumor cells with agonists, however, induced rapid phosphorylation within 
10 min, while total EphA2 levels were preserved (Figure 6, A and B). Treatment of the EphB1+ 
SLR20.A2 or SLR24 tumor cells with ephrinB1-Fc (a ligand for EphB1, but not EphA2) or 
control mIgG MOPC21 failed to induce EphA2 phosphorylation (Figure 6, A and B). Substantial 
EphA2 protein degradation was, however, observed after 24h treatment with agonists but not 
with their control ephrinB1-Fc or MOPC21 mAb (Figure 6C). Such degradation was EphA2-
specific, as neither agonists altered expression levels of the control proteins EGFR (another 
cancer-related RTK) or β-actin (Figure 6C). A repeat of these experiments in the absence or 
presence of chloroquine or MG-132 suggested that EphA2 degradation in SLR20.A2 cells was 
predominantly 26S proteasome-dependent (Figure 6D). Flow cytometric analysis of agonist-
treated SLR20.A2 tumor cells indicated that cell surface EphA2 is rapidly lost (i.e., internalized) 
within hours, preceding loss of total tumor cell EphA2 protein as analyzed by Western blotting, 
after treatment with ephrinA1-Fc and mAb208, but not with ephrinB1-Fc or MOPC21 mAb 
(Figure 6E).  
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Figure 6. EphA2 agonists induce the phosphorylation and proteasome-dependent 
degradation of tumor cell EphA2 in vitro.  
To determine whether agonist treatment promotes EphA2 phosphorylation, SLR20.A2 (A) and 
SLR24 (B) renal carcinoma cells (2–4 x 106) were left untreated or were treated for 10 or 30 min 
with ephrinA1-Fc, ephrinB1-Fc, MOPC21 mAb, or mAb208 (each at 10 µg/ml) at 37°C. Cellular 
lysates were resolved by SDS-PAGE, and EphA2 protein was immunoprecipitated using the 
anti-EphA2 Abs D7 in pull-down assays. Western blot analyses were then performed using anti-
EphA2 and anti-phosphotyrosine Abs, respectively. To determine whether agonist treatment 
induces EphA2-specific degradation, SLR20.A2 (left panel of C) and SLR24 (right panel of C) 
tumor cells were treated as in A above for 24h with consequent cell lysates resolved by SDS-
PAGE and Western blot analyses performed using polyclonal anti-EphA2 and control anti-β-
actin Abs. Anti-EGFR Ab was used to image identically prepared lysates as a specificity 
(negative) control in these experiments. To assess the proteasome dependence of agonist-induced 
EphA2 degradation, MG-132 (50 µM) or chloroquine (100 µM) were also added to SLR20.A2 
cell cultures, where indicated, 30 min before the addition of ephrin-Fc proteins or mAb208 (D). 
After 24h, cell lysates were generated and Western blot analyses were then performed using anti-
EphA2 Abs and negative control anti-β-actin Abs. In E, the kinetics of EphA2 down-modulation 
on the surface of treated (with the indicated agents) SLR20.A2 cells was investigated by flow 
cytometry. Data are reported as percentage control EphA2 cell surface expression (versus 
untreated cells) based on MFI values obtained. All data are representative of three independent 
experiments performed. Data in Figure 6 were generated by C.J. Herrem, C. Vasquez and M. 
Kawabe. 
 
0   10   30   10   30   10   30   10   30   10   30 0   10   30   10   30   10   30   10   30   10   30
pY
EphA2
EphA2
EGFR
β-actin
- C    M    - C     M     - - C    MC
on
tro
l
Ep
hri
nA
1-F
c
Ep
hri
nB
1-F
c
MO
PC
21
 m
Ab
mA
b2
08
EphA2
β-actin
Ep
hri
nA
1-F
c
Ep
hri
nB
1-F
c
MO
PC
21
 m
Ab
mA
b2
08
Co
ntr
ol
Ep
hri
nA
1-F
c
Ep
hri
nB
1-F
c
MO
PC
21
 m
Ab
mA
b2
08
Co
ntr
ol
Ep
hri
nA
1-F
c
Ep
hri
nB
1-F
c
MO
PC
21
 m
Ab
mA
b2
08
Co
ntr
ol
Ep
hri
nA
1-F
c
Ep
hri
nB
1-F
c
MO
PC
21
 m
Ab
mA
b2
08
Co
ntr
ol
0 5 10 15 20 25 30
0
20
40
60
80
100
MOPC21 Ab
EphrinA1-Fc
EphrinB1-Fc
mAb208
%
 C
on
tro
l C
el
l S
ur
fa
ce
E
ph
A
2 
E
xp
re
ss
io
n
Time Post-Treatment (h)
A.
E.
B.
D.
C.
C
on
tro
l
%
 C
on
tro
l C
el
l S
ur
fa
ce
E
ph
A
2 
E
xp
re
ss
io
n
%
 C
on
tro
l C
el
l S
ur
fa
ce
E
ph
A
2 
E
xp
re
ss
io
n
 55
2.4.2. Anti-EphA2 mAb208 sensitizes the EphA2+, HLA-A2+ tumor cell line SLR20.A2 to 
recognition by anti-EphA2 CD8+ T cells in vitro. 
Since agonistic Abs triggered the proteasomal destruction of EphA2, we hypothesized that this 
could preferentially increase presentation of EphA2 peptides in tumor cell surface MHC class I 
complexes. Such a change would be expected to be tied directly to the ability of EphA2-specific 
CD8+ T cells to recognize agonist-treated tumor cells. To address this question, EphA2+ tumor 
cell lines were incubated with mAb208 for 24 or 48 h before evaluating the ability of these target 
cells to be recognized by HLA-A2-restricted CD8+ T cell lines and clones specific for the 
EphA258–66 (located in EphA2 extracellular domain) or EphA2883–891 (located in the EphA2 
intracellular domain) peptide epitopes. Rather than assessing differential tumor sensitivity to T 
cell killing (which could involve changes in both T cell and tumor cell functions induced by 
agonists), we instead chose to more directly interrogate changes in T cell functional recognition 
of treated tumor cells using the IFNγ ELISPOT assay as readout for effector T cell reactivity.  
 
Pretreatment of SLR20.A2 (EphA2+, HLA-A2+, Figure 7A) tumor cells with mAb208 
significantly enhanced their recognition by both anti-EphA2 CD8+ T cell lines (Figure 7, B and 
C) and moderate avidity (Figure 8, A and B) CD8+ T cell clones 15/9 and 3C1 (Figure 8, C and 
D, respectively). Notably, improved T cell recognition of treated tumor cells was sustained for a 
period of at least 48 h (Figure 7, B and C, Figure 8, C and D). SLR20 (EphA2+, HLA-A2neg) 
tumor cells failed to be recognized by any of these T cell populations, even after treatment with 
mAb208 (that promotes EphA2 degradation of SLR20, data not shown). Furthermore, treatment 
of SLR20.A2 cells with control IgG (MOPC21 mAb) failed to enhance tumor cell recognition by 
anti-EphA2 CD8+ T cells (Figure 7, B and C, Figure 8, C and D). 
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Figure 7. Anti-EphA2 mAb208 sensitizes the EphA2+, HLA-A2+ tumor cell line SLR20.A2 
to recognition by anti-EphA2 CD8+ bulk T cells in vitro.  
A. SLR20.A2 tumor cells were analyzed for expression of cell surface HLA-A2 and by flow 
cytometry using specific mAbs (open profiles) versus isotype control mAbs (filled profiles). 
Bulk CD8+ T cell lines were developed from HLA-A2+ normal donors against the EphA258–66 
(B) and EphA2883–891 (C) peptides, as described in Materials and Methods, and evaluated for 
their differential recognition of SLR20 (EphA2+, HLA-A2neg) and SLR20.A2 (EphA2+, HLA-
A2+) tumor cell targets using IFNγ ELISPOT assays. SLR20.A2 cells were pretreated with no 
Ab, control IgG (MOPC21 mAb), or mAb208 (10 µg/ml each) for 24 or 48h, as indicated, before 
ELISPOT analyses. Data are reported as mean IFNγ-specific spots/105 CD8+ T cells ± SD from 
triplicate determinations. SLR20.A2 cell line was generated by M. Kawabe, T cell bulks and 
clones were generated by A.K. Wesa and M Mandic, ELISPOT analyses were performed by 
A.K. Wesa, M. Mandic and M. Kawabe.  
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Figure 8. Anti-EphA2 mAb208 sensitizes the EphA2+, HLA-A2+ tumor cell line SLR20.A2 
to recognition by anti-EphA2 CD8+ clone T cells in vitro. 
The HLA-A2-restricted CD8+ T cell clones 15/9 (specific for EphA258–66) (A) and 3C1 (specific 
for EphA2883–891) (B) were developed, as described in Materials and Methods, and exhibited 
moderate to low functional avidity against specific peptide-pulsed T2 cells (EC50 ~1 µM peptide 
for both clones) as assessed by IFNγ ELISA (mean ± SD from triplicate determinations). These 
clones recognize SLR20.A2 tumor cells selectively in IFNγ ELISPOT assays, with recognition 
increased at 24 and 48h by pretreatment of tumor cells with mAb208, but not with control IgG. 
Data are reported as mean IFNγ-specific spots/104 CD8+ 15/9 (C) and 3C1 (D) T cells ± SD from 
triplicate determinations. All data are representative of three independent experiments 
performed. *, p < 0.05 versus control IgG-treated tumor cells. SLR20.A2 cell line was generated 
by M. Kawabe, T cell bulks and clones were generated by A.K. Wesa and M Mandic, ELISPOT 
analyses were performed by A.K. Wesa, M. Mandic and M. Kawabe.  
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2.4.3. EphA2 agonist-enhanced recognition of SLR20.A2 tumor cells by anti-EphA2 T cell 
clone is proteasome-dependent. 
To demonstrate whether enhanced CD8+ T cell recognition of tumor cells was due to processing 
through the proteasome, SLR20.A2 tumor cells were pretreated with MG-132 or lactacystin 
(reversible or irreversible 20S/26S proteasome inhibitors, respectively). Due to concerns for the 
toxicity of proteasome inhibitors during a prolonged exposure period, we chose a short 3h period 
for tumor pretreatment, which showed no negative impact on tumor cell morphology or viability 
(data not shown). Cells were then cultured with EphA2 agonists for 24-48h, before use as targets 
for CD8+ T cell recognition.  Consistent with the data depicted in Figure 6D, co-application of 
MG-132 or lactacystin prevented agonist-induced EphA2 degradation (Figure 9A). These 
proteasome inhibitors also completely abrogated any enhancement in recognition of SLR20.A2 
cells by anti-EphA2 T cells resulting from treatment with either of the EphA2 agonists (Figure 
9B).  
 
2.4.4. EphrinA1-Fc and mAb208 sensitize EphA2+, HLA-A2+ SLR24 tumor cells to lysis 
mediated by anti-EphA2, but not by anti-HLA2 allospecific CD8+ T cell clones in vitro. 
INFγ production assay indicates that CD8+ T cell recognizes tumor cells and is activated. To 
confirm the increased IFNγ production observed above indeed links to the actual tumor killing 
function of CD8+ T cells, we performed 51Cr-release assay that is a more direct measure of 
killing activity of CD8+ T cell. SLR24 tumor cells were treated with either EphA2 agonist 
(ephrinA1-Fc or mAb208) or control protein (ephrinB1-Fc) for 24h before targeted by either 
CD8+ T cell clone reactive to EphA2883–891 (E883) or HLA-A2 (2E4). Anti-HLA-A2 mAb 
treatment was included to demonstrate the observed lysis is a specific lysis in HLA-A2 restricted 
manner. As depicted in Figure 10A, clone E883 mediates the lysis of SLR24 tumor cells in vitro 
in an HLA-A2-restricted manner, with cytolysis dramatically increased  when the tumor cell line 
is pretreated with either ephrinA1-Fc or mAb208, but not with ephrinB1-Fc. Those sensitization 
of SLR24 cells to T cell-mediated cytolysis is specific to anti-EphA2 CD8+ T cells, since 
alloreactive (anti-HLA-A2) CD8+ T cell clone lysed SLR24 tumor cells to a comparable degree 
regardless of pretreatment conditions applied to the tumor cells (Figure 10B).  
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Figure 9. EphA2 agonist-enhanced in vitro recognition of SLR20.A2 tumor cells by anti-
EphA258–66 T cell clone 15/9 is proteasome-dependent.  
SLR20.A2 cells were pretreated with MG-132 (10 µM) or lactacystin (20 µM) or media alone 
for 3h, before being treated with 1 µg/ml MOPC-21 (control IgG), 1 µg/ml mAb208, or 0.1 
µg/ml ephrinA1-Fc for an additional 3h. No toxicity was observed under any conditions. The 
effect of proteasomal inhibitors on agonist-induced degradation of EphA2 expression was 
confirmed by Western blot (A). After harvesting and washing the treated tumor cells extensively, 
these cells were used as targets for clone 15/9 (anti-EphA258–66) in IFN-  ELISPOT assays (B) as 
outlined in Materials and Methods. Data from a representative experiment are reported as 
percentage control (mean ± SD) T cell response to SLR20.A2 versus tumor cells treated with 
control IgG (i.e., MOPC21). *, p < 0.05 versus control IgG-treated tumor cells. Western blot 
analyses were performed by C.J. Herrem, C. Vasquez and M. Kawabe, SLR20.A2 cell line was 
generated by M. Kawabe, T cell bulks and clones were generated by A.K. Wesa and M Mandic, 
ELISPOT analyses were performed by A.K. Wesa, M. Mandic and M. Kawabe. 
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Figure 10. EphrinA1-Fc and mAb208 sensitize EphA2+, HLA-A2+ SLR24 tumor cells to 
enhanced lysis mediated by anti-EphA2, but not by anti-HLA2 allospecific CD8+ T cell 
clones in vitro. 
SLR24 tumor cells were untreated or pretreated for 24h with ephrinA1-Fc, ephrinB1-Fc, or 
mAb208 before their use as target cells in 4h 51Cr-release assays. Anti-EphA2883–891 CD8+ T cell 
clone E883 and anti-HLA-A2 allo-specific CD8+ T cell clone 2E4 (developed as described in 
Materials and Methods) were used as effector cells at the indicated E:T ratios in A and B, 
respectively. Anti-HLA-A2 mAb BB7.2 was added to wells to demonstrate the HLA-A2-
restricted nature of T cell recognition of SLR24 tumor cells. Data are reported as the mean ± SD 
of triplicate determinations and are representative of three independent experiments performed. 
These data were generated by E. Bruckheimer and M.S. Kinch at MedImmune. 
 
 
2.4.5. EphrinA1-Fc and mAb208 treatment of tumor induces substantial therapeutic 
efficacy of adoptively transferred anti-EphA2 CD8+ T cells in a Hu-SCID tumor model. 
To address whether the conditional (agonist-induced) enhancement of EphA2+ tumor cell 
recognition by EphA2 specific CD8+ T cells could be of therapeutically significant, we 
established a Hu-SCID tumor model system for the analysis of combinational adoptive 
immunotherapy. Human SLR24 (EphA2+, HLA-A2+) renal carcinoma cells were s.c. injected 
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into the right flanks of C.B-17 scid/scid mice and allowed to progress to a size of ~30 mm2, at 
which time animals were either left untreated or were treated with intratumoral injection of 
ephrinA1-Fc, ephrinB1-Fc, or mAb208 and/or i.v. administration of CD8+ T cells specific for 
either EphA2883–891 or HLA-A2. Clone E883 (anti-EphA2) was used due to its ability to be 
expanded to the high numbers of T cells required for these experiments.  
Intratumoral injection of 50 µg ephrinA1-Fc, ephrinB1-Fc, or mAb208 (on day 18 posttumor 
inoculation) had minimal effect on the continued progressive growth of SLR24 lesions (Figure 
11A), despite a profound reduction in EphA2 protein expression in situ at 24 h after injection 
with ephrinA1-Fc or mAb 208, but not with ephrinB1-Fc (Figure 11B). These data are 
contradictory to some previous reports that demonstrated tumor regression after a single 
administration of such agonists in xenograft tumor models [66, 120, 121] [125, 126]. However, 
additional studies failed to show any impact of anti-EphA2 mAb on tumor growth [124], 
consistent with my findings, which may suggest that discrepancies are attributable to the 
differential tumor models employed in each case.  
The adoptive transfer of 5 x 106 CD8+ T cells alone (either the anti-EphA2 clone E883 or the 
anti-HLA-A2 clone 2E4 on day 19 post-tumor inoculation) also failed to significantly alter 
consequent tumor growth in vivo (Figure 11, C and D). However, the combined application of 
ephrinA1-Fc or mAb208 (on day 18) along with the adoptive transfer of E883 T cells (on day 
19) resulted in complete tumor eradication in all treated animals (Figure 11C, Table 2). In 
contrast, combined use of ephrinB1-Fc and E883 T cells yielded a tumor growth curve that was 
indistinguishable from single agent administration, with no animals rejecting their tumors 
(Figure 11C, Table 2). Although the (anti-HLA-A2) allospecific 2E4 CD8+ T cell clone 
efficiently kills SLR24 tumor cells in vitro (Figure 10B), administration of 2E4 T cells alone 
failed to halt the progression of lesional tumor growth, and when applied in combinational 
approaches with agonists, these T cells did not improved  therapeutic efficacy (Figure 11D). This 
result is consistent with the failure of SLR24 pretreatment with ephrinA1-Fc or mAb208 to 
augment tumor sensitivity to 2E4 T cell-mediated lysis in vitro (Figure 10B). 
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Figure 11. EphrinA1-Fc and mAb208 promote EphA2 down-regulation in situ and sensitize 
EphA2+, HLA-A2+ SLR24 tumors to enhanced eradication mediated by adoptively 
transferred anti-EphA2, but not by anti-HLA2 allospecific CD8+ T cell clones in vivo.  
A. Female C.B-17 scid/scid mice were injected with 1 x 106 human SLR24 (HLA-A2+/EphA2+) 
RCC cells s.c. in the right flank and allowed to establish to a size of 30 mm2 (i.e., day 18). 
Animals were then randomized into four cohorts (six animals each) receiving no treatment 
(control) or intratumoral injections of ephrinA1-Fc (50 µg), ephrinB1-Fc (50 µg), or mAb208 
(50 µg) on day 18. Tumor size was evaluated every 3–4 days, with results reported in mean mm2 
± SD. B. Tumors were resected from one mouse per cohort on day 19 (i.e., 24h after treatment 
and Western blots performed to validate EphA2 degradation in situ). In C and D, 5 x 106 CD8+ T 
cells (either anti-EphA2883–891 clone E883 or anti-HLA-A2 allospecific clone 2E4, respectively) 
were adoptively transferred by tail vein injection on day 19 posttumor inoculation alone or in 
combination with prior day 18 intratumoral injections of ephrinA1-Fc, ephrinB1-Fc, or mAb208 
(50 µg each). Tumor size was evaluated every 3–4 days, with results reported in mean mm2 ± 
SD. Data are representative of three independent experiments performed. These data were 
generated by E. Bruckheimer and M.S. Kinch at MedImmune. 
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Table 2. Combined application of EphA2 agonists and the adoptive transfer of Anti-EphA2 
CD8+ T cells results in the therapeutic regression of human SLR24 renal cell carcinomas in 
C.B-17 SCID. 
 
Treatment Group Fraction of Tumor-Free Mice (d44)* 
Control 0/15 
EphrinA1-Fc only 0/15 
EphrinB1-Fc only 0/10 
mAb208 only  0/10 
Clone E883 only 0/15 
Clone 2E4 only 0/15 
EphrinA1-Fc + Clone E883 14/15 
EphrinB1-Fc + Clone E883   0/10 
mAb208 + Clone E883 10/10 
EphrinA1-Fc + Clone 2E4 0/10 
EphrinB1-Fc + Clone 2E4 0/10 
mAb208 + Clone 2E4 0/10 
 
*Aggregate results obtained from 3 independent experiments performed as described in Figure 
11. 
 
Data in Table 2 were generated by E. Bruckheimer and M.S. Kinch at MedImmune. 
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2.5. DISCUSSION 
Immunotherapies designed to stimulate specific T cell-mediated immunity have thus far yielded 
only modest objective clinical response rates [177], despite they are typically capable of 
increasing tumor-specific T cells in the majority of treated patients. Since most tumor-associated 
antigens are non-mutated (“self”) proteins, treatment-enhanced T cells are believed to be derived 
from a low-to-moderate avidity repertoire that has survived negative selection [256, 257]. These 
T cells may become effectively activated by peptide-based vaccines, but they frequently fail to 
recognize tumor cells that naturally present only low levels of relevant MHC/tumor peptide 
complexes [264], often times due to defects in the tumor cell APM [150, 151].   
 
If tolerance selection restricts the anti-tumor CD8+ T cell repertoire to a degree that limits their 
clinical utility, I hypothesized that tumor cells might instead be manipulated in order to exceed 
the cognate antigen threshold requirements for effective immune surveillance. In particular, I 
believe that by conditionally enhancing the proteasome-mediated processing of tumor antigens, 
such as EphA2, the level of class I/EphA2 peptide complexes might be (at least transiently) 
increased on the tumor cell surface, allowing for improved recognition by modest avidity anti-
EphA2 CD8+ T cells [3].   
Recombinant ligand (ephrinA1-Fc) and agonistic anti-EphA2 mAb208 were selected as 
candidate reagents for this purpose, since they have been demonstrated to be capable of selected 
promotion of EphA2 degradation and reduction of EphA2 expression/signaling. The major 
finding of the present study is; 1) the treatments of tumor cells with agonists promote EphA2 
autophosphorylation, rapid internalization and proteasomal degradation/processing, 2) those 
treatment result in improved recognition by EphA2-specific and moderate-to-low functional 
avidity CD8+ T cells both in vitro and in vivo, 3) as a consequence, moderate-to-low functional 
avidity (i.e., about 1 µM ED50 for peptide recognition on T2 cells) EphA2-reactive CD8+ T cells 
are rendered to be capable of mediating the EphA2+ tumor regression in vivo. 
Several mechanisms of EphA2 overexpression have been suggested including gene 
amplification, decreased rates of protein degradation, and increased or stabilized mRNA 
transcription/translation. Despite our findings that constitutive tumor cell-expressed EphA2 
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exists in a hypophosphorylated state, the chosen agonists readily promoted the rapid 
phosphorylation and internalization of EphA2 protein, prior to its subsequent destruction via a 
proteasome-dependent pathway. The impairment of endogenous EphA2 protein degradation in 
tumor cells under standard conditions may stem from the disrupted interaction of EphA2 with its 
ligands, or from overexpression of protein tyrosine phosphatase (PTP) that enforces the recycling 
of internalized EphA2. Western blot analyses of our RCC cell lines for PTPs (LMW-PTP, PTP-
1b, SHS-PTP), however, were not conclusive in demonstrating gross protein overexpression 
(Appendix Figure 1). Hence, I believe the mechanism underlying EphA2 overexpression by my 
tumor cell lines may be due to a destabilization in intercellular cell-cell contacts involving 
EphA2 and its ligands (i.e. both the SLR20.A2 and SLR24 cell lines express the EphA2 ligands 
ephrinA1 and ephrin A5; Appendix Figure 2) expressed by proximal tumor cells.  
 
Notably, EphA2 was capable of yielding epitopes (EphA258–66 and EphA2883–891, located in the 
extracellular domain and intracellular domain of EphA2, respectively), which could consequently 
be presented by MHC class I molecules for extended periods of time. This suggests the superior 
processing/presentation of peptides derived from the full-length, transmembrane protein may be 
anticipated as a consequence of agonist application. However, how both domains of the EphA2 
transmembrane protein become accessible to proteasome-dependent degradation in the cytosol 
remains unclear. The classical direct presentation pathway describes a mechanism whereby 
peptides derived from cytosolic proteins may become presented in the context of MHC class I 
complexes. In this model, proteasomally-cleaved peptides may be transported by TAP into the 
ER and then be loaded into nascent MHC class I complexes that are consequently exported to the 
cell surface. However transmembrane proteins, such as EphA2, are generally thought to undergo 
degradation within the acidic microenvironment of mature lysosomes after ligand-induced 
internalization [15]. This would suggest a non-classical mechanism of antigen processing is 
involved in the case of EphA2. Such processing could occur via 
retrotransportation/retrotranslocation, in which an internalized protein may be shunted from an 
early endosome through the trans-Golgi/ER and then back into the cytosol [207, 265-267]. This 
is an intracellular trafficking mechanism employed by several bacterial toxins and viral proteins 
and is associated with their pathology. Alternatively, EphA2+ endosomes may fuse with the ER 
which possesses the machinery required to mediate the retrotranslocation of transmembrane 
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proteins into the cytosol. Another plausible explanation for EphA2 entry into the cytoplasm is 
the loss of endocytic vesicle integrity, resulting in the release of internalized EphA2 into the 
cytosol. We are currently undertaking pharmacologic studies to delineate the relevance of these 
various pathways by which agonist agents impact cell membrane EphA2 proteins give rise to 
enhanced, specific tumor recognition by anti-EphA2 CD8+ T cells. A better understanding of the 
mechanism(s) involved in agonist-induced EphA2 processing may allow for the therapeutic 
accentuation of relevant pathways, allowing for enhanced treatment benefits to be obtained in the 
setting of patients harboring EphA2+ tumors.  
 
While unlikely, I also considered the trivial explanation that increased tumor cell recognition by 
anti-EphA2 CD8+ T cells could be the result of a general up-regulation in tumor cell expression 
of HLA-A2 class I molecules (and hence a compensatory increase in the cohort of HLA-A2 
complexes containing EphA2-derived peptides). To address this possibility, the SLR20.A2 and 
SLR24 cell lines were treated with ephrinA1-Fc or mAb208 and analyzed by flow cytometry for 
cell surface expression levels of total HLA class I complexes, empty HLA-class I complexes, 
peptide-loaded HLA-A2 complexes, and empty HLA-A2 complexes. The empty molecules were 
defined based on their immunoreactivity with (positive for) mAbs HC-10 and/or HC-A2 [259]. 
We noted no significant changes in the MFIs of any of these parameters as a consequence of 
tumor treatment with these EphA2 agonists (data not shown), suggesting that increased IFNγ 
production by specific CD8+ T cells is the direct result of increased MHC class I presentation of 
EphA2-derived peptides on the tumor cell surface.  
 
Both bulk T cell lines and cloned T cells exhibiting low-to-moderate functional avidity 
recognized agonist-treated tumor cells to a greater extent than control, untreated tumor cells. 
This is an important finding since tolerance circuitry limits the avidity of self-reactive (i.e. anti-
EphA2) CD8+ T cells, which may be functionally incompetent to mediate anti-tumor effects in 
the clinical setting (i.e. the tumor does not provide signals sufficient to exceed the activation 
threshold of the T cells). Therefore, it may prove clinically important that agonist treatment of 
tumor cells conditionally enables such “weak” T cells to now effectively recognize and respond 
to cancer cells (based on increased IFNγ production and the frequency of responder T cells as 
analyzed by ELISPOT in Figure 7 and Figure 8). While bulk T cell populations reactive against 
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tumor antigens are a clinically-relevant (adoptive therapeutic) modality, analyses of cloned T 
cells with various functional avidities might provide a more detailed picture as to the 
comparative benefits imparted to T cell recognition of tumor cells as a consequence of agonist 
treatment.  
   
It is rather surprising that the combinational therapy works or fails in vivo, presumably based on 
an ~2–4-fold increase in tumor cell recognition by anti-EphA2 CD8+ T cells after agonist 
treatment in vitro (measured by IFNγ production or cytotoxic analyses; Figure 7-10). This may 
suggest that additional mechanisms of action are in play in vivo. Clearly one might envision that 
EphA2 processing/presentation might be more efficient in vivo than in vitro for a given tumor 
cell line. Although overall efficiency of APM might be estimated by the expression level of cell 
surface HLA molecule, EphA2-specific processing/presentation can only be addressed by mass 
spectrometry analyses for the EphA258–66 and EphA2833–891 peptides extracted from HLA-A2 
complexes expressed on SLR24 tumor cells. We are currently preparing SLR24 tumor cell 
extracts from cultured tumor cells versus resected tumors (in vivo), with and without agonist 
treatment for 24 h (via addition to culture or intratumoral injection). Another possible mechanism 
might be distinct from any peptide presentation mechanism, but act via improved T cell 
activation, recruitment, and/or survival in the tumor microenvironment. Since our T cell 
lines/clones do not express discernable levels of EphA2 (data not shown), it is not likely that 
EphA2 agonists impact T cells directly. Rather EphA2 agonists might act on tumor cells to 
induce a change in the expression pattern of molecules that contribute to preferred (in the cancer 
setting) Type-1 CD8+ T cell-mediated immune responses. Since agonists are capable of inducing 
the phosphorylation of EphA2, and down-stream signaling (i.e. MAPK), hence corollary protein 
synthesis would be anticipated as a  result of such activation. We have not yet identified such 
byproduct proteins, however, I would hypothesize that such changes might include alterations in 
inflammatory chemokines expression (e.g. IP-10, Mig, I-TAC), in integrin expression (e.g. VLA-
4) and in activatory/inhibitory co-stimulatory molecules expression (e.g. B7 family molecules) 
by tumor cells, each of which would improve T cell trafficking into tumor lesions in situ and/or 
effector T cell reactivity (for an extended period of time) against tumor cells. To address such 
possibilities, we will repeat the adoptive transfer studies and harvest tumors 24h after injection of 
CFSE-labeled CD8+ T cells in order to determine whether the recruitment of transferred CD8+ T 
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cells into the tumor site has been appreciably altered as a consequence of agonist “conditioning”.  
Another possibility is that host macrophages and NK cells may play important anti-tumor roles 
(in addition to the transferred CD8+ T cells), since those immune cell functions remain intact in 
SCID mice. Although both the ephrinA1-Fc and mAb208 agents would be anticipated to be 
rapidly internalized along with EphA2, it remains formally possible that FcR+ mouse 
macrophage and NK cells could recognize the Fc portion of these agonists on the tumor cell 
surface, allowing for antibody-dependent cellular cytotoxicity to occur. The destruction of tumor 
cells initiated by transferred CD8+ T cells might also activate and/or may recruit innate FcR+ 
effector cells into the tumor site, leading to a more effective elimination of tumor cells in the 
context of our combinational treatment group. Alternative, and perhaps of greatest intrigue, 
agonists may allow for the immune targeting of the EphA2+ tumor-associated vasculature [112] 
by specific CD8+ T cells, thereby providing multiple targets (i.e. tumor cells and the associated 
tumor stroma) for immune intervention. Indeed, we have recently shown that the vaccination of 
mice with peptides derived from the murine EphA2 protein inhibits the growth of EphA2-
negative tumor cells in vivo, at least in part, by limiting neoangiogenesis in the tumor 
microenvironment [63]. This data suggests that combinational treatments using EphA2 agonists 
and T cell-based immunotherapies will likely have multiple strategic EphA2+ cellular targets 
within the tumor microenvironment, potentially opening patient accrual to individuals harboring 
any form of vascularized (solid) cancer.  
 
Overall our present results strongly suggest the potential therapeutic benefits of using "off-the-
shelf"’ agonists to sensitize EphA2+ tumor cells to anti-EphA2 CD8+ T cells that could be 
preactivated via specific immunization [8, 130] or provided by the adoptive transfer of Ag-
specific ex vivo-expanded, autologous CD8+ T cell populations.  
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Preface Chapter 3 
My goal was to determine whether HSP90 inhibitors, which disrupt refolding/stabilization of 
misfolded HSP90 client proteins, induce proteasomal degradation of EphA2 and the subsequent 
improvement in MHC class I presentation of EphA2 derived peptides on the tumor cell 
membrane.  Enhanced presentation was monitored as improved reactivity mediated by anti-
EphA2 CD8+ T cells in vitro. I also aimed to discern the mechanisms by which such increased 
“antigenicity” of tumor cells occurs and whether treatments consisting of EphA2 agonists and 
HSP90 inhibitors would yield to even further improvement in specific T cell recognition of 
tumor cells. Western blot and ELISPOT/ELISA analyses were performed to monitor EphA2 
degradation and the MHC-presentation of EphA2-derived peptides on tumor cells, respectively. I 
determined that EphA2 is a novel client protein of HSP90 and that the HSP90 inhibitor, 17-
DMAG, promotes EphA2 degradation in tumor cells via a mechanism that is dependent on 
Sec61-mediated retrotranslocation, proteasome-mediated cleavage and TAP-mediated delivery 
of EphA2 peptides into the MHC class I biosynthetic pathway.  I noted that 17-DMAG treatment 
of EphA2+ tumor cells improves their recognition by low-to-moderate avidity anti-EphA2 CD8+ 
T cells for at least a period of 24h, and that such recognition could be further enhanced using a 
combinational treatment including both 17-DMAG and EphA2 agonists. These data were 
reported in an in press Cancer Research report (2009), on which I was the first author. 
 
The studies in Chapter 3 suggest that clinical-grade 17-DMAG may help in defining novel 
combinational immunotherapies (in concert with vaccines to elicit anti-EphA2 CD8+ T cells or 
adoptively transferred anti-EphA2 CD8+ T cells) for the treatment of EphA2+ cancers. These 
studies using drugs that act in a mechanistically distinct manner from those used in Chapter 2, 
again support my hypothesis that the conditioning of tumor cells to promote acute EphA2 protein 
degradation leads to improve immune recognition by CD8+ T cells of modest functional avidity. 
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3. HSP90 Inhibitor 17-DMAG Enhances EphA2+ Tumor Cell Recognition by Specific 
CD8+ T cell 
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All the results reported in this study were obtained by Mayumi Kawabe, except for ELISPOT 
analyses which were performed in collaboration with Drs. Maja Mandic and Amy Wesa. 
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3.1 ABSTRACT 
EphA2, a member of the receptor tyrosine kinase (RTK) family, is commonly expressed by a 
broad range of cancer types, where its level of (over)expression correlates with poor clinical 
outcome.  Since tumor cell expressed EphA2 is a non-mutated “self” protein, specific CD8+ T 
cells are subject to self-tolerance mechanisms and typically exhibit only moderate-to-low 
functional avidity, rendering them marginally competence to recognize EphA2+ tumor cells in 
vitro or in vivo. We have demonstrated in Chapter 2 that the ability of specific CD8+ T cells to 
recognize EphA2+ tumor cells can be augmented after the cancer cells are pretreated with EphA2 
agonists that promote proteasomal degradation and upregulate expression of EphA2/class I 
complexes on the tumor cell membrane. In the current study we show that treatment of EphA2+ 
tumor cells with the irreversible HSP90 inhibitor, 17-DMAG, similarly enhances their 
recognition by EphA2-specific CD8+ T cell lines and clones in vitro via a mechanism that is 
dependent on proteasome and TAP function, as well as, the retrotranslocation of EphA2 into the 
tumor cytoplasm. When 17-DMAG and agonist anti-EphA2 mAb are co-applied, T cell 
recognition of tumor cells is further increased over that observed for either agent alone. These 
studies suggest that EphA2 represents a novel HSP90 client protein and that the treatment of 
cancer patients with 17-DMAG-based “pulse” therapy may improve the anti-tumor efficacy of 
CD8+ T effector cells reactive against EphA2-derived epitopes. 
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3.2. INTRODUCTION 
EphA2 represents an attractive target for therapeutic intervention in the majority of patients with 
solid tumors, due to the observations that EphA2 is commonly overexpressed in a broad range of 
cancer types, and that the level of EphA2 overexpression by tumor cells link to poor prognosis. 
Among several treatment strategies considered for translation into the clinic, one strategy 
involves the implementation of EphA2 agonists (agonist mAb or recombinant ligands) that 
promote the proteasome-mediated degradation of tumor EphA2 protein, thereby limiting its 
oncogenic function [120, 125].  As reported in Chapter 2, we have determined that such agonists 
also promote a corollary enhancement in tumor cell presentation of EphA2 peptides in tumor cell 
MHC class I complexes, thereby facilitating tumor cell recognition by low-to-modest avidity 
CD8+ T cells [260]. Since EphA2-specific CD8+ T cells have been detected in the peripheral 
blood of patients with renal cell carcinoma (RCC [8]), prostate carcinoma [130] or glioma [132], 
the frequencies of these protective T cells would be anticipated to be augmented as a 
consequence of active vaccination [63, 255]. Novel combinational therapies that sensitize 
EphA2+ tumors for specific CD8+ T cell eradication, therefore, may yield enhanced clinical 
benefits in the cancer setting [3].   
 
Interestingly, some RTK, such as EGFR and Her2/neu, serve as client proteins for the molecular 
chaperone HSP90 (see http://www.picard.ch/downloads/Hsp90interactors.pdf), a protein 
designed to stabilize or refold denatured proteins into their native conformations to preserve their 
function and utility in normal and stressed cells [238]. HSP90 is commonly overexpressed in 
tumor cells, where it is believed to protect client oncogenic/survival proteins important to tumor 
progression and metastasis, in part, by preventing their proteasome-dependent destruction [242]. 
As a consequence, many small molecules have been developed to inhibit HSP90 function as 
potential clinical agents.  Among these, 17-DMAG represents one of the newest generation of 
HSP90 inhibitors, exhibiting an increased solubility, the ability to be administered orally, and a 
lower toxicity index versus older generation drugs [246, 249]. 
 
Although EphA2 had not been previously reported to represent a client protein for HSP90, given 
that several alternate RTKs had been identified as HSP90 clients, I felt this was a logical 
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possibility. Therefore, I hypothesized that inhibition of HSP90 function might lead to the 
degradation of EphA2 proteins most probably via the proteasome and that derivative peptides 
might gain access to nascent MHC class I molecules through the direct presentation pathway. 
Data detailed in the current chapter suggests that EphA2 indeed represents a previously unknown 
HSP90 client protein. Furthermore, treatment of tumor cells with 17-DMAG for 24-48h, at 
clinically well-tolerated doses of this agent [242, 246], results in the proteasome-dependent 
degradation of tumor cell-expressed EphA2 protein and in the augmentation of tumor cell 
recognition by anti-EphA2 CD8+ T cells in vitro.   
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3.3. MATERIALS AND METHODS 
3.3.1. Cell lines and Media 
SLR20 (EphA2+, HLA-A2neg), SLR22 (EphA2+, HLA-A2+) and SKOV3 (EphA2+, HLA-A2neg), 
as well as, the SLR20.A2 (EphA2+, HLA-A2+) and SKOV3.A2 (EphA2+, HLA-A2+) cell lines 
(established via transduction of the corresponding parental cell lines with a recombinant 
retrovirus encoding HLA-A2.1 provided by Dr. Peter Cresswell, Yale University) were used 
both in Western blot analyses and ELISPOT/ELISA analyses. SLR24, Mel397, Mel526, Mel624, 
SKBR3 were used in Western blot analyses.  SLR [8] and Mel [268], cell lines were previously 
established from renal cell carcinoma and melanoma respectively, and SKOV3 and SKBR3 cell 
lines (both kindly provided by Dr. Nora Disis, University of Washington) were previously 
established from ovarian carcinoma and breast carcinoma respectively. All cell lines were 
maintained in RPMI-1640 media supplemented with 10% heat inactivated fetal bovine serum, 
100 U/ml penicillin, 100 mg/ml streptomycin and 10 mM L-glutamine (all reagents from 
Invitrogen, Carlsbad, CA) and free of mycoplasma contamination. 
 
3.3.2. HSP90 inhibitor and Peptides 
HSP90 inhibitors, 17-(allylamino)-17-demethoxygeldanamycin (17AAG, NSC 330507) and 17-
(Dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG, NSC 707545) were 
obtained by National Cancer Institute (Bestheda, Maryland). Lyophilized 17-AAG and 17-
DMAG were dissolved in DMSO or sterile water respectively as stock solution and diluted with 
RPMI-1640 before use. HLA-A2 presented EphA2 peptides, EphA258-66 (IMNDMPIYM; [130]) 
and EphA2883-891 (TLADFDPRV; [8]) were synthesized using 9-fluorenylmethoxycarbonyl 
(Fmoc) chemistry by University of Pittsburgh Cancer Institute’s (UPCI) Peptide Synthesis 
Facility, as previously described [8]. The purity of peptides was >96% based on high 
performance liquid chromatography, with peptide identity validated by mass spectrometric 
(MS/MS) analyses performed by the UPCI Protein Sequencing Facility (a Shared Resource). The 
ICP471-35 and ICP4735-1 synthetic peptides [265] were kindly provided by Dr. Peter Cresswell. 
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3.3.3. Western Blot Analyses 
Tumor cell lines at 80-90% confluency were incubated with 17-DMAG (10-1000 nM) in 2% 
human serum supplemented RPMI-1640 media for 24-48h, as indicated in text. To assess the 
impact of proteasome function, endosomal acidification and retrotranslocation on EphA2 protein 
degradation promoted by the HSP90 inhibitor, MG-132 (5-10 μM; Sigma-Aldrich, St. Louis, 
MO), chloroquine (30-100 μM; Sigma-Aldrich) and Pseudomonas aeruginosa exotoxin A (10-
50 μg/ml; Sigma-Aldrich),  respectively, were added at the initiation of 24h tumor cell cultures, 
as indicated in individual experiments. Harvested cells were then incubated with lysis buffer (1% 
TritonX-100, 150 mM NaCl, 10 mM Tris-HCl pH7.4, 1 mM EDTA, 0.2 mM sodium 
orthovanadate, 0.5% NP-40 in PBS; all reagents from Sigma-Aldrich) containing a protease 
inhibitor cocktail (Complete mini, Roche Diagnostic, Mannheim, Germany) for 30 minutes at 
4oC. Lysates were cleared by centrifugation at 13,500 x g for 10 min, and proteins in the lysate 
were resolved by SDS-PAGE before electro-blotting onto PVDF membranes (Millipore, 
Bedford, MA). Polyclonal anti-EphA2 Ab (Santa Cruz Biotechnology, Santa Cruz, CA), CAIX 
mAb (R&D, MD) and MART-1 mAb (NeoMarkers, Fremont, CA) were used to detect each 
protein. Monoclonal antibodies against TAP-1 and TAP-2 (NOB-1 and NOB-2, respectively) 
were kindly provided by Dr. Soldano Ferrone, University of Pittsburgh. Monoclonal antibodies 
against β-actin (clone AC-15, Abcam), GAPDH and HLA-A2 heavy chain (HC-A2; the kind gift 
of Dr. H. Ploegh, Massachusetts Institute of Technology, [259]) were used for the detection of 
loading control. Horseradish peroxidase (HRP)-conjugated goat anti-rabbit antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA) or HRP-conjugated goat anti-mouse IgG (BioRad) were used as 
secondary antibodies. Probed proteins were then visualized by Western LightingTM 
chemiluminescence detection kit (Perkin Elmer, Boston, MA) and exposed to X-Omat film 
(Eastman Kodak, Rochester, NY) for 1-5 min. 
 
3.3.4 Flow Cytometry 
Control or treated tumor cells were harvested with Trypsin-EDTA (Invitrogen), washed and then 
incubated with anti-EphA2 mAb (B2D6, Upstate Biologicals, Inc., Lake Placid, NY) for 30 
minutes at 4oC. After washing with PBS/0.2% BSA/0.02% NaN3, cells were stained with FITC-
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conjugated anti-mouse IgG (MP Biomedicals, Solon, OH) for 30 min at 4oC. Cells were washed 
twice, then analyzed using an LSRII flow cytometer (BD Biosciences, San Jose, CA).  Total 
HLA class I complexes, HLA-A2 complexes and empty HLA-A2 molecules were monitored by 
W6/32 (Serotec Inc., Raleigh, NC), BB7.2 (American Type Culture Collection) and HC-A2 (the 
kind gift of Dr. H. Ploegh, Massachusetts Institute of Technology, [259]) respectively. Purified 
mIgG1 (Sigma-Aldrich) was served as isotype control mAb for those antibodies. B7 family 
molecules were analyzed by PE conjugated mAbs against CD80, CD86, B7-H1, B7-H2 and B7-
H4 along with PE conjugated isotype control (All eBiosciences, CA).  
 
3.3.5. Proteasome Function Analysis 
SLR20 cells were transfected with the proteasome sensor vector (PSV; BD Biosciences) using 
lipofectamine 2000 (Invitrogen) and selected in cultures containing G418 (Invitrogen), thus 
generating SLR20.PSV cells. PSV expresses a fluorescent substrate for the proteasome [269], 
which accumulates in the cytoplasm of cells if proteasome function is inhibited. SLR20.PSV 
cells were grown to 80-90% confluency, before being cultured in the absence or presence of 17-
DMAG or the proteasome inhibitors MG-132 (Sigma-Aldrich) or PS-341 (Bortezomib; kindly 
provided by Dr. Ram Ganapathi, Cleveland Clinic Foundation) at the indicated concentrations 
for 24h at 37oC and 5% CO2 tension. Fluorescence was detected in the FITC bandwidth (i.e. 
488nm) by flow cytometry.   
 
3.3.6. Analysis of EphA2 Proteins in Cytosol and Membrane Fractions 
SLR20.A2 cells were treated with 17-DMAG (0-1000 nM) and/or mAb208 for 24h and 
harvested with Trypsin-EDTA (Invitrogen).  Half of cells were incubated with lysis buffer for 30 
min at 4oC, centrifuged at 13,500 x g for 10 min as described in Western blot section, then both 
of obtained supernatant and pellet fractions were mixed with Laemmli Sample buffer with 2% β-
Mercaptoethanol. The other half of cells were subjected to repeated freeze-thaw cycle, 
centrifugation at 17,000 x g for 5h, then both of supernatant (cytosolic fraction) and pellet 
fractions (crude membrane fraction) were mixed with Laemmli Sample buffer with 2% β-
Mercaptoethanol. All samples were then analyzed for EphA2 protein by Western blot.  
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3.3.7. T cell lines and Clones 
Bulk CD8+ T cell lines and clones specific for EphA258-66 or EphA2883-891 were generated as 
previously described [8]. Briefly, mature dendritic cells (DC) were developed from peripheral 
blood mononuclear cells (PBMC; obtained with written consent under an IRB-approved 
protocol) isolated from normal HLA-A2+ donors in 7 day cultures containing rhGM-CSF 
(Sargramostim; Amgen, Thousand Oaks, CA) and rhIL-4 (Peprotech, Rocky Hill, NJ), then 
pulsed with either the EphA258-66 or EphA2883-891 peptides (10 μM) for 4h at 37oC at 5% CO2 
tension. Autologous CD8+ T cells were stimulated on a weekly basis with peptide-pulsed 
autologous DC or PBMC for 3-4 cycles (at a T:DC ratio of 10:1, or at a T:PBMC ratio of 1:1) to 
generate a bulk population of peptide-specific CD8+ T cells. These T cells were used in tumor 
recognition assays and for cloning via limiting dilution assays [260]. T cells were maintained in 
IMDM media supplemented with 10% human AB serum, 100 U/ml penicillin, 100 mg/ml 
streptomycin, 10 mM L-glutamine and MEM Non-essential amino acids (all reagents from 
Invitrogen, except human AB serum that was purchased from Sigma-Aldrich). After their initial 
isolation, T cell clones were expanded in vitro in IMDM media supplemented with 1 μg/ml 
phytohemagglutinin (PHA; Sigma-Aldrich) and 200 U/ml rhIL-2 (Peprotech). 
 
3.3.8. Tumor Recognition Assays 
Tumor recognition by anti-EphA2 T cells was evaluated by IFN-γ ELISPOT assays as described 
before [8, 260] or using a commercial hIFN- γ ELISA (BD-Biosciences). For both the ELISPOT 
and ELISA protocols, tumor cells were treated with 100-500 nM 17-DMAG and/or 10 μg/ml 
anti-EphA2 mAb208 (agonistic mAb, kindly provided by MedImmune, [66]) for 24-48h, prior to 
their harvest using Trypsin-EDTA (Invitrogen). MOPC21 mAb (mouse IgG; Sigma-Aldrich) 
was served as specificity controls of mAb208. After washing with PBS (Invitrogen), tumor cells 
were co-cultured with anti-EphA2 T cell lines/clones at an effector:target cell ratio of 2:1 for 24h 
at 37oC and 5% CO2 tension. In some assays, where indicated, the class I-restricted nature of 
CD8+ T cell recognition of tumor cells was assessed by inclusion of 10 μg/well W6/32 (pan 
HLA-class I) mAb. To assess the impact of proteasome function, TAP function, endosomal 
acidification and retrotranslocation on 17-DMAG-treated tumor cells recognition by anti-EphA2 
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CD8+ T cells, MG-132 (10 μM), ICP471-35 peptide (10 μg/ml), chloroquine (100 μM) or 
Pseudomonas aeruginosa exotoxin A (10-50 μg/ml), respectively, were added to tumor cells 
during the 24h treatment period.  As a negative control for the ICP471-35 peptide in these studies, 
the “reverse”, scrambled ICP4735-1 peptide [265] was used at a concentration of 10 μg/ml. After 
harvest, tumor cells were washed twice with PBS, prior to using these cells as targets for T cell 
recognition. 
 
3.3.9. Statistical Analyses 
Two-tailed Student’s t tests were used to evaluate the difference between groups, with p values < 
0.05 considered significant. 
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3.4. RESULTS 
3.4.1. The HSP90 inhibitor 17-DMAG induces EphA2 degradation that is blocked by 
inhibitors of proteasome function, but not endosomal acidification. 
The EphA2 (over)expressing RCC cell line SLR20 was incubated in the absence or presence of 
17-DMAG (0-1000 nM) for 24-48h. The resultant cells were then analyzed for EphA2 protein 
levels by Western blotting (i.e. total protein; Figure 12A) and flow cytometry (i.e. cell surface 
protein; Figure 12B). In both cases, tumor EphA2 levels were reduced at both 24h and 48h post-
treatment with 17-DMAG treatment (IC50 approximately 250 nM). Inclusion of the proteasome 
inhibitor MG-132 blocked the ability of 17-DMAG to promote EphA2 protein loss (Figure 12C), 
suggesting HSP90 effects on EphA2 are at least partially proteasome-dependent. In contrast, 
inclusion of chloroquine, which disrupts endosomal acidification [270], failed to impact 17-
DMAG-induced degradation of EphA2 protein (Figure 12C). Single and combinational (17-
DMAG + inhibitors) drug treatments did not lead to tumor cell death based on retention of 
control β-actin signal in the Western Blot experiments and appropriate forward/side scatter 
gating profiles in the flow cytometry assays (Figure 12 and data not shown).  
 
Unexpectedly, a greater degree of EphA2 reduction was noted in Western blot analyses than in 
flow cytometry analyses. To address the pool of EphA2 protein most sensitive to 17-DMAG 
effects, SLR20 was treated with 17-DMAG (0-1000 nM) and/or EphA2 agonistic antibody 
mAb208 for 24h.  Cell lysate and cell lysate pellet obtained from regular cell lysate preparation 
(Figure 13A) and intracellular fraction and crude membrane fraction obtained by freeze-thaw 
cycle (Figure 13B) were analyzed by Western blotting. Comparable patterns of EphA2 reduction 
were observed regardless of the sample preparation and regardless of the reagents used to trigger 
EphA2 degradation. Twenty-four hour treatment with 17-DMAG was effective in reducing 
EphA2 levels in both the cytoplasmic and cell membrane fractions of tumor lysates. The reason 
for the discrepancy between Western blot analysis and flow cytometry analyses conceivably 
might be attributed to the high back ground staining of certain cells by mAb (B2D6) used in the 
flow cytometry analyses.   
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Figure 12. HSP90 inhibitor 17-DMAG promotes the loss of tumor EphA2 protein (via 
degradation) in a dose-, time- and proteasome-dependent manner.  
A. The EphA2+ SLR20 RCC line was incubated in the absence or presence of 17-DMAG (10-
1000 nM) for 24h or 48h at 37oC, before generation of cell lysates and Western blot analysis to 
determine levels of EphA2 protein expression. β-actin was monitored as an internal control 
protein. B. SLR20 cells were treated as above, with cell surface expression of EphA2 protein 
monitored by flow cytometry. Differences in tumor cell MFI expression of EphA2 were 
significant for 17-DMAG-treated versus control, untreated tumor cells evaluated in flow-based 
assays (i.e. p = 0.008 at 24h for 500 nM 17-DMAG treated (MFI = 28 +/- 13) versus untreated 
(MFI = 60 +/- 12). C. SLR20 cells were treated with 500 nM 17-DMAG in the absence or 
presence of MG-132 (10 μM) or chloroquine (100 μM) prior to Western blot analysis in order to 
analyze the dependency of EphA2 (versus control β-actin) protein loss on proteasome function 
or endosomal acidification, respectively. Data in each panel are representative of 4 independent 
experiments performed. 
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Figure 13. 17-DMAG-induced changes in EphA2 protein are similarly reflected in the 
membrane-associated pool of proteins. 
SLR20.A2 cells were treated with 17-DMAG (0-1000 nM) and/or mAb208 for 24h and 
harvested with Trypsin-EDTA. Half of the cells were incubated with lysis buffer for 30 minutes 
at 4oC, centrifuged at 13,500 x g for 10 min, and the obtained supernatant and pellet fractions 
were mixed with Laemmli Sample buffer containing 2% β-Mercaptoethanol, After separation of 
proteins by 7.5% SDS-PAGE gel electrophoresis,  levels of EphA2 protein expression were 
determined by Western blotting (A). The other half of cells were subjected to repeated freeze-
thaw cycle, centrifugation at 17,000 x g for 5h, and both the supernatant (cytosolic fraction) and 
pellet fractions (crude membrane fraction) were mixed with Laemmli Sample buffer with 2% β-
Mercaptoethanol, and levels of EphA2 protein determined by Western blotting (B). β-actin or 
MHC class I heavy chain was monitored as internal control proteins, as indicated.  
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I believe this to be unlikely, since this mAb did not stain EphA2 negative cell lines, B16 (mouse 
melanoma), Colo38, LNCap (Appendix Figure 3A).  Since no other mAb for flow cytometric 
detection of EphA2 was available, we tried to detect EphA2 by flow cytometry using the ephrin-
A1 Fc fusion protein and FITC conjugated anti-human Fc antibody as a “sandwich stain” 
(Appendix Figure 3B). Like the B2D6 results, I was still unable to reduce the level of EphA2 
reduction to the level suggested by Western blotting. Finally, the cell harvesting procedure did 
not appear to introduce differences in the perceived results, since I noted no change in EphA2 
staining intensity when comparing results obtained using cell harvested using Trypsin/EDTA 
versus EDTA alone (Appendix Figure 3C).  Although Western blot analyses of the crude 
membrane fraction of SLR20.A2 cells did not reveal the existence of 17-DMAG resistant 
membrane associated EphA2, we observed quantitative variance between flow cytometry and 
Western blotting analyses.  
 
To address the generality of reduction in EphA protein expression levels as a consequence of 17-
DMAG treatment, I repeated these initial experiments using a panel of tumor cell lines, including 
RCC (SLRs) and melanoma (Mel) cell lines, as well as the breast carcinoma (SKBR3) and 
ovarian carcinoma (SKOV3) cell lines. Overall, over a broad range of 17-DMAG concentrations 
(0-2000 nM), I observed losses in EphA2 expression post-17-DMAG treatment versus control, 
regardless of the cell line evaluated (Figure 14).  SKBR3 and SKOV3 were very sensitive to 17-
DMAG treatment with regard to EphA2 protein reduction, while the RCC line SLR24 was 
somewhat “resistant”.  This difference in sensitivity could have simply been the result of 
differential expression levels of HSP90 in these cell lines, however, both SLR20 (17-DMAG 
sensitive) and SLR24 (less sensitive) exhibited comparable levels of HSP90 protein expression 
even after 17-DMAG treatment (Appendix Figure 4). Differential surface features of the EphA2 
protein, such as charge, hydrophobicity, and phosphorylation may underlie why these cell lines 
respond somewhat variably to 17-DMAG, and clearly more studies are warranted to provide an 
answer to this question.   
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Figure 14. RCC, Melanoma, Breast and Ovarian tumors are all sensitive to 17-DMAG-
induced reduction in EphA2 protein levels. 
The SLR22, SLR24 (RCC, A), Mel397, Mel526, Mel624 (melanoma, B), SKBR3 (breast 
carcinoma, C) and SKOV3 (ovarian carcinoma, D) cell lines were incubated in the absence or 
presence of 17-DMAG (10-2000 nM) for 24h at 37oC, before the generation of cell lysates and 
the performance of Western blot analyses to determine levels of EphA2 protein expression. β-
actin was monitored as an internal control protein. 
 
 
 
Although 17-DMAG reduced EphA2 protein levels on/in tumor cells of various histological 
types at a concentration of 500 nM, such treatment did not affect control (non-HSP client) 
protein expression levels (i.e. CAIX in RCC or MART-1 in melanoma cell lines; Figure 15).    
 
In addition to 17-DMAG, another Geldanamycin derivative HSP90 inhibitor, 17-AAG, was 
tested for its efficacy in reducing tumor cell EphA2 protein expression levels. A strong reduction 
in EphA2 protein expression was observed by Western blotting, as well as, flow cytometry 
(Appendix Figure 5). This result is consistent with those obtained using 17-DMAG.  However, 
higher concentration of 17-AAG versus 17-DMAG were required in order to obtain comparable 
reduction levels. Importantly, the presence of serum in culture medium impaired the efficacy of 
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17-AAG to reduce EphA2 level, while 17-DMAG was only minimally affected (Appendix 
Figure 6), thus with translation of this work in mind, I employed 17-DMAG alone for all further 
studies. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15. Tumor cell CAIX and MART-1 protein levels are not affected by 17-DMAG 
treatment. 
The SLR22 (RCC, A) and Mel397, Mel526, Mel624 (melanoma, B) cell lines were incubated in 
the absence or presence of 17-DMAG (100 or 500 nM) for 24h at 37oC, before the generation of 
cell lysates and the performance of Western blot analyses to determine levels of CAIX or 
MART-1 proteins expression. β-actin was monitored as an internal control protein. 
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3.4.2. Treatment of tumor cells with HSP90 inhibitor does not significantly alter major 
components of the tumor MHC class I antigen processing machinery (APM) 
Since my ultimate goal was to discern potential augmentation in immune recognition of EphA2+ 
tumor cells after treatment with 17-DMAG, we next assessed the impact of drug treatment on the 
expression and/or function of components of tumor cell MHC class I APM. Proteasome activity 
was analyzed using a model employing SLR20 cells transfected with a proteasome sensor vector 
(i.e. SLR20.PSV cells), in which intracellular fluorescent protein accumulates when proteasome 
function is inhibited. As depicted in Figure 16A, the proteasome inhibitors MG-132 and PS-341 
both increased the fluorescence of SLR20.PSV cells, while 17-DMAG had minimum effect even 
after 48h at concentrations in excess of that required to promote EphA2 degradation (as shown in 
Figure 12).  Transporter associated protein (TAP) levels (both TAP-1 and TAP2) were next 
analyzed by Western blot, and were also shown to be unaffected by 17-DMAG treatment (Figure 
16B).  Finally, tumor cell surface MHC class I levels were shown to be unaltered by 17-DMAG 
as assessed by flow cytometry using a pan-class I-reactive mAb (Figure 16C). These results 
suggest that 17-DMAG does not have a deleterious effect on tumor cell MHC class I/peptide 
complex generation and corollary expression of such complexes on the tumor cell surface.         
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Figure 16. The tumor cell MHC class I antigen processing machinery (APM) is not 
impaired by 17-DMAG treatment at doses capable of promoting EphA2 degradation.   
A. Proteasome sensor vector transfected SLR20 (SLR20.PSV) cells were treated with the 
indicated concentrations of 17-DMAG for 24h or 48h, or they were incubated with the 
proteasome inhibitors MG-132 (10 μM) or PS-341 (10 μM) for 24h. Fluorescence intensity of 
control versus treated tumor cells was then monitored by flow cytometry (i.e. fluorescence 
intensity increases as a function of inhibiting proteasome-mediated degradation of the 
fluorescent transgene product). B. SLR20 cells were incubated with 17-DMAG at the indicated 
concentrations for 24h or 48h, with subsequent whole cell lysates subjected to Western blot 
analyses for TAP-1 and TAP-2 protein content. C. SLR20 cells were treated with 17-DMAG 
(500 nM) either for 24h or 48h and cell surface MHC class I levels determined using W6/32 (a 
pan-class I reactive mAb) and flow cytometry. Isotype control mAb staining = filled histograms; 
W6/32 staining = empty histograms. Representative data from 1 of 3 independent experiments 
performed is presented in each case.  
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3.4.3. 17-DMAG treatment of tumor cells transiently enhances tumor recognition by bulk 
and cloned CD8+ T cells specific for EphA2 in a proteasome dependent manner 
Bulk CD8+ T cell lines and clones reactive against EphA2 were generated from normal HLA-
A2+ donors using an in vitro stimulation protocol employing autologous DC pulsed with either 
the EphA258-66 or EphA2883-891 (HLA-A2-presented) peptide epitopes as stimulator cells. After 2-
3 rounds of identical restimulation, responder CD8+ T cells were assessed for recognition of 
RCC cell lines (control or 17-DMAG pre-treated) in IFN-γ ELISPOT assays. As shown in Figure 
17, bulk (Figure 17, A and B) or cloned (Figure 17C) peptide-primed CD8+ T cells recognized 
EphA2+, HLA-A2+ RCC lines (SLR22 (Figure 17A) and SLR20.A2 (Figure 17, B and C)) in a 
manner that was class I-restricted (i.e. inhibited by W6/32 mAb; Figure 17A). These same T cell 
lines or clone reacted poorly against the EphA2+, but HLA-A2neg SLR20 cell line (Figure 17, B 
and C). When SLR20.A2 was pretreated with 17-DMAG for 24h prior to co-culture with bulk or 
cloned T cells reactive against either of the EphA2 peptides, tumor cell recognition by T cells 
was significantly enhanced (p < 0.05; Figure 17, B and C). However, this enhanced immune 
recognition was transient in nature, since tumor cells pre-treated for 48h with 17-DMAG were 
recognized to a degree that was comparable with untreated tumor cells (Figure 17C). 
 
To address the question of whether the reduction of T cell recognition at 48h versus 24h is 
related to tumor cell expression of co-stimulatory/co-inhibitory molecules, SLR20.A2 cells were 
untreated or treated for 24-48h with 17-DMAG at doses of 100-1000 nM. Cells were then 
analyzed for cell surface expression of the co-stimulatory CD80 (B7.1) and CD86 (B7.2) versus 
co-inhibitory molecules B7-H1, B7-H2 and B7-H4 by flow cytometry (Figure 18). While 
SLR20.A2 cells expressed strong levels of B7-H1, expression levels for CD80, CD86, B7-H2 
and B7-H4 were weak to negative. There might be a slight increase of B7-H2 staining of 
SLR20.A2 cells after 17-DMAG treatment, however, an increase in isotype staining intensity 
was also noted under these conditions. No significant differences were noted in expression 
profiles for any of these co-inhibitory receptors +/- 17-DMAG treatment and 24h versus 48h 
incubation time. Data are representative of 2 independent assays performed. 
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Figure 17. Recognition of EphA2+ SLR20.A2 tumor cells by bulk anti-EphA2 CD8+ T cells 
is enhanced after treatment with 17-DMAG.  
A. HLA-A2-restricted CD8+ T cells were generated in vitro by repeated stimulation with 
autologous DC pulsed with the EphA258-66 or EphA2883-891 peptide epitopes. These bulk CD8+ T 
cells were then co-cultured with the EphA2+, HLA-A2+ SLR22 RCC line alone (black bars) or in 
the presence of blocking anti-class I mAb W6/32 (gray bars) for 24h at 37oC in IFN-γ ELISPOT 
assays. B. SLR20 (EphA2+, HLA-A2neg; light gray bars) or SLR20.A2 (EphA2+, HLA-A2+; 
black bars) cells were cultured in the absence or presence of 500 nM 17-DMAG for 24h or 48h, 
prior to analysis of these target cells in IFN- γ ELISPOT assays. Bulk anti-EphA258-66 or anti-
EphA2883-891 CD8+ T cell lines were used as responder cells. C. An HLA-A2-restricted, EphA258-
66 peptide-specific CD8+ T cell clone was established from bulk CD8+ T cell cultures in limiting 
dilution cultures. This T cell clone (15/9) exhibited low functional avidity based on recognition 
of T2 (HLA-A2+) cells pulsed with titrations of the EphA258-66 peptide (i.e. half-maximal T cell 
reactivity at a peptide concentration of approximately 1 μM; Figure 8A.). SLR20 (EphA2+, 
HLA-A2neg; light gray bars) or SLR20.A2 (EphA2+, HLA-A2+; black bars) cells were cultured in 
the absence or presence of 500 nM 17-DMAG for 24h, prior to analysis of these target cells in 
IFN- γ ELISPOT assays. In all panels, data are reported as the mean +/- SD of triplicate 
determinations from a single representative IFN- γ ELISPOT assay, with 3 independent assays 
performed in each case.  *p < 0.05 for all indicated comparisons.     
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Figure 18. 17-DMAG treatment has minimal impact on tumor cell expression of co-
inhibitory receptors.  
SLR20.A2 cells were untreated or treated for 24h (A) or 48h (B) with 17-DMAG at doses of 
100-1000 nM. Cells were then analyzed for cell surface expression of the co-stimulatory CD80 
(B7.1) and CD86 (B7.2) versus co-inhibitory molecules B7-H1, B7-H2 and B7-H4 by flow 
cytometry. While SLR20.A2 cells expressed strong levels of B7-H1, expression levels for CD80, 
CD86, B7-H2 and B7-H4 were weak to negative. No significant differences were noted in 
expression profiles for any of these co-inhibitory receptors +/- 17-DMAG treatment and 24h 
versus 48h incubation time. Data are representative of 2 independent assays performed.  
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I also assessed whether the loading ability of exogenous peptide by tumor cells is differential at 
48h (Figure 19). SLR20.A2 tumor cells were cultured in the absence or in the presence of 500 
nM 17-DMAG for 24h or 48h. Tumor cells were then loaded with the indicated concentrations of 
synthetic EphA258-66 peptide and analyzed for their ability to be recognized by bulk T cells using 
the IFN-γ content of culture supernatants as an indicator. The ability of 17-DMAG treated tumor 
cells to be loaded by exogenous peptide was somewhat diminished when compared with 
untreated tumor cells (Figure 19A), but the loading ability of these target cells was not different 
at the 24h versus 48h time points post-DMAG application.  Alternatively, untreated or 17-
DMAG-treated SLR20.A2 cells were analyzed in flow cytometry assays using the mAb HC-A2 
which reacts against “empty” HLA-A2 complexes [271]. In these studies, a cohort of tumor cells 
treated briefly with citrate buffer (pH 3.0 for 1 minute) was used as a positive control; i.e. such 
treatment denatures cell surface MHC class I complexes, leading to the enhanced expression of 
“empty” HLA-A2 complexes reactive with the HC-A2 mAb. As shown in Figure 19B, there was 
no discernable change in the prevalence of “empty” HLA-A2 complexes on the tumor cell 
surface at 24h or 48h.  All of these data indicate that the reduction in the ability of 17-DMAG to 
enhance T cell reactivity at 48h versus 24h post-treatment is not due to a defect in the ability of 
tumor cell MHC class I molecules to functionally present peptide epitopes.  
 
To determine whether 17-DMAG could sensitize tumor cells of an alternate lineage to anti-
EphA2 CD8+ T cell recognition, we treated SKOV3.A2 ovarian carcinoma cells (EphA2+, HLA-
A2+; Figure 20A) with 17-DMAG for 24h in vitro. As previously shown in Figure 14D, 17-
DMAG (500 nM)-treated SKOV3.A2 cells displayed reduced EphA2 protein expression (versus 
control untreated tumor cells). Anti-EphA258-66 bulk CD8+ T cells exhibited enhanced 
recognition of 17-DMAG-treated SKOV3.A2, but not parental SKOV3 (EphA2+, HLA-A2neg), 
tumor cells (Figure 20, B and C). Such recognition was 17-DMAG dose-dependent (Figure 20B), 
as well as, MHC class I-restricted in nature based on the inhibitory effects associated with 
inclusion of mAb W6/32 during the co-culture period (Figure 20C). Since the ability of 17-
DMAG to promote EphA2 degradation in tumor cells was inhibited by MG-132, but not by 
chloroquine (Figure 12), we next evaluated the impact of these agents on anti-EphA2 CD8+ T 
cell recognition of HSP90 inhibitor-treated tumor cells.  As shown in Figure 20D, enhanced T 
cell recognition of 17-DMAG-treated SKOV3.A2 cells was effectively ablated by the 
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Figure 19. The ability of anti-EphA258-66 T cells to recognize peptide-pulsed SLR20.A2 
tumor cells is reduced equitably after 24h and 48h treatment with 17-DMAG, however, this 
appears unrelated to the level of “empty” HLA-A2 complexes expressed on the tumor cell 
membrane.  
SLR20.A2 tumor cells were untreated or treated with 500 nM 17-DMAG for 24h or 48h. A. 
Tumor cells were then loaded with the indicated concentrations of synthetic EphA258-66 peptide 
and analyzed for their ability to be recognized by clone 15/9 T cells. After 24h incubation, 
culture supernatants were harvested and analyzed for IFN-γ content using a specific ELISA. 
Results are reported as the mean +/- SD of triplicate determinations. Alternatively, in B., 
untreated or 17-DMAG-treated SLR20.A2 cells were analyzed in flow cytometry assays using 
the mAb HC-A2 which reacts against “empty” HLA-A2 complexes [271]. In these studies, a 
cohort of tumor cells treated briefly with citrate buffer (pH 3.0 for 1 minute) was used as a 
positive control; i.e. such treatment denatures cell surface MHC class I complexes, leading to the 
enhanced expression of “empty” HLA-A2 complexes reactive with the HC-A2 mAb. Isotype 
control mAb staining = filled histograms; HC-A2 staining = empty histograms. Two independent 
assays were performed in each case. 
 
 
 
proteasome inhibitor, but not by the lysosomotropic drug (chloroquine). Notably, MG-132 also 
reduced basal recognition of SKOV3.A2 cells by anti-EphA2 T cells (Figure 20D), supporting 
the normal loading of tumor cell class I complexes with EphA2 peptides occurs via a 
proteasome-dependent pathway.      
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Figure 20. 17-DMAG promotes enhanced recognition of the EphA2+, HLA-A2+ ovarian 
carcinoma cell line SKOV3.A2 in vitro via a mechanism likely involving EphA2 
retrotranslocation and proteasome-mediated degradation, but not lysosomal acidification. 
A. SKOV3.A2 tumor cells were analyzed for expression of cell surface HLA-A2 protein by flow 
cytometry using BB7.2 mAb (open profiles) versus isotype control mAbs (filled profiles). B. 
SKOV3.A2 tumor cells were untreated or treated with 17-DMAG (500 or1000 nM) for 24h. 
Cell-free supernatants were harvested after a 24h co-culture of bulk anti-EphA258-66 T cells (105) 
and tumor cells (0.5x105; +/- 17-DMAG pretreatment) and analyzed for IFN- γ content by 
specific ELISA. Light gray bars indicate untreated SKOV3, and black bars indicate SKOV3.A2. 
C. SKOV3.A2 tumor cells were untreated or treated with 17-DMAG (500 nM) for 24h and co-
cultured with bulk anti-EphA258-66 T cells in the absence or in the presence of W6/32 or 
EphA258-66 peptide (T cell 105, tumor cell 0.5x105). Cell-free supernatants were harvested and 
analyzed for IFN-γ content by specific ELISA. D. SKOV3 or SKOV3.A2 tumor cells were 
untreated or treated with 500 nM 17-DMAG +/- MG-132 (10 μM) or chloroquine (100 μM) or 
exotoxin A (50 μg/ml) for 24h, before being used as targets for bulk anti-EphA258-66 CD8+ T 
cells (106) responses monitored using IFN- γ ELISA. All ELISA data is reported as the mean +/- 
SD of triplicate assay determinations; *p < 0.05 for all indicated comparisons. Data in all panels 
are from 1 representative experiment of 3 performed.      
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3.4.4. 17-DMAG treatment of tumor cells enhances tumor recognition by a low avidity 
CD8+ T cell clone specific for EphA2 via an ERAD- and TAP-dependent mechanism.  
17-DMAG promotes enhanced recognition by CD8+ T cells capable of recognizing peptides 
derived from both the extracellular (i.e. EphA258-66) and the intracellular (i.e. EphA2883-891) 
domains of this RTK (Figure 17B). This suggests that both domains of this transmembrane 
protein must become accessible for proteasomal processing into peptides that are then conveyed 
via TAP into the ER for loading in nascent HLA-A2 complexes in tumor cells. Current 
paradigms [207, 266, 267] suggest that cytosolic access for the extracellular domains of 
transmembrane proteins may be accomplished through a retrotranslocation process involving 
Sec61-dependent “ratcheting” of the target protein into the cytoplasm, where it may become a 
substrate for the proteasome. To test this hypothesis, we added the ERAD inhibitor exotoxin A 
[265] to tumor cells during culture with 17-DMAG, before their analysis in Western blotting and 
T cell assays. As shown in Figure 21A, exotoxin A inhibits 17-DMAG-induced degradation of 
tumor cell EphA2 protein. Notably, exotoxin A also prevents enhanced recognition of SLR20.A2 
tumor cells by anti-EphA2 (clone 15/9) CD8+ T cells after 24h treatment with 17-DMAG (Figure 
21, B and C), but does not negatively impact the recognition of EphA2 peptide-pulsed tumor 
cells (Figure 21B). Similar results were obtained using a bulk anti-EphA258-66 CD8+ T cell line 
and the SKOV3.A2 tumor cell line (Figure 20D).    
 
The dependence of the anti-EphA2 T cell sensitizing effects of 17-DMAG on tumor cell TAP 
function was next addressed.  We observed that co-treatment of tumor cells with 17-DMAG and 
an N-terminal fragment of the ICP47 protein (ICP471-35), a (Herpes Simplex) viral inhibitor of 
TAP [265], ablated enhanced T cell recognition when compared to tumor cells treated with 17-
DMAG alone (p < 0.05). This effect was specific, as inclusion of a scrambled peptide ICP35-1 
(bearing the reverse AA sequence of ICP471-35) exhibited no such inhibitory effect (Figure 21C).  
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Figure 21. 17-DMAG treatment improves recognition of the SLR20.A2 RCC cell line by a 
low avidity, anti-EphA258-66 CD8+ T cell clone in a TAP- and ERAD-dependent manner. 
 A. SLR20.A2 tumor cells were untreated or treated for 24h with 500 nM 17-DMAG  +/- 10, 30 
or 50 μg/ml exotoxin A, then analyzed for expression of EphA2 versus control β-actin protein by 
Western blotting. B. Untreated SLR20 cells (light gray bars) or SL20.A2 cells (black bars) 
pretreated as in panel A using 10 μg/ml exotoxin A were used as targets for recognition by anti-
EphA258-66 CD8+ T cell clone 15/9 in IFN- γ ELISPOT assays. Drug-treated tumor cells pulsed 
with exogenous EphA258-66 peptide (10 μg/ml) to clone 15/9 was included as a positive control. 
C. SLR20 (light gray bars) and SLR20.A2 (black bars) tumor cells were untreated or treated with 
500 nM 17-DMAG +/- 50 μg/ml exotoxin A, 10 μg/ml ICP471-35 peptide or 10 μg/ml ICP4735-1 
scrambled peptide for 24h, prior to use as target cells for clone 15/9 T cell recognition in IFN- γ 
ELISPOT assays. All ELISPOT data are reported as the mean +/- SD of triplicate 
determinations. In all cases, data are representative of that obtained in 3 independent assays 
performed. * p < 0.05 for all indicated comparisons. 
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3.4.5. Combined treatment of EphA2+, HLA-A2+ tumor cells with both 17-DMAG and 
agonist (anti-EphA2) mAb208 results in superior recognition by a low avidity CD8+ T cells 
specific for EphA2.   
As I previously reported (in Chapter 2) that EphA2 agonist mAb208 promotes the proteasomal 
destruction of tumor EphA2 protein and enhances specific CD8+ T cell recognition of treated 
tumor cells [260], I next investigated whether the combined use of both 17-DMAG and mAb208 
would result in an even greater degree of tumor cell recognition by specific T cells when 
compared to either treatment modality alone. SLR20.A2 cells were cultured for 24h in the 
absence or presence of 17-DMAG +/- mAb208 or control IgG, with IFN-γ ELISPOT assays 
subsequently performed using the 15/9 CD8+ T cell clone and a bulk anti-EphA2883-891 CD8+ T 
cell line. As depicted in Figure 22, A and B, while both 17-DMAG and mAb208 treatment 
resulted in reduced EphA2 expression on SLR20.A2 cells, combined treatment with both 
reagents yielded an even greater degree of EphA2 protein loss. T cell assays similarly supported 
the greatest degree of tumor cell recognition by CD8+ T cells (targeting either of the EphA2 
epitopes) after SLR20.A2 cells were pretreated with both 17-DMAG and mAb208 versus either 
reagent alone (p < 0.05; Figure 22, C and D).  
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Figure 22. Superior in vitro recognition of SLR20.A2 tumor cells by anti-EphA2 CD8+ T 
cells after combined treatment with 17-DMAG and agonistic mAb208. 
 A. SLR20.A2 cells were untreated or treated for 24h with 17-DMAG (100 nM) +/- 10 μg/ml of 
(anti-EphA2) mAb208 or control IgG (cIgG), after which, cells were washed and analyzed by 
flow cytometry for expression of cell surface EphA2 molecules. Data in parentheses represents 
the mean fluorescence intensity value for each cell population analyzed and are representative of 
4 independent assays performed. p < 0.05 for differences in the MFI between all cohorts in pair-
wise comparisons.  In B., SLR20.A2 cells were untreated or treated with 17-DMAG (100-1000 
nM) +/- control IgG (10 μg/ml) or agonist anti-EphA2 mAb208 (10 μg/ml) for 24h. After 
harvest, cells were lysed in TritonX-100-containing buffer. After centrifugation, the soluble 
lysate was recovered and analyzed via Western blotting for comparative levels of EphA2. β-actin 
served as a control protein. In panels C. and D., SLR20 control cells (light gray bars) or 
SLR20.A2 (black bars) tumor cells pre-treated for 24h (as indicated) were used as targets for 
recognition by anti-EphA258-66 clone 15/9 or bulk anti-EphA2883-891 T cells, respectively, in IFN-
 γ ELISPOT assays. *p < 0.05 for all indicated comparisons. Representative data are provided 
from 1 of 3 independent experiments performed in each case.    
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3.5. DISCUSSION 
In 2004, Rosenberg et al. reported that the objective clinical response rates for cancer patients 
treated with immunotherapies was less than 10 % [177], despite the majority of reported studies 
claiming that tumor-specific T cells were increased in peripheral blood of treated patients [257, 
264]. One of the reasons for this discrepancy could be that therapy-induced T cells are only able 
to respond to high levels of specific MHC class I-peptide complexes expressed on professional 
APC versus tumor cells. Such differential recognition could be attributed to the clearance of 
high-avidity T cells capable of reacting against “self”(tumor) antigens as a consequence of 
negative selection. I, therefore, hypothesized that improved clinical benefits might be gained by 
conditionally and selectively enhancing tumor antigen processing and presentation in order to 
allow for improved tumor recognition by tumor antigen-specific CD8+ T cells that exhibit only 
low-to-moderate intrinsic avidity [3]. 
 
Indeed, in the current study I have determined that; 1) EphA2, which is commonly overexpressed 
in a broad range of cancer types, is a novel client protein of HSP90 and that HSP90 inhibitors, 
such as 17-DMAG, promote tumor cell EphA2 degradation; 2) 17-DMAG treatment of EphA2+ 
tumor (RCC and ovarian carcinoma) cells improves recognition by low avidity anti-EphA2 CD8+ 
T cells; 3) enhanced T cell recognition of 17-DMAG-treated tumor cells is MHC-dependent and 
appears unrelated to tumor cell expression of co-stimulatory/co-inhibitory molecules which 
remains unchanged upon HSP90 antagonism, and 4) EphA2+ tumor cell recognition by specific 
CD8+ T cells may be further enhanced by combined treatment with 17-DMAG and EphA2 
agonists (versus treatment with either single modality).  
 
Notably, tumor recognition by T cells reactive against peptides found in the extracellular (i.e. 
EphA258-66) as well as intracellular (i.e. EphA2883-891) domains of the target protein was 
improved by treatment with 17-DMAG. This suggests the superior processing/presentation of 
peptides derived from the full-length, transmembrane protein may be anticipated as a 
consequence of drug application. Mechanistically, I observed that enhanced T cell recognition of 
17-DMAG-conditioned tumor cells was ablated upon inclusion of proteasome (MG-132), TAP 
(ICP471-35) or Sec61 (Pseudomonas aeruginosa exotoxin A) inhibitors. In contrast, there was 
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minimal impact associated with the inclusion of the lysosomotropic agent chloroquine, which 
interferes with endosomal acidification and lysosomal processing of protein antigens. These data 
suggest that the major pool of EphA2 protein undergoing (constitutive as well as) enhanced 
proteasomal processing as a consequence of 17-DMAG inhibition likely enters the tumor cytosol 
via a retrotranslocation event [207, 265-267].  
 
However, at present, I cannot exclude the possibility that the observed ablation of CD8+ T cell 
recognition of tumor cells after treatment with exotoxin A is also, at least partly, due to 
secondary effects on the ER stress response or to protein synthesis inhibition. My rationale to use 
exotoxin A as an inhibitor of retrotranslocation was based on the study reported by Koopmann et 
al. [272], in which this drug was applied to a free microsome model system and shown to inhibit 
Sec61-mediated retrotranslocation of antigenic peptides. In the Koopmann paper, it was found 
that exotoxin A molecules block the Sec61p channel from the ER-luminal side and thereby 
inhibit peptide export (i.e. into the cytosol). However the effective concentration of exotoxin A 
required in the ER for this affect appeared much higher than which one might approach via the 
treatment of a whole cells with exogenous exotoxin A. This leads one to question whether 
exogenous “loading” with exotoxin A can effectively inhibit retrotranslocation in the absence of 
confounding secondary effects. However, in defense of the selectivity of exotoxin A on the 
retrotranslocation pathway in intact cells, Ackerman et al. [265] showed that the treatment of 
myelogenous KG1.Kb cells with exotoxin A effectively blocked the cross-presentation of 
exogenous OVA to specific CD8+ T cells without limiting protein synthesis or the ability of 
treated cells to process and present antigenic peptides derived from proteins in the cell cytoplasm 
(i.e. conventional, direct presentation). Nevertheless, additional studies will be required in my 
model to strictly implicate the mechanism(s) of action associated with exotoxin A-mediated 
antagonism of the beneficial effects of HSP90 inhibitors on tumor cell recognition by CD8+ T 
cells.    
 
At present, we also cannot distinguish whether this pool of EphA2 protein affected derives from 
an early endosomal compartment (i.e. internalized after interaction with the EphA2 ligands co-
expressed by adjacent tumor cells that is unaffected by chloroquine) and/or from newly-
synthesized, miss-folded EphA2 proteins within the exocytic pathway. However, given the 
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observed quantitative variance in 17-DMAG-induced EphA2 degradation as imaged using flow 
cytometry versus Western blotting analyses, and the apparent synergy of agonist mAb208 and 
17-DMAG in promoting EphA2 protein loss and enhanced T cell recognition, it could be 
suggested that mAb208 primarily affects the membrane pool of EphA2 protein, while 17-DMAG 
primarily affects the intracellular this protein. In either case, derivative EphA2 peptides would 
then appear to be integrated into “empty” class I complexes after TAP-dependent transfer into 
the MHC class I loading compartment.   
 
While several HSP90 inhibitors (including geldanamycin, 17-AAG and 17-DMAG) have now 
entered advanced clinical trials, to our knowledge, very few papers have addressed the potential 
effects of HSP90 inhibitors on tumor cell recognition by T cells. In this regard, Castilleja et al. 
reported that the HSP90 inhibitor geldanamycin induced degradation of non-mutated Her2/neu in 
a treated ovarian carcinoma cell line, resulting in enhanced recognition by an HLA-A2-restricted 
CTL line reactive against the Her2/neu369-377  epitope [273]. They also noted that the level of 
HLA-A2 class I molecules expressed by their tumor cell line was increased after treatment [273]. 
Even though this latter result is somewhat in contrast to our current results, the mechanistic 
paradigm(s) for HSP90 inhibitor effects on immune augmentation appear consistent in the two 
studies. In marked contrast, Callahan et al. reported that H-2Ld expression was reduced on cells 
treated with HSP90 inhibitors radicicol, geldanamycin or 17-AAG due to the inhibited loading of 
peptides into MHC class I complexes, and that radicicol treatment of SV40 large T-antigen 
(TAg)-expressing SVB6 cells impaired their recognition by an anti-TAg T cell clone (K11; 
[274]). However the doses of HSP90 inhibitors used by these investigators were high compared 
to those used (50x and 16x) in our study and by Castilleja et al. [273], respectively. Such drug 
excess could result in adverse effects at the level of the tumor cell APM or in the expression of 
alternate integrins/adhesion molecules required for cognate T cell recognition. Moreover, while 
TAg may interact with HSP90, its degradation is only modestly induced by HSP90 inhibitors 
[275], which could limit the pool of derivative TAg peptides for the consequent loading of MHC 
class I complexes required for specific T cell reactivity to occur.   
   
My data suggest that 17-DMAG enhances tumor cell recognition by EphA2-specific CD8+ T 
cells in a transient manner, with improved recognition observed 24h, but not 48h, after drug 
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treatment. This contrasts slightly with the inhibitory effects of 17-DMAG on tumor EphA2 
expression levels which were comparable or somewhat greater at 48h versus 24h. One possible 
explanation for this dichotomy may involve differential rates at which the diverse array of 
HSP90 client proteins undergo proteasomal destruction upon application of 17-DMAG  (Kawabe 
et al., unpublished results). As a result, the competitor substrates for proteasomal processing of 
EphA2 protein may vary over time after drug treatment. If this hypothesis is correct, EphA2 may 
be more efficiently processed and/or be less effectively competed for loading MHC class I 
complexes during the first 24h of HSP90 inhibitor administration. We noted that the ability of 
17-DMAG treated tumor cells to be loaded by exogenous peptide was somewhat diminished 
when compared with untreated tumor cells, but that this was not differential at the 24h versus 
48h time points post-DMAG application and that this did not appear to reflect any change in the 
prevalence of “empty” HLA-A2 complexes on the tumor cell surface as a consequence of drug 
treatment. I interpret these results to suggest that the average affinity of presented peptides 
(including EphA2 epitopes) in tumor cell HLA-A2 (and corollary stability of MHC complexes 
that limit loading of exogenous peptides) may be increased as a consequence of 17-DMAG 
treatment (for 24 or 48h). These findings appear to mitigate concerns that the class I APM is 
substantially altered in tumor cells after extended treatment (i.e. 48h versus 24h) with HSP 
inhibitors, which could have logistically prevented the sustained MHC presentation of EphA2 
peptides.  
 
It is also possible that “chronic” treatment of tumor cells with 17-DMAG suppresses the 
production of EphA2 based on direct (or indirect) effects on EphA2 transcription, etc. In this 
context, activation of the Ras-Raf-MAPK signaling pathway has been shown to enhance EphA2 
transcription [81], however, Raf is a client protein of HSP90 (see 
http://www.picard.ch/downloads/Hsp90interactors.pdf). Hence, HSP90 inhibitors may 
antagonize this signaling cascade [276] and consequently limit EphA2 transcription by 
promoting Raf degradation. We are currently in the process of analyzing such possibilities in 
order to establish an optimal treatment regimen capable of improving tumor cell presentation of 
EphA2 epitopes to the immune system.   
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Although my data supports the increased presentation of EphA2 peptides in tumor cell HLA-A2 
complexes after treatment with 17-DMAG, there is some concern for the mechanistic 
implications of the cross-reactivity of 17-DMAG with another HSP90 family member, gp96 
(GRP94). Gp96 is now known to play important roles in antigen (cross)presentation based on its 
ability to deliver chaperoned, antigenic peptides to nascent MHC class I and class II molecules 
[277, 278]. This has resulted in intense research designed to utilized this protein as an “adjuvant” 
in cancer vaccines [279]. A preferred binding capacity of 17-AAG and 17-DMAG for HSP90 
versus gp96 has been previously reported by Chandarlapaty et al. [251], however, these results 
may be controversial and I cannot formally exclude a role for HSP90 inhibitors on tumor gp96 in 
the results obtained in my model system.  
 
Prospectively, we will perform in vivo experiments in which EphA2+ tumor-bearing mice will be 
treated with orally administered 17-DMAG in hopes of enhancing tumor elimination by 
adoptively-transferred or vaccine-induced anti-EphA2 CD8+ T cells.  However, it may still be 
difficult to discern the specific impact of improved MHC class I/EphA2 peptide complex 
presentation on therapy outcome given the pleiotropic effects of 17-DMAG on tumor cells in 
vivo [242]. Additionally, tumor growth could be substantially inhibited as a consequence of 17-
DMAG’s effects on the tumor vasculature, since EphA2, VEGFR1, VEGFR2, PDGFR and c-
KIT are molecules important for tumor neoangiogenesis and also known client proteins of 
HSP90 (see http://www.picard.ch/downloads/Hsp90interactors.pdf). In addition, overexpression 
of STAT-3 (an HSP90 client protein) has been implicated in more aggressive tumor cells and has 
been suggested to be involved in the tumor-induced accumulation of regulatory T cells [280], 
that may limit therapeutic efficacy.  Hence, the accentuated and sustained degradation of STAT-
3 that could occur under the influence of 17-DMAG [281] may lead to a reduction in regulatory 
T cells found in the tumor microenvironment and improved tumor eradication mediated by anti-
tumor CD8+ T cells. We believe the ability to discriminate between the underlying influences of 
these various mechanisms will be optimized via the study of “pulse” (acute) versus chronic 
administration treatment with 17-DMAG.  In particular, enhancement in tumor cell RTK antigen 
presentation may be best interpreted in the context of short 24-48h treatment cycles, where the 
effects of 17-DMAG on the tumor vasculature and Treg may require extended periods of drug 
administration.   
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In conclusion, my results suggest that an effective combinational immunotherapy for clinical 
translation [3] may be defined by short-term 17-DMAG administration to improve EphA2+ 
tumor cell recognition by CD8+ T cells that have been previously elicited in response to EphA2-
based vaccination or that are provided via adoptive transfer. Such combinational approaches 
might be further improved by inclusion of Type-I or -II interferon co-administration to further 
improve tumor cell APM function and the MHC class I (and II) presentation of targeted epitopes 
by tumor cells in vivo [149, 282]. 
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Preface Chapter 4 
My goal was to determine whether treatment of tumor cells with the HSP90 inhibitor 17-DMAG 
results in the coordinate degradation of multiple (overexpressed) RTK, leading to improved 
recognition by RTK-specific CD8+ T cells in vitro.  As in the case of studies outlined in Chapter 
3, Western Blot and ELISA analyses were performed to monitor Her2/neu (ErbB2) and EGFR 
(ErbB1) degradation and corollary MHC class I-presentation of RTK-derived peptides on tumor 
cells, respectively. I observed that 17-DMAG concomitantly reduced tumor cell expression of 
the Her2/neu and EGFR oncoproteins on diverse types of solid cancers. I also showed that tumor 
cell treatment with 17-DMAG enhanced specific recognition by anti-Her2/neu reactive CD8+ T 
cells (as was the case of EphA2 specific T cells in Chapter 3).  Together with the studies detailed 
in Chapter 3, the current data suggest that HSP90 inhibitors are capable of conditionally 
promoting the enhanced processing and presentation of RTK-derived epitopes allowing for 
superior immune recognition, based on these findings, I believe that drugs, such as 17-DMAG 
have potential as conditional “sensitizers” of tumor cells to immune intervention and may be 
used as a co-therapy to vaccines or adoptive T cell transfer modalities.  
 104
4. HSP90 Inhibitor Coordinately Enhance Recognition of RTK+ Tumor Cells by 
Specific CD8+ T cells  
Mayumi Kawabe*, Maja Mandic , Jennifer L. Taylor , Cecilia A. Vasquez ,  
Amy K. Wesa , Leonard M. Neckers  and Walter J. Storkus*, , . 
 
From the Departments of *Immunology and Dermatology, University of Pittsburgh School of 
Medicine, Pittsburgh, PA 15213, the Urologic Oncology Branch, National Cancer Institute, 
Bethesda, MD 20892 and the University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All the results reported in this study were obtained by Mayumi Kawabe. 
 105
4.1. ABSTRACT 
Published reports, including our own, have documented the coordinate overexpression of 
multiple receptor tyrosine kinases (RTKs) by tumor cells [1], which may contribute to the 
proliferative or metastatic potential of cancer cells and to the typically poorer clinical prognosis 
for patients harboring such cancer lesions. Many current therapies have focused on the silencing 
or neutralization of RTK expression or their associated signaling pathways.  Based on results that 
I presented in Chapter 3, as well as published works, we know that many (if not all) RTKs 
represent client proteins for salvage by HSP90.  Hence, I believe that my previous findings that 
HSP90 inhibitor 17-DMAG promotes tumor cell EphA2 degradation and conditional 
enhancement in tumor cell recognition by anti-EphA2 CD8+ T cells, may be generalized as a 
paradigm for alternate RTKs, such as EGFR and Her2/neu. In the current chapter, I demonstrate 
multiple RTKs that are concomitantly overexpressed by RCC tumor cell lines may be driven into 
the proteasomal degradation pathway by HSP90 inhibitor 17-DMAG, leading to improved tumor 
cell recognition by specific anti-RTK T cells in vitro. When taken together with the data 
previously reported in Chapter 3, I believe this suggests the likely efficacy of a generalized 
combinational therapy for RTK+ tumors consisting of specific vaccination or adoptive T cell 
transfer and cyclical 1-2 day administrations of an HSP90 inhibitor to maximize the therapeutic 
potential of the anti-RTK immune response.   
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4.2. INTRODUCTION 
Receptor tyrosine kinases (RTKs) are comprised of 58 known members (Table 1) and regulate 
diverse cellular functions including proliferation, differentiation, migration, and survival [1].  
Slightly more than half of the known RTKs have been reported to be either mutated or 
overexpressed in cancer cells, including EGFR, ErbB2-4, PDGFR-α/β, VEGFR1-3, FGFR1-4, 
MET, RON, EphA2, EphB2/4, AXL, TIE, TEK [1, 7, 16-18, 20-23].  
 
Among these, Her2/neu (ErbB2) and EGFR (ErbB1) have been the most intensively studied, and 
arguably, the most clinically-relevant RTKs to date. These receptors trigger downstream 
signaling pathways that are not linear but consist of a rich multilayered network, which allows for 
horizontal interactions and permits multiple combinatorial responses [283-285]. An interesting 
feature of this subfamily is that they form homo- or heterodimeric complexes among the four 
ErbB (ErbB1-4) family members, thereby providing signal amplification and diversification 
under physiologic conditions. In tumor cells, these receptors may be activated by additional 
mechanisms such as ligand-independent receptor dimerization due to their overexpression and 
signaling pathways may be disrupted due to mutations. 
 
Her2/neu is a “ligand-less” receptor, but it represents the preferred heterodimerization partner for 
all other ErbB subfamily members. Hence, it exerts its function through a co-receptor function, 
with Her2/neu-containing heterodimers providing stronger intracellular signaling than those 
originating from other ErbB complex receptors [286]. Overexpression of Her2/neu is observed in 
30% of breast and prostate cancers and its overexpression has been linked with poor clinical 
prognosis [287-289]. One of the immunotherapeutic approaches targeting Her2/neu is passive 
immunotherapy using the anti-Her2/neu antibody Trastuzumab, which represents a standard of 
care for patients with Her2 overexpressing, metastatic breast cancer.  The clinical efficacy of this 
Ab appears clear, especially when administered in conjunction with chemotherapy. However not 
all patients with Her2/neu overexpressing tumors display benefits after treatment with 
Traszumab, and the provision of this drug is associated with profound cardiotoxicity (particularly 
in combinational protocols with chemotherapy agents). Another developing therapy strategy 
involves patient vaccination with MHC class I- and class II-restricted Her2/neu-derived peptides, 
or recombinant Her2/neu protein or cDNA [283, 290].  Among several Her2/neu peptide 
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epitopes, the Her2/neu369-377 peptide (also known as E75) is a naturally-processed and MHC class 
I-presented peptide which has been extensively evaluated in pre-clinical studies and clinical 
trials. This epitope is now in Phase II clinical trials after Phase I trials demonstrated that it 
promotes specific CD8+ T cell responses in vivo in patients [291, 292]. 
 
In contrast to Her2/neu, EGFR has a series of well-known ligands, including epidermal growth 
factor (EGF) and transforming growth factor-alpha (TGFα) [286], which are also frequently 
overexpressed in tumors [293]. Specific ligand binding to the receptor triggers both homo- and 
heterodimer formation, and dysregulation of EGFR has been reported to be induced by its 
overexpression and/or mutation of tumor cell [286].  Overexpression promotes homodimer 
formation in the absence of ligand binding.  EGFR has been reported to be overexpressed in 
wide range of human cancers including carcinomas of the bladder, breast, colon, head-and-neck, 
lung, ovary, prostate and glioblastoma, as well as, in glioma, where overexpression is linked to 
poorer clinical outcome [294-297]. Treatment strategies targeting the EGFR pathway involve 
antibody-based immunotherapy and small molecule RTK inhibitors (e.g. Gefitinib). Two 
antibodies (Cetuximab, Pantitumumab) have recently been FDA-approved and have become 
standard care for metastatic colorectal cancer, where they have been associated with 10-20% 
objective response rates based on RECIST criteria [298, 299].  On the contrary and somewhat 
surprisingly, only one study to my knowledge, has reported the ability of EGFR to serve as a 
target for T cell recognition. 
 
I showed in Chapter 3 that the MHC class I-presentation of peptides derived from EphA2 (a 
novel client protein of HSP90) could be conditionally increased by tumor treatment with the 
HSP90 inhibitor 17-DMAG.  Since both Her2/neu and EGFR are also known to represent HSP90 
client proteins [242, 300-302], the treatment of tumor cells with 17-DMAG would be 
hypothesized to result in the coordinate, facilitated generation of epitopes derived from multiple 
RTKs (ErbB family members as well as EphA2). In this chapter, I studied how 17-DMAG (at 
concentrations that do not disrupt the MHC class I APM) affects EGFR and Her2/neu protein 
levels expressed by various types of solid cancer cell lines, as well as, how this drug augments 
specific CD8+ T cell recognition of treated tumor cells in vitro.  
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4.3. MATERIALS AND METHODS 
4.3.1. Cell lines and Media 
SKOV3 (Her2/neu+, HLA-A2neg; kindly provided by Dr. Nora Disis, University of Washington) 
and SKOV3.A2 (Her2/neu+, HLA-A2+) ovarian carcinoma cell lines (established via 
transduction of the corresponding parental cell lines with a recombinant retrovirus encoding 
HLA-A2.1 provided by Dr. Peter Cresswell, Yale University) were used both in Western blot 
and ELISA analyses. RCC (SLR20, SLR22, SLR24; [8]), melanoma (Mel397, Mel526, Mel624; 
[268]) and breast carcinoma (SKBR3; kindly provided by Dr. Nora Disis) cell lines were used in 
Western blot analyses. All cell lines were maintained in RPMI-1640 media supplemented with 
10% heat inactivated fetal bovine serum, 100 U/ml penicillin, 100 mg/ml streptomycin and 10 
mM L-glutamine (all reagents from Invitrogen, Carlsbad, CA, unless otherwise indicated) and 
were free of mycoplasma contamination. 
 
4.3.2. HSP90 inhibitor and Peptides 
HSP90 inhibitor 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG, NSC 
707545) was obtained from the National Cancer Institute (Bethesda, Maryland). Lyophilized 17-
DMAG was dissolved in sterile water as a stock solution and then diluted with RPMI-1640 
before use. The HLA-A2-restricted, Her2/neu369-377 (KIFGSLAFL; also known as E75, [303]) 
peptide epitope was synthesized using 9-fluorenylmethoxycarbonyl (Fmoc) chemistry by 
University of Pittsburgh Cancer Institute’s (UPCI) Peptide Synthesis Facility, as previously 
described [8]. The purity of peptides was >96% based on high performance liquid 
chromatography, with peptide identity validated by mass spectrometric (MS/MS) analyses 
performed by the UPCI Protein Sequencing Facility (a Shared Resource).  
 
4.3.3. Western Blot Analyses 
Tumor cells at 80-90% confluency were incubated with 17-DMAG (10-1000 nM) in 2% human 
serum supplemented RPMI-1640 media for 24-48h, as indicated in the text. Harvested cells were 
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then incubated with lysis buffer (1% TritonX-100, 150 mM NaCl, 10 mM Tris-HCl pH7.4, 1 
mM EDTA, 0.2 mM sodium orthovanadate, 0.5% NP-40 in PBS; all reagents from Sigma-
Aldrich) containing a protease inhibitor cocktail (Complete mini, Roche Diagnostic, Mannheim, 
Germany) for 30 minutes at 4oC. Lysates were cleared by centrifugation at 13,500 x g for 10 
min, and proteins in the lysate resolved by SDS-PAGE before electro-blotting onto PVDF 
membranes (Millipore, Bedford, MA). Polyclonal antibodies against AXL, EGFR, Her2/neu, c-
Met, RON-β, VEGFR1 and VEGFR2, and horseradish peroxidase (HRP)-conjugated goat anti-
rabbit antibody (all from Santa Cruz Biotechnology, Santa Cruz, CA, with the exception of the 
anti-Her2/neu Ab purchased from DAKO) were used to probe blot. Mouse anti-β-actin Ab (clone 
AC-15, Abcam) and goat anti-mouse mAb (BioRad) were used to detect β-actin as a loading 
control. Probed proteins were visualized by Western LightingTM chemiluminescence detection 
kit (Perkin Elmer, Boston, MA) and exposed to X-Omat film (Eastman Kodak, Rochester, NY) 
for 1-5 min. 
 
4.3.4. Flow Cytometry 
Control or treated tumor cells were harvested with Trypsin-EDTA (Invitrogen), washed and then 
incubated with anti-EGFR (Santa Cruz Biotechnology) or anti-Her2/neu mAbs (Calbiochem; 
TA-1) for 30 minutes at 4oC. After washing with PBS/0.2% BSA/0.02% NaN3, cells were 
stained with FITC-conjugated anti-mouse IgG (MP Biomedicals, Solon, OH) for 30 minutes at 
4oC. Cells were washed twice, then analyzed using an LSRII flow cytometer (BD Biosciences, 
San Jose, CA).  Isotype control mAb was mIgG1 (Sigma-Aldrich).   
 
4.3.5. T cell lines 
Bulk CD8+ T cell lines specific for Her2/ner369-377 were generated as previously described [8]. 
Briefly, mature dendritic cells (DC) were developed from peripheral blood mononuclear cells 
(PBMC; obtained with written consent under an IRB-approved protocol) isolated from normal 
HLA-A2+ donors in 7 day cultures containing rhGM-CSF (Sargramostim; Amgen, Thousand 
Oaks, CA) and rhIL-4 (Peprotech, Rocky Hill, NJ), then pulsed with Her2/ner369-377 peptides (10 
μM) for 4h at 37oC at 5% CO2 tension. Autologous CD8+ T cells were stimulated on a weekly 
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basis with peptide-pulsed autologous DC or PBMC for 2-3 cycles (at a T:DC ratio of 10:1 or at a 
T:PBMC ratio of 1:1) to generate a bulk population of peptide-specific CD8+ T cells. T cells 
were maintained in IMDM media supplemented with 10% human AB serum, 100 U/ml 
penicillin, 100 mg/ml streptomycin, 10 mM L-glutamine and MEM Non-essential amino acids 
(all reagents from Invitrogen, except human AB serum that was purchased from Sigma-Aldrich).  
 
4.3.6. Tumor Recognition Assays 
Tumor recognition by Her2/neu specific bulk T cells was evaluated by commercial hIFN-γ 
ELISA (BD-Biosciences). SKOV3.A2 cells were treated with 500 or 1000 nM 17-DMAG for 
24-48h, prior to their harvest with Trypsin-EDTA (Invitrogen).  HLA-A2 null SKOV3 cells were 
served as control target cells. After washing with PBS (Invitrogen), tumor cells were co-cultured 
with anti-Her2/neu bulk T cells at an effector:target cell ratio of 2:1 for 24h at 37oC and 5% CO2 
tension.  
 
4.3.7. Statistical Analyses 
Two-tailed Student’s t tests were used to evaluate the difference between groups, with p values < 
0.05 considered significant. 
 
 111
4.4. RESULTS 
4.4.1. HSP90 inhibitor induces multiple RTK degradation concomitantly  
The relative protein levels of various RTKs were assessed by Western blot analyses of a range of 
RCC cell lines (Figure 23). The RTKs AXL, EGFR, Her2/neu and c-Met were expressed at high 
levels by most of the RCC cell lines tested, while Ron-β and VEGFR2 were overexpressed in a 
more restricted subset of RCC cell lines. VEGFR1 overexpression was not observed. These data 
suggest that EphA2, AXL, EGFR, Her2/neu and c-Met represent attractive RTK target proteins, 
at least, in the setting of RCC. Of these cancer-related RTKs, I selected EGFR and Her2/neu for 
the further analyses, in large part, due to the availability of clinical-grade monoclonal antibodies 
targeting these two RTKs that have shown some degree of efficacy in phase I/II trials.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Multiple RTKs are simultaneously highly expressed by individual renal cell 
carcinoma (RCC) cell lines.  
The protein expression levels of the RTKs AXL, EGFR, Her2/neu, c-Met, Ron-β, VEGFR1, 
VEGFR2, or control β-actin were analyzed in RCC cell lines (SLR20, 21, 22, 24, 25) by Western 
blotting.  
RON-b
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I first analyzed the impact of 17-DMAG on tumor cell expression of these two RTKs initially 
assessing the RCC cell line SLR20 (which overexpresses both EGFR and Her2/neu).  SLR20 
cells were incubated for 24h in the absence of in the presence of 17-DMAG (500 nM), and 
analyzed for EGFR and Her2/neu protein levels by Western blotting (i.e. total protein; Figure 
24A) and flow cytometry (i.e. cell surface protein; Figure 24B). The profound reductions in 
expression of both EGFR and Her2/neu as a result of treatment with 17-DMAG suggested an 
extension of the paradigm established in my former studies based on EphA2.  
 
To address the generality of 17-DMAG’s ability to promote the degradation of EGFR and 
Her2/neu, I repeated these assays using a diverse panel of tumor cell lines, including other RCC 
(SLRs), melanoma (Mel), breast carcinoma (SKBR3), and ovarian carcinoma (SKOV3) cell 
lines. After a 24h treatment with 17-DMAG, the levels of EGFR and Her2/neu protein expressed 
by tumor cells were dramatically reduced (Figure 25).   
 
 
 
 
 
 
 
 
 
 
 
Figure 24. 17-DMAG promotes a coordinate loss in expression of multiple RTKs by the 
RCC cell line SLR20.  
A. The RCC line SLR20 was incubated in the absence or presence of 17-DMAG (500 nM) for 
24h at 37oC, before the generation of cell lysates and the performance of Western blot analyses 
to determine levels of EGFR and Her2/neu protein expression. β-actin was monitored as an 
internal control protein. B. SLR20 cells were treated as above, with cell surface expression of 
EGFR and Her2/neu protein monitored by flow cytometry using specific mAbs (open profiles) 
versus isotype control mAbs (filled profiles). 
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Figure 25. RCC, Melanoma, Breast and Ovarian tumors are all sensitive to 17-DMAG-
mediated reduction in expression of EGFR and Her2/neu.  
The SLR22, SLR24 (RCC, A), Mel397, Mel526, Mel624 (melanoma, B), SKBR3 (breast 
carcinoma, C) and SKOV3 (ovarian carcinoma, D) cell lines were incubated in the absence or 
presence of 17-DMAG (10-1000 nM) for 24h at 37oC, before the generation of cell lysates and 
the performance of Western blot analyses to determine levels of EphA2 protein expression. β-
actin was monitored as an internal control protein. 
 
 
4.4.2. 17-DMAG treatment of tumor cells enhances tumor recognition by bulk CD8+ T cells 
specific for Her2/neu   
Bulk CD8+ T cell line specific for Her2/neu was generated from normal HLA-A2+ donors using 
an in vitro stimulation protocol employing autologous DC pulsed with Her2/neu369-377 (HLA-A2-
presented) peptide as stimulator cells. After 2-3 rounds of restimulation, responder CD8+ T cells 
were cultured with SKOV3.A2 cells (Her2/neu+, HLA-A2+) which were untreated or pre-treated 
with 17-DMAG (500nM or 1000nM) for 24h. The content of IFNγ in the culture supernatant was 
analyzed by ELISA as an indicator of Her2/neu-derived peptide recognition by specific CD8+ T 
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cells. As shown in Figure 26, Her2/neu-reactive, bulk CD8+ T cells recognized Her2/neu+, HLA-
A2+ SKOV3.A2 cells, while recognition of Her2/neu+, HLA-A2neg SKOV3 cells was observed to 
occur at a low, basal level. The SKOV3.A2 recognition was increased significantly after 24h 
treatment, and further increased after 48h treatment.  The improved recognition of tumor cells at 
48h over 24h was somewhat in contrast to Chapter 3’s results for EphA2-specific T cell 
reactivity, which was stronger at 24h versus 48h. I believe that this may indicate that the 
processing of these RTKs is kinetically differential, or that the durability of the Her2/neu 
peptide-class I complexes is more stable that those formed with EphA2 peptides.  The 
improvement of SKOV3.A2 recognition was not significantly different between 500nM and 
1000nM treatments, consistent with the comparable levels of Her2/neu protein reduction shown 
in Figure 25, and suggests that a sufficient level of the peptide epitope (exceeding the T cell 
activation threshold) occurs at a 17-DMAG concentration of 500nM. 
 
 
 
 
 
 
 
 
Figure 26. Recognition of Her2/neu+ SKOV3.A2 tumor cells by bulk anti-EphA2 CD8+ T 
cells is enhanced after treatment with 17-DMAG.  
An HLA-A2-restricted CD8+ T cell line was generated in vitro by repeated stimulation with 
autologous DC pulsed with the Her2/neu369-377 peptide. These CD8+ T cells (105) were then co-
cultured for 24h at 37oC with the Her2/neu+, HLA-A2+ SKOV3.A2 ovarian carcinoma cells (0.5 
x 105) that had be pre-cultured in the absence or presence of 17-DMAG (500 nM or 1000 nM) 
for 24h or 48h. IFNγ content in the cell-free culture supernatant was then analyzed by ELISA. 
Light gray bar indicates untreated SKOV3 cells, and black bars indicate SKOV3.A2 cells. *p < 
0.05 for all indicated comparisons.     
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4.5. DISCUSSION 
Since most TAA are overexpressed self antigen, tolerance selection restricts the anti-tumor CD8+ 
T cell repertoire to a degree that limits their clinical utility. My thesis is based on the hypothesis 
that tumor cells might be therapeutically manipulated in order to exceed the cognate antigen 
threshold requirements for effective immune surveillance by normally non-self reactive T cells. 
In Chapter 3 we showed that treatment of EphA2+ tumor cells with the irreversible HSP90 
inhibitor, 17-DMAG, enhances their recognition by EphA2-specific CD8+ T cell lines and clones 
in vitro. While Her2/neu and EGFR, overexpressed in various cancer histologies is association 
with poor prognosis [287-289, 294-297], these proteins have been reported to serve as clients for 
HSP90[242, 300-302], making them targets for the action of the HSP90 inhibitor, 17-DMAG.   
 
The major findings of this chapter are that; 1) multiple RTKs proteins are concomitantly 
overexpressed in a broad range of tumor cell lines; 2) 17-DMAG coordinately reduces Her2/neu 
and EGFR, as well as EphA2, protein levels expressed by tumor cells; and 3) 17-DMAG 
sensitizes Her2/neu overexpressed tumor cells for recognition by anti-Her2/neu CD8+ T cells. 
These findings, when coupled with those reported in Chapter 3, strongly suggests that the 
treatment of tumor cells with HSP90 inhibitors has the potential to promote the coordinate 
proteasomal processing of multiple RTKs. My data are consistent with the study of Castilleja et 
al., which showed another HSP90 inhibitor geldanamycin was able to induce Her2/neu 
degradation and improved recognition by anti-Her2/neu369-377 CD8+ T cells in vitro [273]. Even 
though there is a slight discrepancy in my report versus that of Castilleja et al. regarding drug 
effects on tumor cell HLA-A2 class I expression levels (upregulated in the Casteilleja study 
versus no change in my studies), the mechanistic paradigm(s) for HSP90 inhibitor effects on 
immune augmentation appear consistent between the two studies. 
 
We also noted that Her2/neu protein is very sensitive for 17-DMAG treatment. A profound 
reduction in Her2/neu protein by tumor cells was achieved at low doses of this drug in all tumor 
cell lines evaluated, even the SLR24 RCC line in which EphA2 and EGFR protein expression 
levels were relatively resistant to the effects of 17-DMAG. It has been reported that HSP90 
associates with Her2/neu intracellularly (involving the cytoplasmic kinase domain) and stabilizes 
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Her2/neu expression on the plasma membrane [304, 305]. HSP90 inhibitors disrupt the 
interaction of these two molecules, resulting in rapid degradation of Her2/neu. In addition, cell 
surface expression of HSP90 has recently been reported, in which the HSP was found to interact 
specifically with the extracellular domain of Her2/neu, leading to an enhancement in actin 
rearrangement and improved cell motility (involved in cancer cell invasion) [306]. HSP90 thus 
appears to modulate Her2/neu expression at multiple levels, and this may make this RTK 
particularly salient as a target for this HSP90 inhibitor. 
 
Interestingly HSP90 inhibitor induce the MHC class I presentation of peptides derived from both 
EphA2 and Her2/neu, but with somewhat different kinetics; i.e. EphA2 presentation was best at 
24h (Chapter 3), while Her2/neu presentation was best at 48h (Chapter 4).  These findings 
suggest that the observed decrease of EphA2  presentation at 48h (versus 24h)  was not likely 
due to adverse effects of 17-DMAG on the tumor cell MHC class I APM, nor due to an 
increase/decrease of inhibitory/activation (“co-receptor”) molecules.  Rather differential 
competition of peptides for loading MHC class I complexes and/or differential dissociation 
profiles for these class I complexes may represent logical reasons for the observed behavior of 
this drug’s action in the current studies. To address this hypothesis, we are currently performing 
mass spectrometry analysis of extracted peptides from untreated tumors versus tumors treated 
with 17-DMAG for 24h versus 48h, which may reveal the relative abundance of relevant 
peptides over time in tumor cell MHC class I complexes.   
 
Our finding that 17-DMAG is capable of coordinately inducing the enhanced MHC class I 
presentation of peptide epitopes from multiple RTKs might make pre-administration of 17-
DMAG a generalized strategy to enhance the clinical efficacy of vaccines promoting specific 
CD8+ T cell responses against HSP90 client proteins. Such poly-specific T cell targeting of 
tumors may have a profound clinical benefit by providing a multi-pronged attack against tumor 
cells. In addition, the corollary impact of “epitope spreading” that may be initiated by such a 
diversified initial round of immune attack against the tumor cells might be anticipated, which has 
been previously associated with far better treatment outcomes in the cancer therapy setting.  
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GENERAL DISCUSSION 
RTKs are frequently overexpressed and may be constitutively activated in the majority of human 
cancers, hence, the silencing of their associated signaling pathways or immune targeting of these 
proteins may yield clinical benefit [1-3].  In particular, my thesis project has endeavored to 
define strategies by which the frequency of RTK-derived antigenic peptides presented in MHC 
class I complexes on the tumor cell surface may be transiently increased in order to improve 
tumor cell recognition by RTK-specific CD8+ T cells that are capable of mediating tumor 
regression [3].  
 
Immunotherapies (including cancer vaccines) designed to stimulate specific T cell-mediated 
immunity have thus far yielded rather modest objective clinical response rates, despite their 
ability to enhance circulating frequencies of tumor-specific T cells in the blood of many treated 
patients [177]. This may be attributed to the low-to-moderate avidity of the negatively-selected T 
cell repertoire (reactive against non-mutated, “self” RTK peptides) that is activated by such 
therapies [256, 257]. These T cells may become effectively activated by APCs presenting 
abundant levels of tumor antigen-derived peptides, but they typically fail to recognize tumor 
cells that naturally present low stochastic frequencies of relevant MHC/tumor peptide complexes 
[264]. Poor immune reactivity of tumor cells may be further exacerbated by defects in the tumor 
APM that limit the overall level of tumor cell expressed MHC molecules [150, 151].   
 
Consequently interferons continue to attract attention as clinical therapeutic agents given their 
ability to improve antigen presentation (by APC and tumor cells) via the transcriptional up-
regulation of components of the antigen processing machinery (APM).  However, MHC class I-
restricted T cell-mediated immune responses are typically only modestly enhanced by pre-
treatment of tumor cells with interferons [258], and moreover, interferons do not selectively 
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increase the processing and MHC presentation of epitopes derived from a particular antigen 
(such as RTK). The evaluation of strategies to conditionally and selectively manipulate tumor 
cell presentation of T cell epitopes derived from endogenous antigens remains an understudied 
area of translational cancer research.  
 
My thesis was, therefore, based on the hypothesis that tumor cells might be therapeutically 
manipulated in order to exceed the cognate antigen threshold requirements for effective immune 
surveillance by host T cells that have been (thymically and peripherally) educated to ignore “self 
antigens”. In particular, I believe that by conditionally enhancing the proteasomal processing of 
tumor antigens, such as non-mutated RTKs, the level of class I/RTK peptide complexes might be 
(at least transiently) increased on the tumor cell surface, allowing for improved recognition by 
modest avidity anti-RTK CD8+ T cells [3].  While I believe the core principles will likely 
translate to most (if not all) RTKs, I initially focused my studies on the RTK, EphA2, which is 
overexpressed/dysregulated in virtually all solid cancers (and where its degree of overexpression 
is associated with a poor clinical prognosis). Since EphA2 peptide epitopes recognized by HLA-
A2-restricted CD8+ T cells had been previously defined by the Storkus laboratory and others [8, 
130], it was feasible to evaluated the presentation levels of EphA2 derived peptide in tumor cell-
expressed MHC class I by monitoring the degree of tumor recognition by specific CD8+ T cells 
(e.g. IFNγ production detected by ELISPOT/ELISA). Using EphA2 as a model target, I initiated 
a search of reagents with which to promote RTK epitope presentation selectively in tumor cell 
MHC class I complexes. 
 
First, I was interested in evaluating groups of agents that had the potential to alter the life cycle 
of EphA2, particularly with regard to its ultimate degradation via the proteasome. I selected 
ephrinA1-Fc and agonistic EphA2 mAb208 as reagents to trigger the internalization of tumor 
cell EphA2 protein. I found that both agonists promote EphA2 autophosphorylation, rapid 
internalization and proteasomal degradation/processing, with a corollary improvement observed 
in tumor recognition by moderate-to-low functional avidity anti-EphA2 CD8+ T cells in vitro and 
in vivo. These results suggest that the strategy of targeting the conditional proteasome-mediated 
destruction of tumor cell-expressed EphA2 protein may be effective for improving the anti-tumor 
efficacy of CD8+ T effector cells reactive against EphA2-derived epitopes. Notably while single 
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administration of either agonist was provided into EphA2+ tumor lesions in our Hu-SCID model, 
this approach failed to inhibit tumor progression. In marked contrast, when agonists were 
administered prior to the adoptive transfer of human anti-EphA2 CD8+ T cells (which were also 
poorly therapeutic as a single modality), this combinational treatment resulted in complete tumor 
eradication. These results suggest that conditional proteasome-mediated destruction of tumor cell 
EphA2 may be therapeutically critical in order to enable the existing (or induced) EphA2-
specific CD8+ T cell repertoire to mediate a clinically-meaningful anti-tumor response in vivo,  
 
During a search of alternative approaches to enhance EphA2 presentation on tumor cells, I 
became interested in the chaperone function of HSP90. Although EphA2 had not been previously 
reported to represent a client protein for HSP90, given that several alternate RTKs had been 
identified as HSP90 clients [242, 300-302], I felt this was a logical possibility. Therefore, I 
hypothesized that inhibition of HSP90 function might lead to the degradation of EphA2 proteins 
most probably via the proteasome, and that derivative peptides might gain access to nascent 
MHC class I molecules through the direct presentation pathway.  Using a newest generation 
HSP90 inhibitor, 17-DMAG, I determined that EphA2 is a novel client protein of HSP90. 
Furthermore, treatment of tumor cells with 17-DMAG for a period of 24-48h, using a clinically 
well-tolerated dose of this agent, results in: 1) the proteasome-dependent degradation of tumor 
cell-expressed EphA2 protein and 2) the augmentation of tumor cell recognition by low avidity 
anti-EphA2 CD8+ T cells in vitro.  I further discerned that the mechanism underlying enhanced 
tumor cell recognition by T cells after 17-DMAG treatment was dependent on Sec61-mediated 
retrotranslocation, proteasome-mediated enzymatic cleavage and TAP-mediated delivery of 
EphA2 peptides into the MHC class I biosynthetic pathway. While 17-DMAG acts in a 
mechanistically distinct manner from EphA2 agonists, both of these modalities yield similar 
immunologic endpoints with regard to specific tumor cells recognition. Furthermore, I found that 
these 2 approaches synergize as a combinational treatment regimen in promoting EphA2 protein 
loss and enhanced T cell recognition was observed.  Such synergy could reflect the 
complementation in the targeted pools of tumor cell EphA2 protein being affected by each 
modality, i.e. mAb208 or ephrinA1-Fc may primarily target the plasma membrane pool of 
EphA2 protein, while 17-DMAG may primarily affect the intracellular pool of this protein. The 
differential source of EphA2 may also determine the kinetics with which enhanced T cell 
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recognition occurs. Indeed, I noticed that the 17-DMAG induced-improvement of tumor 
recognition was optimal at 24h versus 48h (return to basal level), while agonists treatment 
yielded a more prolonged period of enhanced tumor cell recognition by anti-EphA2 CD8+ T 
cells.  
 
In corollary studies, I also noted that 17-DMAG treatment of tumor cells improves the MHC 
class I presentation of Her2/neu-derived CD8+ T cell epitopes, and that the kinetics for improved 
recognition differed from those I previously observed for the EphA2 model. These data may 
indicate differential competition of specific peptides for loading into MHC class I complexes 
and/or differential dissociation profiles for specific MHC class I/RTK peptide complexes exists.  
 
Interestingly, I found that both EphA2 agonist and HSP90 inhibitor treatment led to the enhanced 
tumor cell recognition by CD8+ T cells reactive against peptides derived from the extracellular 
(i.e. EphA258-66), as well as, intracellular (i.e. EphA2883-891) domains of the EphA2 protein.  This 
suggests that both domains of this transmembrane protein are driven into the proteasomal 
processing and MHC class I presentation pathways.  To date, however, I have only investigated 
one peptide derived from each domain, and it would be warranted to analyze the comprehensive 
pool of MHC class I-presented EphA2 peptides using mass spectrometric analyses. This would 
allow for a better understanding of the kinetics with which such epitopes are presented and how 
this may relate to a given treatment applied to enhance immune recognition.  Furthermore, such 
information may be important to the selection of specific peptide species (i.e. those with the most 
prolonged periods of elevated presentation) for integration into vaccine formulations in order to 
expand specific CD8+ T cells in vivo, or ex vivo for ultimate delivery via adoptive transfer.  
 
As described above, I found that both domains of EphA2 are driven into the proteasomal 
processing pathway of tumor cells by either agonist or HSP90 inhibitor treatment. How both 
domains of the EphA2 transmembrane protein become accessible to proteasome-dependent 
degradation in the cytosol remains unclear. The intracellular domain (ICD) is anticipated to be 
naturally accessible to the action of cytosolic proteasomes, while the extracellular domain (ECD) 
is thought to be compartmentalized (protected) within intracellular vesicles, such as ER, Golgi, 
endosomes, etc. So, how is the ECD of the RTK released from such protective compartments and 
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delivered into cytosol where proteasome resides? For nascent and mis-folded proteins, such 
delivery may be achieved by protein retrotranslocation as employed during ERAD, where Sec61, 
Derlin-1 and/or Doa10 play pivotal roles in “ratcheting” transmembrane proteins into the cytosol 
in a C-terminus to N-terminus manner [207, 265-267, 307]. A similar/identical mechanism 
appears to underlie my observed results, since enhanced anti-EphA2 T cell recognition of 17-
DMAG-conditioned tumor cells was ablated upon inclusion of the Sec61 inhibitor, Pseudomonas 
aeruginosa exotoxin A.  This suggests that the major pool of EphA2 protein undergoing 
enhanced proteasomal processing as a consequence of HSP90 inhibition likely enters the tumor 
cytosol via retrotranslocation. However, at present, I cannot distinguish whether this pool of 
EphA2 protein derives from an early endosomal compartment (i.e. internalized after interaction 
with the EphA2 ligands co-expressed by adjacent tumor cells) and/or from newly-synthesized, 
mis-folded EphA2 proteins within the exocytic pathway. In the case of agonist-induced EphA2 
peptide presentation by tumor cells, the process by which the ECD of EphA2 becomes accessible 
to the proteasome after internalization is more enigmatic. Possible mechanisms include 
retrotransportation/retrotranslocation, fusion of EphA2+ endosomes with ER and loss of early 
endocytic vesicle integrity (since chloroquine does not inhibit the impact of agonists in this 
model), however, these possibilities will need to be addressed thoroughly in prospective 
experiments.  
 
There are indeed complexed transportation pathways among early/sorting endosome, late 
endosome, lysosome, trans-Golgi network, Golgi and ER, that have been predominantly 
identified through the study of bacterial and viral toxins, since many of these pathogens have 
evolved diverse strategies for traversing membrane barriers in order to reach their preferred 
substrates in the cytosol of mammalian cells [308-310]. In fact, some reagents used in Chapter 2 
and Chapter 3 investigations to assess mechanistic dependency on TAP and retrotranslocation 
are derived from viral or bacterial (herpes simplex virus ICP47 and Pseudomonas aeruginosa 
exotoxin A, respectively) sources [265]. Several strategies may be conceived to incriminate the 
relevant intracellular pathways taken by EphA2 proteins after agonist or HSP90 inhibitor 
treatment, including siRNA knockdown of critical proteins associated with vesicle transportation 
(e.g. Rab5, Rab9, Syn16), as well as, pharmacologic inhibition (e.g. U18666A) [265, 309, 310]. 
However, more direct evidence might be obtained by detailed imaging analyses of EphA2 
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protein translocation after agonist or HSP90 inhibitor treatment, and in the absence or presence 
of pharmacologic inhibitors for each pathway. We are currently considering the use of a novel 
tracking technology LumioTM Green (Invitrogen Life Technologies), with which one can 
visualize subcellular localization of FlAsH-tagged (a short amino acid tag that is less likely to 
negatively affect the natural behavior/function of a protein versus tagging with a prohibitively 
large molecule such as EGFP, etc.) proteins by fluorescence microscopy with high sensitivity 
and specificity [311].  We have generated multiple FlAsH-tagged EphA2 constructs that are in 
the initial stages of validating their utility in imaging analyses. Ultimately, a better understanding 
of the mechanism(s) involved in agonist- or HSP90 inhibitor-enhanced presentation of EphA2-
derived T cell epitopes may allow for the therapeutic accentuation of relevant pathways, allowing 
for even further optimization of therapy benefits in patients harboring EphA2+ tumors.  
 
Furthermore, I asked whether the treatment of tumor cells with the HSP90 inhibitor 17-DMAG 
would result in the coordinate degradation of multiple (overexpressed) RTK, leading to 
improved recognition by multiple RTK-specific CD8+ T cells in vitro. While not exhaustive (in 
screening all known RTKs), I found that 17-DMAG can coordinately promote the proteasomal 
degradation of, at least, Her2/neu, EGFR and EphA2 in treated tumor cells. In the cases of 
Her2/neu and EphA2, such proteolysis sensitizes tumor cells to recognition by specific CD8+ T 
cells. Thus, my data would support a generalizeable paradigm that might be extended to 
additional RTKs. Interestingly, HSP90 is critical for the folding of nascent Her2/neu protein, but 
it also serves to stabilize mature Her2/neu on the cell membrane [304, 305]. The same is true for 
mutant EGFR, while HSP90 is only responsible for the folding of nascent wild-type EGFR [312, 
313]. Therefore, it will be intriguing to determine whether therapy benefits observed for HSP90 
inhibitors depend on HSP90 interaction with RTKs (including EphA2) on the tumor cell plasma 
membrane versus the same RTK proteins localized to alternative intracellular organelles. 
  
In the clinic, EphA2 agonists would be expected to be superior with regard to targeting the 
EphA2 protein specifically, when compared with the targeting of a broad class of client proteins 
(that include EphA2) in the case of HSP90 inhibitors. However, the promiscuous and coordinate 
effects of HSP90 inhibitors on multiple oncoprotein clients might argue for the use of these 
drugs in combinational immunotherapies designed to promote the concomitant immune targeting 
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of multiple tumor-associated antigens (such as EphA2, EGFR and Her2/neu, etc.). HSP90 
inhibitors may be preferred to agonists based on their selective accumulation in tumor versus 
normal EphA2+ tissue sites. For example, 17-AAG binds to tumor cell-derived HSP90 up to 2-
logs more tightly than it does to normal cell-derived HSP90 [314]. Furthermore, in mouse 
models, 17-DMAG persists within tumor lesions far longer than in normal tissues, with 
detectable levels selectively observed in tumors 48h after a single i.v. administration of drug 
[249]. This suggests that drug dosing far below the MTD may be capable of modulating T cell 
recognition of cancer cells within the tumor microenvironment in vivo. However, it is also 
possible that the application of 17-DMAG and/or EphA2 agonists may promote increased 
immune recognition of normal EphA2+ tissues that express a fully functional class I APM. This 
raises the specter of autoimmune pathology that would need to be closely monitored in 
prospective clinical trials applying these agents, particularly should they be combined. In this 
regard, no untoward, immune-mediated effects on patient EphA2+ organs (i.e. lungs, kidney) 
have been reported in clinical trials employing HSP90 inhibitors to date [315], and EphA2 
agonist therapies have yet to be investigated in phase I trials.  
 
Based on the aggregate data I have presented in this thesis, I believe that it is warranted to 
translate my in vitro findings with 17-DMAG into mouse (in vivo) tumor models. The Hu-SCID 
tumor model used in Chapter 2 may be a good one to consider for this purpose, as it allows us to 
establish human tumors in mice and to evaluate the efficacy of oral administration of 17-DMAG, 
adoptive T cell transfer or a combinational treatment integrating both of these modalities. 
However, given severe immunodeficiency in this mouse strain, we would not be able to analyze 
potential autoimmune pathology resulting from therapy. Tumor-bearing, HLA-A2 Tg (HHD) 
mice would be alternate model to consider, as this would allow for the direct testing of 
combinational vaccine therapies that could be directly translated into clinical trials accruing 
HLA-A2+ patients with solid cancers [316]. We are currently breeding HHD mice for use in the 
analysis of combinational EphA2 vaccine + 17-DMAG-based therapies. In such a system, we 
can analyze normal EphA2+ tissues for inflammation and immune infiltration, and determine 
whether 17-DMAG exerts any adverse effects on the immune system, i.e. DC and T cell 
maturation/function may have concerns based on recent publications [317-319].  
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Overall, I have demonstrated that two reagent groups (RTK agonists, HSP90 inhibitors), that 
appear to mediate their effects via different mechanisms, enhance tumor cell recognition by 
specific CD8+ T cells. Such improved immune recognition may translate into improved 
therapeutic benefit, particularly when combinational immunotherapies (i.e. agonists + adoptive T 
cell transfer) are administered to tumor-bearing animals. I have also shown that HSP90 inhibitor 
treatment is capable of coordinately regulating the delivery of multiple RTKs (i.e. their 
derivative peptides) into the direct class I presentation pathway, suggesting the generality of this 
approach and potential augmentation of treated tumor cell recognition by low avidity CD8+ T 
cells capable of recognizing virtually any HSP90 client protein. Such poly-specific T cell 
targeting of tumors may have a profound clinical benefit by providing a multi-pronged attack 
against tumor cells, limiting concerns for tumor variants that fail to express a given target 
antigen. My data will hopefully assist in the future development of novel combinational 
immunotherapies employing RTK agonists and HSP90 inhibitors, which in concert with vaccines 
designs to elicit anti-RTK CD8+ T cells or adoptively-transferred anti-RTK CD8+ T cells, would 
be expected to provide far greater clinical benefits to RTK+ cancer patients.  
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APPENDICES 
 
 
Appendix Figure 1. PTP expression by 
RCC cell lines. 
Protein expression levels of LMW-PTP, 
PTP-1b and SHS-PTP by RCC cell lines 
SLR20, 22, 24 were analyzed by Western 
blotting using specific antibodies (all from 
Santa Cruz Biotechnology). β-actin was 
monitored as an internal control protein. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Figure 2. ephrin-A1 and ephrin-A5 protein expression by RCC cell lines. 
Levels of ephrin-A1 and ephrin-A5 protein expressed by RCC cell lines SLR 20, 20.A2, 22, 24 
were determined by Western blotting using specific antibodies (both from Santa Cruz 
Biotechnology), with PBMC serving as negative control cells. β-actin was monitored as an 
internal control protein. 
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Appendix Figure 3. EphA2 negative cell lines are not recognized by anti-EphA2 mAb B2D6 
and the reduction of cell surface EphA2 expression by 17-DMAG on EphA2+ SLR20 tumor 
cells appears incomplete as monitored by flow cytometry.  
A. Melanoma cell lines B16, Colo38 and the prostate carcinoma cell line LNCap were harvested 
with Trypsin-EDTA, and their cell surface expression of EphA2 protein was monitored by flow 
cytometry by using the B2D6 anti-EphA2 mAb. B. SLR20 RCC cells were incubated in the 
absence or presence of 1000 nM 17-DMAG for 24h. Cell were harvested with Trypsin-EDTA, 
washed and then incubated with 10 μg/ml of ephrinA1-Fc (R&D Systems; a chimeric protein 
consisting of the ligand binding domain of the EphA2 ligand ephrinA1 fused with the Fc portion 
of a human IgG Ab) or ephrinB1-Fc (control staining; Sigma-Aldrich) for 1h at 4oC. Cell-bound 
ephrinA1-Fc or ephrinB1-Fc was then probed with FITC-conjugated anti-human IgG (MP 
Biomedicals, Solon, OH) and analyzed by flow cytometry. C. SLR20 RCC cells were incubated 
in the absence or presence of 500 nM 17-DMAG for 24h. Cells were harvested with either 
EDTA (Invitrogen) or Trypsin-EDTA (Invitrogen) and cell surface expression of EphA2 was 
monitored by flow cytometry using the B2D6 mAb. 
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Appendix Figure 4. HSP90 protein expression is not affected by 17-DMAG. 
The RCC cell lines SLR20, 22, 24 were incubated in the absence or presence of 17-DMAG (500 
nM) for 24h at 37oC, before the generation of cell lysates and the performance of Western blot 
analyses to determine levels of HSP90 (using a specific Ab purchased from Stressgen 
Bioreagents Corp.) protein expression. β-actin was monitored as an internal control protein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix Figure 5. EphA2 is conditionally degraded by HSP90 inhibitor, 17-AAG, in RCC 
cell line SLR20. 
A. SLR20 RCC cells were incubated in the absence or presence of 17-AAG (10-1000 nM) for 
48h at 37oC, before the generation of cell lysates and the performance of Western blot analyses 
to determine levels of EphA2 protein expression. β-actin was monitored as an internal control 
protein. B. SLR20 RCC cells were incubated in the absence or presence of 17-AAG (100 or 1000 
nM) for 24h at 37oC, with cell surface EphA2 expression monitored by flow cytometry.  
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Appendix Figure 6. Effect of serum on the EphA2 protein reduction triggered by the 
HSP90 inhibitors, 17-AAG and 17-DMAG 
SLR20 RCC cells were untreated or treated with either 17-AAG (1000 nM, panel A.) or 17-
DMAG (500 nM, panel B.) in the absence or presence of fetal bovine serum (FBS; 1-10%) or 
human AB serum (hSerum; 1-5%) for 24h at 37oC, with cell surface expression of EphA2 
protein monitored by flow cytometry. Data are reported as percentage control EphA2 cell surface 
expression (versus untreated cells) based on MFI values obtained. 
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